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“The aim of science is not to open the door to infinite wisdom, but to set a limit to
infinite error.” 
Bertolt Brecht, The life of Galileo (sc.9)
Nothing in biology makes sense except in the light of evolution.
Theodosius Dobzhansky
3ABSTRACT
Urocortin 1 (UCN) and its homologues Urocortin 2 (UCN2/SRP) and urocortin 3 
(UCN3/SCP) belong to the corticotropin releasing factor (CRF) family of peptides. CRF 
peptides have been shown to affect cardiovascular physiology.
The effects of the peptides on cardioprotection after hypoxia/reoxygenation injury and on 
hypertrophy were examined. As SCP and SRP have a higher affinity for the CRF receptor 
2(3, the only CRF receptor expressed in the rat heart, compared to UCN that additionally 
binds to the CRF receptor 1, the hypothesis was posed that the actions of SCP and SRP 
on cardiomyocytes will be more pronounced and more specific than UCN. As the 
pathways that are downstream of CRF receptors are not fully characterised, a possible 
mechanism of action is examined.
The protective effect of the three peptides was compared and it was shown that all three 
are protective. Moreover, SCP and SRP are induced by hypoxia/reoxygenation injury. 
Examining the hypertrophic effects of the peptides it was concluded that all three 
exhibited such properties with SCP being the most potent. Furthermore, it is shown that 
UCN homologues require activation of MAPK p42/44 and PKB/Akt for their 
cardioprotective effects, but only PKB/Akt for hypertrophy.
The involvement of two other important signalling molecules, iPLA.2 and protein kinase 
Ce (PKCe) was also examined. iPLA2 protein levels are down-regulated by UCN peptides, 
- attenuating the effects of the enzyme after hypoxia/reoxygenation. PKCe protein levels 
are induced by UCN peptides indicating that PKCe is involved in the action of the 
peptides. Finally, UCN peptides upregulate the Sensitive to Apoptosis Gene (SAG) and
the K atp channel, Kir 6.1 and these are two of the downstream effectors of 
cardioprotection. In addition, SAG appears to be a cardioprotective molecule that 
interacts with caspase-3.
In conclusion, UCN peptides generate a multifaceted effect on cardiomyocyte physiology 
and we provide information on new mechanisms of action by the peptides. In addition, 
we illustrate that SCP is the most potent peptide of the three and provide additional 
evidence on the notion that C-terminal amidation of the CRF peptides is a requirement 
for their biological effect.
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CHAPTER I
1. GENERAL INTRODUCTION
1.1 CARDIOVASCULAR DISEASES
The heart is one of the major organs of the body. Its function is to pump blood 
around the body. It is mainly comprised of differentiated muscle cells, the 
cardiomyocytes. Cardiomyocytes, being terminally differentiated cells, rarely 
divide. However, recent reports show that cell division might be occurring among 
cardiomyocytes in failing hearts (Kajstura et al., 1998). Nevertheless, the rate of 
division is too small to be able to make up for the loss of cells in an infarct area. It 
is not surprising therefore that Cardiovascular Diseases are the major killer 
worldwide, accounting for approximately 12 million deaths annually (Gill et al.,
2002).
Coronary heart diseases are caused by the obstruction of the blood flow in the 
coronary arteries, leading to minimised oxygenation and nutrient supply of the 
cardiomyocytes. This insufficient blood flow in the coronary arteries is called 
ischaemia. As a result, cardiomyocyte physiology becomes compromised and 
may lead to cell death and ultimately heart failure.
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Restoration of blood flow after an ischaemic episode is called reperfusion and 
although it is required for the survival of the cardiac tissue, the reintroduction of 
oxygen in an ischaemic cell, is the main cause for the cellular injury that is 
described by the term reperfusion injury.
Cardiac hypertrophy is the cellular response to an increase in biomechanical 
stress, either extrinsic as in arterial hypertension or valvular heart disease, or 
intrinsic as in familial hypertrophic cardiomyopathy (Braunwald et al., 2002; 
Marian, 2002; Wilkins and Molkentin, 2002; Lips et al., 2003). Cardiac 
hypertrophy is a compensatory mechanism striving to normalise the increase in 
wall tension. Hypertrophy in response to pathologic stimuli has been considered 
an adaptive response, required in order to sustain cardiac output during stress 
(Braunwald et al., 2002; Marian, 2002; Wilkins and Molkentin, 2002; Lips et al., 
2003). However, prolonged hypertrophy is associated with a significant increase 
in the risk for sudden death or progression to heart failure, independent of the 
underlying cause of hypertrophy, suggesting that the hypertrophic response is 
not entirely beneficial (Braunwald et al., 2002; Marian, 2002; Wilkins and 
Molkentin, 2002; Lips et al., 2003).
Current clinical methodologies do not allow us to measure the impact of mortality 
caused by hypertrophic heart failure. However, it is well documented that 
hypertrophic heart failure has a considerable contribution to the mortality of 
patients (Braunwald et al., 2002; Lips et al., 2003).
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Coronary heart disease is estimated to cost the UK economy a total of £7,055 
million in 1999 alone. This represents a cost that is higher than that for any other 
single disease for which a comparable analysis has been carried out (Petersen et 
al., 2003).
Regardless of the enormous cost of the disease in the UK economy, the death 
rate from CHD in the UK is amongst the highest in the world (Petersen et al.,
2003). Clearly, current strategies for disease prevention and therapy are not 
entirely adequate, even if the rate of deaths from CHD has been falling in the UK. 
Deaths from cardiovascular diseases constituted 40% of all causes of death in 
the UK in 2001 (Petersen et al, 2003). Coronary Heart disease is accountable for 
half of them and is the single biggest killer in the UK alone.
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1.2 CELL DEATH
The mode of cell death of the cardiomyocytes in ischaemia-reperfusion injury 
involves both necrosis and apoptosis (Kajstura et al., 1996; Grubel et al., 1998; 
Takahashi and Ashraf, 2000 and Gill et al., 2002). The extent to which each form 
of cell death contributes to the formation of the infarct is not yet clear. Although 
both necrosis and apoptosis result in the death of the cell, they differ in several 
morphological and cellular regulatory features.
1.2.1 Necrosis
Necrosis is a rapid and irreversible process that occurs when cells are severely 
damaged (Table 1.1). Necrosis is characterised by mitochondrial and 
cytoplasmic swelling, membrane rupture and cell lysis. The release of the cellular 
contents into the extracellular milieu causes further damage to neighbouring 
cells, leading to secondary inflammation. Phagocytosis of the remnants is 
delayed until accumulation of inflammatory cells. The resulting lesions contain 
groups of necrotic cells and inflammatory leucocytes (Saraste and Pulkki 2000; 
Yaoita et al., 2000; Gill et al., 2002 and Krijnen et al., 2002).
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1.2.1.1 Necrosis in myocardial ischaemia
Myocardial necrosis has been well documented in animal studies, and it has 
been shown that it develops rapidly after ischaemia (Zhao and Vinten-Johansen,
2000). Work done in rat hearts where the left coronary artery was occluded for 
10-30 minutes and reperfused for 120 minutes, showed that myocytes undergo 
necrosis after 20 minutes of occlusion and 26.6% percent of the cells in the 
infarct area were found to be necrotic in this study (Takahashi and Asraf, 2000). 
A similar study in rats has also shown that necrotic cell death is observed in 
cardiomyocytes in heart that was subjected to coronary artery occlusion for 20 
minutes to 7 days. The results show that necrotic cells do exist in the infarct area 
and that the amount of necrotic cells was increasing with increasing duration of 
occlusion and peaked after 1 day. However, the study showed that apoptosis 
was the main form of cell death of the cardiomyocytes in the infarct area (Grubel 
etal., 1998).
Similarly, in a chronic canine model where the heart was subjected to 6-72 hours 
of reperfusion following 1hour of ischaemia, the necrotic area increased with 
increasing time of reperfusion and peaked after 24 hours of reperfusion (Zhao et 
al., 2000).
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1.2.2 Apoptosis
Apoptosis is used as a contrasting term to necrosis. Apoptosis is a highly 
organised and energy dependent form of death distinguished in its later stages, 
by the activation of a specific group of proteases, the caspases. Apoptosis is 
characterised by membrane blebbing, cell shrinkage and formation of apoptotic 
bodies, chromatin condensation, DNA fragmentation and exposure of 
phosphatidyl serine on the outer leaf of the plasma membrane prior to membrane 
disintegration, finally leading to cell death. There is no resulting inflammation and 
the apoptotic cells are phagocytosed (Saraste and Pulkki 2000; Yaoita et al., 
2000; Gill et al., 2002 and Krijnen et al., 2002). Table 1.1 shows the main 
differences between apoptosis and necrosis.
1.2.2.1 Apoptosis in ischaemia and hypertrophy
Apoptotic cell death is an important process in the pathology of heart disease 
(Fliss and Gattinger, 1996 and Narula et al., 1996). Myocyte apoptosis has been 
demonstrated in humans suffering from myocardial infarction as well as in rabbit, 
rat and mouse models of cardiac ischaemia or ischaemia followed by reperfusion 
(Gottlieb et al., 1994; Cheng et al., 1996; Tomei and Umansky, 2001; Stephanou 
et al., 2001; Scarabelli et al., 2002a). In order to prevent extensive death after an 
ischaemic episode, the myocardium needs to be reperfused to restore the
18
TABLE 1.1
Apoptosis vs. necrosis (Adapted from Yaoita et al., 2000)
Apoptosis Necrosis
Plasma membrane Intact until late in the process Destroyed early
Morphological features • Chromatin condensation
• Nuclear fragmentation
•  No mitochondrial swelling 
until late
• Cell shrinkage
•  Swelling of entire cytoplasm
• Mitochondrial and organelle 
swelling
Biochemical features •  DNA fragmentation by 
endonucleases
• Protein degradation by 
caspases
• Surface exposure of 
phosphatidyl serine
• Non-specific DNA degradation
•  Non specific protein degradation
Fate Heterophagic elimination and 
little inflammation
Cell lysis and secondary 
inflammation
Biological meaning Physiological and pathological, 
tightly regulated
Accidental and unregulated
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nutrient and oxygen supply. However, reperfusion has been shown to result in 
augmentation of the damage in the myocardium. Two hypotheses have been 
brought forward to explain the injury after reperfusion (Ashraf, 1997):
• The Calcium hypothesis,
• and the free radical hypothesis.
The calcium hypothesis suggests that ischaemia induces a defect in the 
cardiomyocyte’s ability to regulate calcium and upon reperfusion the cell 
accumulates toxic levels of calcium. Calcium overload can be detrimental to the 
fate of the cell and can cause cell death. Upon reoxygenation mitochondria 
excessively accumulate calcium, which compromises ATP synthesis (Ashraf, 
1997).
The calcium influx occurs upon reperfusion through the damaged sarcolemma 
(Ashraf, 1997). Calcium influx activates Ca-dependent cysteine proteases, 
calpains, which can activate pro-caspase-12 (Yaoita et al., 2000). Calpains can 
also cleave Bax, promoting its antiapoptotic effects (Gill et al., 2002).
The free radical hypothesis of reperfusion injury is based on the rationale that 
partially reduced forms of molecular oxygen including the superoxide anion (0 '2), 
hydrogen peroxide (H20 2), singlet oxygen (10 2) and hydroxyl radical ( OH) are 
produced at the time of reperfusion or introduction of molecular oxygen 0 2. Free 
radical scavengers, such as superoxide dismutase (SOD) and catalase, can 
reduce the infarct size in regional ischaemia model and support the free radical
20
hypothesis (Asraf, 1997). The free radicals are highly reactive and can readily 
oxidise lipids and proteins causing damage to a number of enzymes and cell 
membranes. Asraf proposes that free radicals might be inducing membrane 
defects which promote calcium entry, thus unifying both these theories (Asraf, 
1997).
H2O2 treatment has been shown to induce cytochrome C release, activation of 
caspase-3 and poly-ADP-ribose polymerase (PARP) cleavage (von Harsdorff et 
al., 1999a). Also, free radicals can directly induce mitochondrial and DNA 
damage and p53 activation (Ashraf, 1997).
Activation of caspases occurs in cardiomyocytes through two main pathways. 
The first pathway is the death receptor pathway (Fig. 1.1).
Both of the death receptors Fas and TNF-a Receptor are involved in ischaemia 
reperfusion injury in the heart. Fas has been shown to be involved in cell death 
following myocardial ischaemia (Jeremias et al., 2000). TNF-a can also induce 
apoptosis in cardiomyocytes (Krown et al., 1996). Activation of the Death 
receptors lead to a cascade of events that lead to the activation of a specific 
caspase, caspase-8 (Fig. 1.1).
The second major apoptotic pathway involves the mitochondrion and is therefore 
called the mitochondrial pathway. Mitochondria are one of the most important
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organelles in the heart. They are not only producing essential energy for the 
cardiomyocytes, but can also regulate its survival. The Bcl-2 family of apoptosis 
regulatory proteins are acting on the mitochondrion and free radicals can be 
produced in the mitochondrion.
Cytochrome C release from the mitochondrion is one of the main mechanisms of 
apoptosis in cardiomyocytes. Cytochrome C release results in formation of the 
apoptosome, a protein complex formed by Apaf-1 (apoptosis promoting factor-1), 
cytochrome C and procaspase-9, in the presence of dATP. Formation of the 
apoptosome results in cleavage of procaspase-9 to active caspase-9 and 
activation of caspase-3 (Fig. 1.1).
Caspase-3, or executioner caspase, so called because it is activated by both the 
major apoptotic pathways and to differentiate it from caspases 8 and 9 (the 
activating caspases) that activate it, cleaves a number of proteins in the cell and 
activates caspase-activated DNAse (CAD) that is needed for DNA fragmentation 
and is one of the last steps in a point of no return for apoptosis (Fig. 1.1).
There is a great need to characterise the pathways that regulate apoptosis in the 
heart, in order to establish new therapeutic strategies in failing hearts. There is 
considerable knowledge of the pathways that lead to activation of caspases from 
extracellular signals and from mitochondrial damage. There is also considerable 
interest in genes that are characterised as anti-apoptotic such as the inhibitors of
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apoptosis (lAPs) (Fig. 1.1), which inhibit the onset of apoptotic cascades by 
interacting with caspases and preventing their activation (Goyal, 2001). However, 
there is so far little knowledge on how these pathways are regulated and on ways 
that we could exploit them in order to minimise the amount of cell death that 
occurs in the heart after hypoxia/reoxygenation.
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Figure 1.1. Schematic overview of major apoptotic pathways involved in 
ischaemic cardiomyocytes. Arrows indicate activation, whereas clubs indicate 
inhibition.
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Cell death in hypertrophic diseases only appears in the late stages of the disease 
as a result of heart failure. The heart is unable to pump blood efficiently around 
the body and as a result the blood supply to the heart itself is compromised. The 
pathways that are responsible for activation of apoptosis in these cases are 
generally the same as in the case of myocardial ischaemia.
The pathways involved in the early stages of the hypertrophic responses and that 
lead to an increased cell size, increase in protein:DNA ratio and activation of 
specific genes will be examined later on when the various pathways are 
discussed in more detail.
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1.3 Signalling Pathways in cardiomyocytes that are involved in 
Ischaemia/reperfusion and hypertrophy
Protein kinases constitute the main mechanism of signal transduction in the cells 
and have been involved in every aspect of cell life regulating cell homeostasis 
and driving the cell to grow, divide, differentiate or die (Johnson and Lapadat, 
2002).
Protein kinases are enzymes that covalently attach phosphate to the hydroxyl 
group of serine, threonine or tyrosine of specific proteins inside cells. Such 
phosphorylation of proteins can control their enzymatic activity, their interaction 
with proteins and other molecules, their location inside the cell, and their 
propensity for degradation from proteases. The kinases are divided into two main 
groups, according to the hydroxyl group of the amino acid that they 
phosphorylate. The two groups are the Ser/Thr kinases and the Tyr kinases 
(Sugden and Bogoyevitch, 1995; Bogoyevitch, 2000; Yaoita et al., 2000; Michel 
et al., 2001; Johnson and Lapadat, 2002).
In cardiomyocytes, protein kinases can regulate contraction, ion transport, fuel 
metabolism, growth and survival or death (Sugden and Bogoyevitch, 1995). We 
will examine the most relevant kinases that are involved in ischaemia/reperfusion 
and in hypertrophy in turn.
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1.3.1 Mitogen Activated Protein Kinases (MAPK)
MAPKs are Ser/Thr kinases that regulate the expression of specific sets of genes 
and can modulate specific responses to extracellular stimuli (Johnson and 
Lapadat, 2002).
They are part of signalling cascades consisting of three levels, a MAPK kinase 
kinase, which activates a MAPK kinase, which finally activates the MAPK (Fig. 
1.3) (Sugden and Bogoyevitch, 1995; Bogoyevitch, 2000; Yaoita et al., 2000; 
Michel et al., 2001; Johnson and Lapadat, 2002). MAPKs compose a family of 
protein kinases whose function and regulation have been conserved from 
unicellular organisms to humans (Johnson and Lapadat, 2002). They are 
phosphorylated after activation of G-protein coupled receptors, and receptor 
protein tyrosine kinases (Fig. 1.3) (Sugden and Bogoyevitch, 1995; Bogoyevitch, 
2000; Yaoita et al., 2000; Michel et al., 2001; Johnson and Lapadat, 2002).
MAPKs are divided into three groups. In the heart the three groups are 
comprised of the:
• Extracellular signalling regulated kinases (ERK -1 and -2, or p42 and p44 
MAPK),
• BMK1/ERK 5 or Big MAPK.
• Jun N-terminal kinases 1 and 2 (JNK 1 and 2)
• P38 MAPKs (p38a, p38P, p38-2, SAPK-3/p38y and SAPK-4/p388).
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Figure 1.3 Schematic representation of the extracellular signal regulated 
kinases. Various stimuli induce activation of membrane bound receptors that 
activate MEKKs that in turn activate MEKs resulting in phosphorylation of ERK, 
JNK or p38. Activated ERK, JNK and p38 translocate to the nucleus and activate 
a number of transcription factors.
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All 4 types of MAPKs have been implicated in modulation of apoptosis in 
cardiomyocytes after ischaemia reperfusion injury (Sugden and Bogoyevitch, 
1995; Bogoyevitch, 2000; Yaoita et al., 2000; Michel et al., 2001) and will be 
discussed in more detail in turn.
1.3.1.1 Extracellular Signalling Regulated protein Kinases (ERKs) and Big 
Mitogen Activated protein kinases (BMK-l/ERK-5)
ERKs have been shown to be involved in cardioprotection in the heart (Sugden 
and Bogoyevitch, 1995; Bogoyevitch, 2000; Yaoita et al., 2000; Michel et al.,
2001). Inhibition of ERKs by PD98059 increased the number of apoptotic rat 
neonatal cardiomyocytes after anthracycline exposure (Zhu et al., 1999). More 
importantly inhibition of ERKs augmented the injury caused by 
ischaemia/reperfusion in rat neonatal cardiomyocytes and rat perfused hearts 
(Yue et al., 2000). Studies on transgenic mice that were heterozygous for ERK 2 
have shown enhanced infarction areas after ischaemia/reperfusion whereas 
transgenic mice with activated MEK1-ERK1/2 in the heart were largely resistant 
to ischaemia/reperfusion injury. In addition to infarct areas the amount of DNA 
laddering and TUNEL positivity was also reduced in the MEK1 transgenics 
compared to littermate controls after ischaemia reperfusion injury (Lips et al.,
2004).
Although, not much is known about the role of BMK1 in cardiomyocytes, it has 
been shown to be important in cardiac development, as ERK57' mice have
29
malformed hearts and die on embryonic day 10.5 (Regan et al., 2002). Work on 
cell lines has revealed that ERK5 is also antiapoptotic. PC-12 cells exposed to 
oxidative stress demonstrated increased amount of apoptosis after inhibition of 
BMK-1 (Suzaki et al., 2002). In similar work, overexpression of dominant 
negative BMK-1 in MEF-7 cells resulted to dose dependant cell death and cell 
death augmentation after oxidative stress (Weldon et al., 2002).
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13.1,2 Jun N-terminal Kinases
Oxidative stress in adult rat hearts has been linked with activation of JNK; JNK 
activation leads to cell death which can be diminished by overexpression of 
dominant negative SEK-1, an upstream activator of JNK (Aoki et al., 2002). 
Overexpression of constitutively active SEK-1 led to induction of apoptosis (Aoki 
et al., 2002).
Administration of antisense constructs of JNK-1 and -2 to perfused hearts has 
shown that JNK-1 and not -2 is responsible for induction of apoptosis in the heart 
after ischaemia reperfusion injury (Hreniuk et al., 2001).
13.1.3 P38 Kinases
Similar to JNK, p38 inhibition resulted in decrease in apoptosis and improved 
postischaemic cardiac function in perfused rat hearts and in rat neonatal 
cardiomyocytes (Ma et al., 1999; Mackay and Mochly-Rosen, 1999; Yue et al.,
2000). Furthermore, administration of vanadate, an inhibitor of p38 MAPK 
phosphatase rendered rat neonatal cardiomyocytes more susceptible to 
ischaemia reperfusion injury in a dose dependant manner over time (Cong et al.,
1997).
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1.3.2 Protein Kinase B
Another Ser/Thr kinase that has an important function in regulating apoptosis is 
protein kinase B (PKB)/Akt. Akt is activated by insulin (Kulik et al., 1997), insulin­
like growth factor-1 (Oh et al., 1998) and gp130 signalling (Mackay and Mochly- 
Rosen, 2000). Akt’s function in attenuating apoptosis has been linked with its 
ability to phosphorylate and inactivate the proapoptotic gene BAD (Fig. 1.1) 
(Yaoita et al., 2000).
Insulin Growth factor treatment of cardiomyocytes resulted in activation of PI-3K 
and Akt and protected cells from apoptotic cell death after ischaemia reperfusion 
injury. Overexpression of dominant negative PI-3K and Akt attenuated apoptosis 
in this model of ischaemia reperfusion injury demonstrating the protective effects 
of the PI-3K/Akt pathway (Mackay and Mochly-Rosen, 2000). Hearts from 
transgenic mice overexpressing IGF-1 were more resistant to apoptotic cell death 
after ischaemia reperfusion. This was attributed to activated Akt, as wortmanin, 
an inhibitor of Akt, attenuated the resistance of the cardiomyocytes to ischaemia 
reperfusion injury (Yamashita et al., 2001). In a rat model of cardiac ischemia 
reperfusion injury in vivo, gene transfer by adenoviruses of constitutively active 
mutant Akt reduced infarct size, the number of apoptotic cells and prevented 
hypoxia-induced abnormalities in cardiomyocytes, calcium transients and 
shortening (Matsui at al., 2001).
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1.3.3 Protein Kinase C
Protein kinase C is a family of Ser/Thr kinases. There are more than 16 isoforms 
of protein kinase C isolated from mammalian cells (Dempsey et al., 2000). 
Protein kinase C family members are involved in almost all aspects of cellular 
physiology, such as proliferation, mitogenesis, apoptosis, platelet activation, 
remodelling of actin cytoskeleton, modulation of ion channels, secretion, 
membrane permeability, cell migration, contraction and hypertrophy (Toker, 
1998; Dempsey et al., 2000). PKC was initially discovered by Nishizuka and 
coworkers and soon after it was shown to be the main target of diacyl glycerol 
(DAG) and phorbol esters. PKC is activated by Ca+2, phosphatidyl serine (PS) 
and DAG (Mackay & Mochly-Rosen, 2001).
The isoforms of PKC are divided into three subfamilies according to sequence 
similarities and activation profiles (Table 1.2):
1. Conventional PKCs (cPKCs) that include the isoforms a, ft, (3n and y.
2. Novel PKCs (nPKCs) including 6, £, r| and 0.
3. Atypical PKCs (aPKC) that have as members the £ and A (also known as i) 
isoforms.
4. The recently described PKCs that include the isoforms p (also known as 
protein kinase D) and v.
5. Lastly in the PKC family there is a category of kinases included that are 
called Protein kinase C related kinases (PRK). The PRK1-3 are also 
known as PKN.
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Table 1.2. Protein Kinase C subfamilies and activation profiles.
PKC
Subfamilies
Isoforms Co-Factor Activator Lipid
activators
Conventional
(cPKC)
o, Pi, pn Phosphatidyl 
Serine and Ca+2 
dependancy
Diacyl
gycerol
Phospho
inositodes,
PMA,
Arachidonic 
acid, LPA, 
Lyso PC
Novel (nPKC) 5, e, n> 0 Phosphatidyl 
Serine, Ca+2 
independent
Diacyl
glycerol
Phospho
and
phosphatidyl
inositodes,
PMA,
arachidonic 
acid, LPA, 
Lyso PC
Atypical
(aPKC)
C A/i Phosphatidyl
Serine
DAG
independent
Phosphatidyl
inositodes,
Ceramide
Recently
described
p/PKD, v Phosphatidyl
Serine
DAG
independent
PKC related
kinases
(PRK/PKN)
PRK1,
PRK2, PRK3
34
The PKC isoenzyme specificity is determined by their subcellular localisation. 
After activation each isoenzyme is translocated to a unique subcellular site, 
where it is anchored by specific proteins the RACKS.
The cPKCs are activated by PS in a Ca+2 dependent manner. They bind to and 
activated by DAG, which increases their specificity for PS that in turn increases 
their affinity for Ca+2 (Table 1.2).
nPKCs are activated by DAG and require PS as a cofactor, like cPKCs, but they 
have lost dependency to Ca+2 (Table 1.2).
aPKCs and the recently discovered PKCs do not respod to DAG or Ca+2, but 
require PS as a cofactor (Table 1.2).
Several lipid second messengers have been shown to activate PKC family 
members. Activation of PLC, leads to production of 1, 2, sn diacyl glycerol (DAG) 
and phosphoinositodes InsP, or Ins-1, 4-P2, or Ins-1, 4, 4-P3. Phosphoinositodes 
lead to release of Ca+2 from intracellular stores that with DAG and PS induce a 
conformational change to PKC, which binds to the plasma membrane and 
becomes activated (Table 1.2). Other lipid second messengers have been shown 
to activate PKCs as well (Table 1.2). The PI-3K products Phosphatidyl Inositols 
Ptdlns-3, 4-P2 and Ptdlns-3, 4, 5-P3 have been shown to activate nPKCs and 
aPKCs. Arachidonic acid is able to contribute to PKC activation as well, but only
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when DAG or phorbol 12-myristate-13-acetate (PMA) is present (Table 1.2). LPA 
and Lyso PC also activate PKCs in the presence of DAG (Table 1.2). Ceramide, 
which is produced by TNFa cell stimulation, is able to activate PKC? and Raf-1 
(Table 1.2).
PKC has been shown to be phosphorylated by the PI-3K dependent kinase PDK-
1. PDK-1 phosphorylation releases PKC from the membrane and allows it to 
remain in the cytosol in an inactive form.
1.3.3.1 Protein Kinase C and apoptosis
Activation of PKC by PMA can be either pro- or anti- apoptotic depending on cell 
type (Lucas and Sanchez-Margalet, 1995).
Overexpression of a PKCa dominant negative construct was shown to induce 
apoptosis in COS-1 cells (Whelan and Parker, 1998) and in salivary gland cells 
(Dempsey et al., 2000). PKCpii was protective against c-myc induced apoptosis 
in small lung carcinoma cells (Barr et al., 1997). PKCA/i and PKC? protect K562 
leukemia cells (Murray and Fields, 1997) and UV irradiation decreased the 
activity of PKC? and PKCA/i (Berra et al., 1997).
Inhibition of PKCS in salivary gland epithelial cells suppresses caspase activation 
and DNA fragmentation (Reyland et al., 1999). Dominant negative PKCS 
overexpression inhibited phorbol ester induced apoptosis in prostate cancer cells
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(Fujii et al., 2000). Also, proteolytic activation of PKCS by caspases produces a 
catallyticaly active fragment in cells induced to undergo apoptosis by DNA 
damaging agents (Emoto et al., 1996).
1.3.3.2 Protein Kinase C in ischaemia reperfusion injury
Cardiac myocytes express at least six different PKC isoenzymes (Disatnik et al., 
1994), but preconditioning results in activation of only PKCS and PKCs (Gray et 
al., 1999). Preconditioning is a phenomenon observed in cardiac cells, where 
short periods of ischaemia are able to minimise the amount of cell death 
occurring after a major ischaemic incident that follows those short periods of 
ischaemia. So the cell seems to become “conditioned” to ischaemia through brief 
ischaemic episodes.
PKC a and £ were shown to be translocated after periods of hypoxia in 
cardiomyocytes, whereas the amount of membrane associated PKCS was 
reduced (Goldberg et al., 1997). PKCa and e were also shown to be membrane 
associated after brief periods of ischaemia and reperfusion in rat hearts (Albert 
and Ford, 1999).Introduction of PKCe selective inhibitory peptide eV1-2 into 
neonatal cardiomyocytes prevented protection from preconditioning, whereas 
inhibitors of other PKC isoenzymes had no effects (Gray et al., 1999). A PKCs 
selective translocation agonist caused significant reduction in ischaemia induced 
cell death of neonatal and adult cardiomyocytes (Dorn et al., 1999). When PKCe 
was introduced as a transgene in mouse hearts there was a faster recovery and 
a significant reduction in cardiac damage after prolonged no flow ischaemia
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(Dorn et al., 1999). Also in isolated cardiomyocytes, perfused hearts and 
transgenic mice the PKCS and e were shown to have opposing effects on 
protection with the latter to have cardioprotective effects (Chen et al., 2001). 
Experiments with constitutive active constructs of PKCS and e have shown that 
their opposing effects on apoptosis are due to a differential regulation of 
extracellular regulated kinases. PKCe was shown to be an activator of p42/44 
and having no effects on p38 and JNK, whereas PKCS had exactly the opposite 
effects (Heidkamp et al., 2001).
1.3.3.3 Protein Kinase C in hypertrophy
PKC 6 and e have both been shown to be involved in induction of hypertrophy 
(Chen et al., 2001). Endothelin-1, an inducer of hypertrophy, was shown to result 
in translocation of PKC S and e, whereas phenylephrine treatment only induced 
PKCe translocation. In both cases, the translocation of the PKC isoforms resulted 
in MAPK p42/44 activation (Clerk et al., 1994). Another study has shown that 
PKC a, but not ft, 6, e or ? induces hypertrophy as shown by increase in cell size, 
ANF expression and [H+] Leucine incorporation. Overexpression of dominant 
negative PKCa blocked hypertrophy. Furthermore, PKCa increased ERK1/2 
activation, whereas dominant negative PKCa reduced activation of ERK1/2 by 
PMA and dominant negative MEK1 inhibited PKCa induced hypertrophy (Braz et 
al., 2002).
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1.3.4 Phospholipases
The phospholipases are a large and diverse group of enzymes with a wide 
variety of biological functions, from membrane synthesis to generation of 
signalling molecules. Phospholipases have been shown to be involved in hypoxia 
reoxygenation in the heart and as such they are good candidates for further 
research in their role in hypoxic injury in the heart.
Phospholipases are categorised into four classes according to the position of the 
hydrolytic cleavage of their substrate. The four classes and the position of the 
hydrolysis are schematically represented on Fig. 1.3.1.
1.3.4.1 Phospholipase A2
Phospholipases of the A class are involved in membrane integrity and the 
production of biological active molecules. They are further divided into two 
categories: PLAi and PLA2. PLA2 are able to hydrolyse the sn-2 bond pf 
phospholipids and produce Lysophospholipids and fatty acids. PLA2s are 
classified into three groups:
1. cytosolic PLA2 (cPLA2)
2. Ca+2-dependent secretory PLA2 (sPLA2). They are of low molecular size 
with a dependency on milimollar quantities of Ca+2 and
3. Ca+2-independent intracellular PLA2 (iPLA2).
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They are of high molecular weight (85kD), are able to translocate to 
membranes in response to increments of intracellular Ca+2 and are specific 
for phospholipids that contain arachidonic acid on sn-2
PLD
o = p
PLC
HC CH
PLA
o=c o=c
Figure 1.3.1. Hydrolytic sites of the different phospholipases on a glycerol 
phospholipid. PLAi and PLA2 cleave at the sn-1 and sn-2 positions, respectively, 
to generate a lysophospholipid and a free fatty acid. PLB enzymes cleave at both 
the sn-1 and sn-2 positions. PLC hydrolyses the bond between the glycerol and 
phosphate, often generating important signalling molecules, such as 
diacylglycerol and phosphoinositodes. PLD removes the polar head group (x) to 
generate phosphatidic acid. (Adapted from Brown et al., 2003).
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Cyclic AMP (cAMP), PKC and MAPK have been shown to decrease the activity 
of PLA2, either by direct phosphorylation or by regulation of PLA2 inhibitory 
proteins, such as lipocortins and annexins.
We will study the effects of iPLA2 in more detail, as the existence of a well used 
iPLA2 inhibitor, bromoenol lactone, facilitates the discovery of the possible role of 
iPLA2 in our system.
1.3.4.1.1 Involvement of iPLAs in ischaemia and hypertrophy
Phospholipase A2 has been shown to be involved in apoptosis. Fas and TNF 
have been shown to activate PLA2 in MCF7 cells and Bcl-2 and Bcl-x 
overexpression are able to inhibit arachidonic acid release (Jaattela et al., 1995). 
It was later found that iPLA2 was the PLA2 involved in Fas mediated fatty acid 
release, and that the role of iPLA2, although not essential was at least modifying 
in apoptosis in U937 cells (Atsumi et al., 1998).
Similarly, bromoenol lactone (BEL), a PLA2 inhibitor, was able to attenuate 
lysosomal rupture and apoptosis caused by prolonged exposure to H2O2 . In 
addition, Bcl-2 overexpression prevented PLA2 activation, lysosomal rupture and 
cell death, showing a role of PLA2 as a positive modulator of cell death in 
oxidative stress (Zhao et al., 2001a; Zhao et al., 2001b).
Likewise, in RAW264.7 cells and in mouse peritoneal macrophage cultures, 
iPLA2 was shown to be the form of phospholipase involved in oxdative stress 
(Martinez and Moreno, 2001). Only iPLA2 was shown to be active after H20 2
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sress. Furthermore, the arachidonic acid release, due to increased activity of 
iPLA2, was dose dependent to H2O2 . Arachidonic acid release by H2O2 was 
blocked by BEL. In addition, antisense CPLA2 had no effect on the arachidonic 
acid release showing that iPLA2 was the isoform activated by H20 2 (Martinez and 
Moreno, 2001).
Recently, it was shown that iPLA2 is crucial for caspase-independent cell death. 
Purified PLA2 induced nuclear shrinkage in permeabilised cells and PLA2 
inhibitors prevented hypoxic nuclear shrinkage and cell death. Hypoxia caused 
elevation of PLA2 activity and translocation to the nucleus. Knockdown of iPLA2 
delayed nuclear shrinkage and cell death (Shinzawa and Tsujimoto, 2003).
A number of experiments have shown the involvement of PLA2 in ischaemia 
reperfusion injury in hearts (Prasad et al., 1991; Schwertz and Halverson, 1992; 
Sargent et al., 1996; Vesterqvist et al., 1996). Interestingly, although BEL was 
able to increase coronary flow and decrease lactose dehydrogenase release 
during reperfusion, the presence of 5  hydroxy decanoate (a KAtp inhibitor) in the 
perfusate during reperfusion abolished the cardioprotective effects of BEL, linking 
Ka t pchannel cardioprotection with PLA2 (Sargent et al., 1996).
Vassopressin induced arachidonic acid release in H9c2 cells (of cardiac origin), 
caused an influx of Ca+2 and activation of PKC a,pl,e and 6. PKC was shown in 
turn to be able to modulate arachidonic acid release through a MAPK pathway, 
creating a positive feedback loop (Chen and Chen, 1999). Also, iPLA2 was 
shown to be involved in lethal malignant tachyarrhythmias during acute cardiac 
ischaemia (Mancuso et al., 2003).
There is not much evidence for involvement of PLA2 in hypertrophy, however Haq 
et al. (2003) shown that cytosolic PLA2 is a negative regulator of growth, 
specifically of striated muscle. Normal growth of skeletal muscle and normal and 
pathologic stress-induced hypertrophic growth of the heart are exaggerated in 
Pla2g4a -/- mice, which lack the gene encoding cytosolic PLA2. They were able 
to show that absence of PLA2 leads to sustained activation of IGF-1, which 
results from the failure of PDK-1 to recruit and phosphorylate PKC?, a negative 
regulator of IGF-1. Arachidonic acid addition was able to restore activation of 
PKC?, correcting IGF-1 signalling.
In conclusion, iPLA2 is an important modulator of cell death following a hypoxic 
insult and it has a considerable role in cardiac hypertrophy.
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1.4 Ubiquitm ation
Ubiquitination or ubiquitytation is a type of protein modification, where a small 
protein, ubiquitin, is attached covalently to other proteins. We are interested in 
the process because ubiquitination of a protein may lead to its destruction and it 
is part of the apoptotic process. As we will show later on, number of enzymes 
involved in the ubiquitination process, like the inhibitors of apoptosis (lAPs) are 
also involved in the apoptotic pathway.
Ubiquitin is a 76 amino acid globular protein that is highly conserved from yeast 
to human. The process of ubiquitination is essential for the degradation of 
proteins whose levels are regulated either constitutively, or in response to the 
cellular environment. As such, ubiquitination, is involved in most if not all of 
cellular processes such as cell cycle progression, organelle biogenesis, 
apoptosis, cellular differentiation, protein transport, inflammation, antigen 
processing, DNA repair and stress responses (Weissman, 2001).
Ubiquitination is a multistep process (Fig. 1.4.1), involving at least three types of 
enzymes. First, an ubiquitin activating enzyme (E1) forms a thiol-ester bond with 
the carboxy-terminal glycine of ubiquitin in an ATP dependant process. Then a 
ubiquitin-conjugating enzyme, or ubiquitin-carrying enzyme (UBC or E2) accepts 
ubiquitin from the E1 enzyme by a trans-thiolation reaction, again involving the 
carboxy terminus of ubiquitin. Finally, an ubiquitin protein ligase (E3) catalyses 
the transfer of ubiquitin from the E2 enzyme to the e-amino group of a lysine 
residue on the substrate (Hochstrasser, 1996; Pickart, 2000; Weissman, 2001; Di 
Fiore et al., 2003).
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Figure 1.4.1. The ubiquitination pathway. Free ubiquitin (Ub) is activated by an 
ATP-dependent manner with the formation of a thiol-ester linkage between E1 
and the carboxyl terminus of ubiquitin. Ubiquitin is transferred to one of a number 
of different E2s. E2s associate with E3s which might or might not have substrate 
already bound. For HECT domain E3s, ubiquitin is next transferred to the active 
site cysteine of the HECT domain followed by transfer to substrate (S) (as 
shown) or to a substrate bound multi-ubiquitin chain. For RING E3s, current 
evidence suggests that ubiquitin might be transferred directly from the E2 to the 
substrate. Adapted from Weissman, 2001.
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Ubiquitination is traditionally linked with protein degradation by an ATP- 
dependent multi-subunit protease called the proteasome (Kloetzel, 2001; 
Weissman, 2001). In addition to its role in such protein degradation, 
ubiquitination also functions as a signal that targets proteins for destruction in 
vacuoles and/or lysosomes (Hicke, 2001). Although, protein degradation is one 
of its key tasks, other cellular functions, such as regulation of translation (Liao et 
al., 1998; Hsueh et al., 2001; Kentsis et al., 2001; Adachi et al., 2004), 
transcription, (Muratani and Tansey, 2003), transcription factors (Hoppe et al., 
2000; Kaiser et al., 2000; Kamura et al., 2000; Ohh et al., 2000), kinases (Baldi 
et al., 1996; Deng et al., 2000) and DNA repair (Spence et al., 1995; Bailly et al., 
1997; Hofmann and Pickart, 1999) have been shown to be controlled by 
ubiquitination.
A protein that has been ubiquitinated may have various fates. For example, 
mono-ubiquitinated p53 is exported from the nucleus, whereas poly-ubiquitinated 
p53 is retained in the nucleus and degraded. Both mono and poly-ubiquitination 
of p53 is catalysed by the same enzyme, Mdm2 (Li et al., 2003). The authors 
suggest that the level of ubiquitination is determined by the levels of Mdm2 in a 
dose dependant manner. This example shows that ubiquitination is a versatile 
signal.
There are many levels of regulation that influence the specificity of the process. 
Specificity is largely generated by the proteins that recognise the substrates and 
mediate ubiquitination. But, as in the example above, the fate of the ubiquitinated 
protein is influenced by the type of the conjugate formed. Thrower et al. have
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shown that mono-ubiquitinated substrates are not destroyed by the proteasome, 
and that the shortest signal for recognition is a tetra-ubiquitin chain (Thrower et 
al., 2000). In addition, there are different ways of building a poly-ubiquitin chain, 
by using different lysine residues of ubiquitin. Also, intracellular location helps to 
determine the fate of the ubiquitinated protein.
Proteins can also be modified by the addition of small proteins other than 
ubiquitin. There is a growing list of ubiquitin like proteins (UBLs) that have been 
identified and characterised. As with ubiquitin, UBLs include a glycine at the 
carboxy terminus that forms an isopeptide bond with the e-amino group of lysines 
on the target protein. Of the UBLs that are homologous to ubiquitin the very first 
to be characterised was a protein that resembles a ubiquitin dimer, the ubiquitin 
cross-reactive protein (UCPR or ISG15) (Loeb and Haas, 1994). RUB1 from 
yeast, which stands for related to ubiquitin, also belongs in this group, and it is 
known as Nedd8 in metazoans. Other UBLs include SUMO-1 (small ubiquitin- 
reiated modifier, also known as UBL1), Sentrin or PIC-1 and Apg12 (Jentsch and 
Pyrowoiakis, 2000; Yeh et al., 2000). Apg12 is a UBL that lacks amino acid 
homology with ubiquitin. Apg12 is involved in a multienzyme process that 
resembles ubiquitination and mediates autophagy (Ohsumi, 2001).
In addition to UBLs, an increasing number of structurally unrelated proteins are 
found that contain domains homologous to ubiquitin. This ubiquitin domain 
proteins (UDPs) have a number of functions and are not known to be involved in 
protein modification. In the UDP group there are proteins that are ubiquitination 
substrates and proteins involved in the addition and/or the removal of ubiquitin
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from proteins. Some UDPs interact with the proteasome as well as with enzymes 
that are involved in mediating ubiquitination (Yeh et al., 2000).
Further specificity is introduced by the presence of deubiquitinating enzymes 
(DUBs) that cleave ubiquitin from residual proteasome associated peptides and 
from multiubiquitin chains (Weissman, 2001). DUBs are also important for 
processing immature ubiquitin, which is encoded on multiple genes and 
translated as fusion proteins either with other ubiquitin molecules or as the amino 
terminal component of two small ribosomal subunits (Finley et al., 1989). These 
are processed by a subfamily of DUBs called the ubiquitin carboxy-terminal 
hydrolases.
1.4.1 E1 Ubiquitin activating Enzymes
E1 is encoded by a single gene, which produces two isoforms, through 
alternative translation start sites (Handley-Gearhart et al., 1994). The localisation 
of the longer isoform is cell cycle regulated and its levels in the nucleus reach a 
maximum in G2 phase (Grenfell et al., 1994).
The carboxy terminal glycine of ubiquitin, SUMO-1 and UBLs is essential for 
activation by E1 (Yeh et al., 2000). However, SUMO-1 and UBLs require their 
own E1-like enzymes (Yeh et al., 2000). E1s and E1 -like enzymes share 
homology at their amino- and carboxy- terminals.
1.4.2 E2 Ubiquitin Conjugating Enzymes
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E2s are extremely diverse. There are at least 13 E2s (Ubc1-13) in yeast and at 
least 25 mammalian counterparts (Weissman, 2001). Of these Ubc 9 is 
dedicated to sumoylation and Ubc 12 to rubylation. Sumoyiation, rubylation and 
nedylation are protein modifications similar to ubiquitination with the difference 
that SUMO-1, RUB-1, or Nedd-8 is covalently attached to the modified protein 
instead of Ubiquitin. E2s share an approximately 35% homologous core of 14-16 
kD (Weissman, 2001). Their role is to receive Ubiquitin from E1 enzymes and 
transfer them to E3s.
1.4.3 Types o f E3 ubiquitin Ligases
There are two main types of E3 ubiquitin ligases. The HECT E3s and the RING 
finger E3s.
1.4.3.1 HECT E3s
The oncogenic strains of the Human Papillomaviruses (HPV) encode a protein 
called E6 that interacts with and inactivates the tumour suppressor protein p53. It 
was found that E6 acts as an adaptor for a cellular protein, called E6 associated 
protein (E6-AP), that catalyses the ubiquitination of p53 (Scheffner et al., 1993). 
The characterisation of E6-AP led to the discovery of a protein family that 
contains a highly conserved 350 amino acid domain at their carboxy termini 
called the HECT domain (for Homologous to the E6-AP carboxy terminus). This
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includes a cysteine that forms a covalent thiol-ester intermediate with ubiquitin 
(Huibregtse et al., 1995).
Another feature that is shared among many HECT E3s is the WW domain, which 
is involved in protein-protein interaction. It is characterised by a pair of 
tryptophans 20-22 amino acids apart, and an invariant proiine within a region of 
40 amino acids. WW domains interact with proline rich regions (Kay et al., 2000). 
Most WW HECT E3s contain another domain at the carboxy terminus, the C2 
domain that mediates translocation to the plasma membrane in response to 
increases in intracellular calcium (Plant et al., 2000).
1.4.3.2 RING finger E3s
The RING finger motif was first identified in the RING1 gene and was categorised 
as a type of Zn finger motif with DNA binding abilities (Freemont et al., 1991, 
Lovering et al., 1993). However, it was first linked with ubiquitination when it was 
observed that PRT1 (Proteolysis 1) protein, an N-end rule E31 from Arabidopsis 
thaliana, shared the RING finger motif with other proteins implicated in 
ubiquitination (Potuschak et al., 1998). Since then, most of the RING finger 
proteins that have been identified are implicated in ubiquitination.
1 The half life o f a protein is governed by a rule that states that the metabolic stability of a protein is 
determined by the identity o f its N-terminal residue. The N-terminal rule exists in prokaryotic and 
eukaryotic cells alike. Those signals that exist in the N-terminal o f proteins targeted for destruction are 
called N-degrons and the machinery that recognises the N-degrons and orchestrates the proteolytic 
destruction o f the degron-containing proteins, forms the N-end rule pathway. In eukaryotes the N-end rule 
pathway is part o f the ubiquitin system (Varshavsky, 1996).
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1.4.3.2.1 Structure of RING Finger
There are two consensus sequences for the RING finger motif: 
CX2CX(9-39)CX(1-3)HX(2-3)CX2CX(4-48)CX2C and CX2CX(9-39)CX(1-3)HX(2-3)HX2CX(4- 
48)CX2C (Weissman, 2001).
The Cys and His residues have Zn binding ability and the difference between the 
two types of motifs is on the amino acid of the fifth coordination site. When this is 
occupied by a Cys the RING finger is of the RING HC type and in the case of a 
His occupying the site it is of the RING H2 type. A schematic representation of 
the RING finger structure is given in figure 1.4.2.
The RING finger E3s can be further divided into two categories:
1. The Single subunit E3s and
2. The multisubunit E3s.
The single subunit E3s contain the substrate recognition element and the RING 
finger on the same polypeptide. Multisubunit E3s contain a small RING finger 
protein and a member of the cullin family of proteins, as well as other subunits 
(Weissman, 2001).
1.4.3.2.1.1 Single subunit E3s.
Single subunit E3s include the Mdm2 protein, which ubiquitinates p53, the proto­
oncogene c-Cbl, which ubiquitinates growth factor receptors and the inhibitors of 
apoptosis (lAPs) (Weissman, 2001). Parkin is also a RING finger E3 that
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contains two RING motifs at its carboxy terminus separated by an IBR (in- 
between RING), a region common to proteins that contain 2 RING motifs (Mizuno 
et al., 2001; Tanaka et al., 2004). Parkin also has an amino-terminal ubiquitin 
domain, making it a member of both the RING and UDP families. Mutations in 
Parkin’s RING are associated with juvenile Parkinson’s disease, and a synaptic 
vesicle associated protein (CDCrel-1) has been identified as a substrate for this 
E3 (Mizuno et al., 2001; Tanaka et al., 2004).
The RING finger is found in a number of diverse and unrelated proteins. So the 
sites of substrate recognition for RING proteins must be highly varied. The 
interactions of c-Cbl depend on its atypical SH2 domain and for the lAPs 
probably on the BIR domain. For Mdm2, interactions with p53 occur through its 
amino-terminal domain, whereas the RING finger lies on the carboxy terminus 
(Weissman, 2001).
1.4.3.2.1.2 Multisubunit E3s.
There are three main types of multisubunit E3s:
1. The Skp1 -Cullin-F-box complex (SCF complex),
2. the von Hippel-Lindau-Cul2/ElonginB/Elongin C (VCB-CUL2 complex), 
and
3. the Anaphase Promoting Complex (APC) (Fig. 1.4.3).
All three complexes contain a small RING finger protein and a member of the 
cullin family (proteins with homology to Cull, which was first shown to be 
involved in the cell-cycle exit in C. elegans). It appears that cullins act as a
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backbone that interacts with linker proteins that recruit the substrate recognition 
components (Fig. 1.4.3).
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Ffgiire 1.4.2. Schematic representation of the structure of the RING finger motif. 
C and H denote the Zinc binding amino acids.
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SCF VCB-CUL2 APC
Elongin B
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Cull
VHL
1 mD MK DXI UDCO ■ KDXI
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Figure 1.4.3. Schematic representation of the different types of multisubunit 
RING E3s. Light blue: substrate recognition protein, Grey: adaptor protein, Red: 
RING finger protein, Yellow: Cullins, Dark Green: E2 protein. (Adapted from 
Weissman, 2001).
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1.4.3.2.1.2.1 The Anaphase Promoting Complex
APC is the most intricate of the three, composed of at least 12 different 
components in the yeast. The first identified substrates for APC were mitotic 
cyclins, but other substrates have now been identified (Weissman, 2001).
1.4.3.2.1.2.2 The VCB-CUL2 complex
The VHL-CBC complex is composed of a dimer of elongin B and elongin C that 
form the adaptor proteins in this complex. The substrate recognition protein is 
mainly VHL, and mutants of VHL that fail to bind to the CBC core have been 
associated with malignacies in the von Hippel-Lindau disease (Iwai et al., 1999; 
Lisztwan et al., 1999). Hypoxia inducible factor 1a (HIF1 a), a regulator of 
vascular endothelial growth factor (VEGF), has been identified as a substrate for 
this E3 (Kamura et al., 2000). The VHL protein contains a suppressor of cytokine 
signalling box (SOCS-box) that interacts with the core of this E3 (Kamura et al.,
1998). SOCS-1 has been shown to act as a substrate recognition protein on a 
multisubunit E3 that regulates the half life of Vav and JAKs (Kile et al., 2002).
1.4.3.2.1.2.3 The SCF complex
SCF E3s recognise and ubiquitinate a large amount of phosphoproteins. The 
substrate recognition is made through proteins that contain a F-box motif and 
Skp1 is the main adaptor protein of the complex. One F-box protein is able to 
recognise more than one substrate, as is the case with the beta-Transducin- 
repeat-containing protein (pTRCP) (Fuchs et al., 2004). SCFpTRCP is able to
56
recognise both IkBo and p-catenin (Fuchs et al., 2004). In addition, nascent 
forms of HIV bound CD4 are indirectly targeted for degradation in the 
endoplasmic reticulum membrane by SCFpTRCP as the HIV encoded Vpu protein 
has phosphorylation sites similar to those of p-catenin and IkBo (Besnard-Guerin 
et al., 2004; Fuchs et al., 2004). Some F-box proteins are themselves 
ubiquitinated and targeted for degradation. This might be a way of autoregulating 
their levels. In addition, another SCF protein, Met30, has been shown to regulate 
the activity of Met4, a transcription factor. Multiubiquitination of Met4, that occurs 
in minimal media in yeast leads to protein degradation, whereas oligo- 
ubiquitination of Met4 in rich medium, leads to recruitment of Met4 on SAM gene 
promoters, rather than MET gene promoters and has no effect on the stability of 
the transcription factor (Kuras et al., 2002).
1.4.4 The Sensitive to Apoptosis Gene
One RING finger gene that was recently identified was named Sensitive to 
Apoptosis Gene (SAG) and was cloned as a factor that is induced after oxidative 
stress (Duan et al., 1999). SAG is a 13 kD protein, containing a C2H2C4 Zn-RING 
finger motif (Fig. 1.4.4). It was recently shown to be expressed in hypoxic 
conditions in the brain and to co-localise with newly produced radical oxygen 
species (ROS), indicating a possible function for SAG as an antioxidant. The 
RING finger motif of SAG has been shown to be important for its antiapoptotic 
function, as mutants of the SAG at the RING motif are unable to protect from 
apoptosis when overexpressed (Ohta et al., 1999a).
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Figure 1.4.4. Sequence alignment and schematic representation of the Sensitive 
to apoptosis gene proteins. A Sequence of Human SAG, B and C possible SAG 
isoforms resulting from alternative splicing in humans and D murine sequence of 
SAG protein. Amino acids in bold are non homologous aminoacids. Amino acids 
highlighted with red are site of protein phosphorylation by CKII, with yellow 
comprising the RING finger motif, with blue important for Zn binding, with green 
and pink parts of the protein resulting from alternative splicing.
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SAG was shown to be localised in the cytoplasm and nucleus of the cell and is 
ubiquitously expressed in many different organs and tissues, but predominantly 
in heart, brain and the gonads (Duan et al., 1999).
SAG belongs to the regulator of Cullins (ROC) family, that bind through cullin to 
the SCF multisubunit proteins (Ohta et al., 1999a). ROC1 has been shown to 
regulate the levels of Sic1, the yeast homologue of p27Kip1 (Ohta et al., 1999b). 
SAG has also been shown to be part of SCF box complexes that regulate the 
levels of p27 (Duan et al., 2001).
Additionally, SAG is overexpressed in several carcinomas (Sun, 1999; Huang et 
al., 2001; Sasaki et al., 2001), although over-expression of SAG alone is not 
enough to induce neoplastic transformation of cells (Huang et al., 2001). SAG 
was shown to promote S-phase and serum free growth of cells (Duan et al.,
2001) and down regulation of SAG, by transient transfection of an antisense SAG 
construct in cancer cells resulted in reduction of the proliferation rate of these 
cells (Huang et al., 2001) demonstrating the importance of SAG in control of cell 
proliferation. Furthermore, the involvement of SAG in cell proliferation was 
demonstrated in yeast, where it was shown by gene chip profiling to regulate 
expression of components of the cell cycle (Sun, 1999; Swaroop et al., 2000).
As SAG is shown to be an antiapoptotic factor that is expressed in the heart and 
that is upregulated by oxidative stress, there is a good possibility to have a role in 
hypoxic stress in cardiac cells.
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1.5 Ion Channels in the cardiomyocytes
The mechanical activity of the heart is controlled by electrical impulses. The 
electric impulses in the heart are a result of series of ion currents through the 
cardiac cell membrane that are regulated by specific ion channels. Any effect on 
an ion channel is bound to be met with serious effects on the cardiac cell 
physiology. For this reason we need to examine the ion channels of the heart in 
more detail.
The electric impulses are intrinsic to the heart, but are also modulated by 
neuronal activity through the autonomic nervous system. Specialized cells in the 
right atrium, known as the sino-atrial node, act as a pacemaker and the impulses 
are conveyed to all the atrial myocytes, leading to a coordinated depolarisation 
and contraction of the atria. On a surface electrocardiogram (ECG) atrial 
depolarisation can be visualised as a P wave (Fig. 1.5.1). The impulse from the 
sino-atrial node is also conveyed to specialised cells that connect the atria to the 
ventricles, known as the atrio-ventricular node. Then the electrical activity is 
conveyed to specialised fibres known as bundle branches, leading to rapid 
coordinated contraction of ventricular myocytes and coordinated contraction of 
the ventricles (Keating and Sanguinetti, 2001). Depolarisation of the ventricles 
can be visualised on the ECG as the QRS complex (Fig. 1.5.1). Ventricular 
myocytes slowly repolarise, which is denoted on the ECG as the T wave (Fig. 
1.5.1), leading to cardiac relaxation and completion of one cardiac cycle (Keating 
and Sanguinetti, 2001).
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Figure 1.5.1 Schematic representation of a typical electrocardiogram (left) and 
the action potential in the ventricle (right).
In a prototypical fast response cell, the membrane is highly permeable to K+. This 
permeability reflects the fact that inward rectifier K+ channels in the membrane 
are open at rest (Keating and Sanguinetti, 2001). By contrast, the resting 
membrane is Na+ impermeant. The cardiac sodium channels in resting cells are 
closed. A change in the membrane potential across the cell is sensed by the Na+ 
channels which alter their conformation and open allowing a large rapid Na+ 
influx, producing the typical rapid phase 0 depolarisation (Keating and 
Sanguinetti, 2001) (Fig. 1.5.1).
In some cells a rapid phase 1 repolarisation then occurs, because of outward K+ 
movement via transient outward channels. During phase 0 and 1, Ca+2 channels 
open. Phase 2 is the characteristically long plateau phase of the cardiac action 
potential and reflects a balance between inward current through mainly L-type 
Ca+2 channels and outward current, largely through delayed rectifier K+ channels. 
The net outward current during phase 3 repolarisation is produced by delayed 
rectifier channels along with inactivation of Ca+2 channels (Keating and 
Sanguinetti, 2001). Final repolarisation during phase 4 is accomplished by 
outward movement of K+ through inward rectifier channels (Keating and 
Sanguinetti, 2001).
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1.5.1 Potassium channels
Potassium channels are a diverse group of membrane proteins that are found on 
excitable and non-excitable cells and are involved in a variety of processes, such 
as neurotransmitter release, heart rate, insulin secretion, neuronal excitability, 
epithelial electrolyte transport, smooth muscle contraction and cell volume 
regulation (Shieh et al., 2000). The role of these membrane proteins is to conduct 
K+ across the membrane. To accomplish this all potassium channels are 
characterised by the following (Shieh et al., 2000):
1. The pore: a water filled permeation pathway that allows K+ to flow across 
the membrane.
2. Selectivity filter: specifies K+ as permeant ion species and
3. Gating mechanism: allows the channel to switch between open and close 
conformations.
Potassium channels can be categorised into three groups according to the 
number of putative transmembrane segments (Shieh et al., 2000).
A. The six-transmembrane-one pore channel,
B. the two-transmembrane-one pore channel and
C. the four-transmembrane-two pore channel
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1.5.1.2 Inward Rectifying Potassium channels (Kir)
The ATP-sensitive potassium ( K a t p )  channels belong to the ATP-binding 
cassette transporter superfamily and are comprised of two subunits:
1. a pore-forming, inward-rectifying potassium subunit (Kir) that belongs to 
the two-transmembrane-one pore potassium channel group, and
2. a regulatory sulfonylurea receptor (SUR).
The Kir and SUR subunits coassemble with a 4:4 stoichiometry to form a hetero- 
octameric K a t p  channel with the Kir subunits forming the K+ permeation pathway 
(Shieh, et al., 2000) (Fig. 1.5.2). Both Kir and SUR subunits are required to form 
functional channels with the SUR subunit cooperating with the Kir subunit to act 
as an ATP-dependent potassium channel complex. The SUR subunit contains 
two transmembrane segments and two nucleotide binding folds (NBD-1 and 
NBD-2) (Fig. 1.5.2.). The NBDs are located near the carboxy terminus of the 
SUR subunit and contain the Walker A and B motifs, essential in providing 
membrane sensitivity to ATP and Mg+2-ADP. The Walker A motif contains the 
characteristic glycine-rich motif GlyX6GlyXXGIyXGIyLys(Ser/Thr) allowing binding 
of ATP or GTP by means of the terminal phosphate group (Shieh, et al., 2000). 
The Walker B motif contains the characteristic amino acid sequence 
ArgXnAspXeAsp and is involved in ATP hydrolysis and binds the Mg+2-ATP 
(Shieh, et al., 2000). The nucleotide binding fold NBD-1 has limited catalytic 
activity, whereas NBD-2 hydrolyses ATP and has been shown to play an 
essential role in K At p  channel gating. Both NBD-1 and - 2  are required for K At p  
channel function (Shieh, et al., 2000).
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Figure 1.5.2 Schematic representation of KAtp channel. Two dimensional 
representations of pore forming inward rectifying potassium channel subunit (Kir) 
and a regulatory sulfonylurea receptor (SUR) during closed and open states. 
Nucleotide binding folds, containing Walker A and Walker B motifs are shown 
(NBD-1 and 2). Under homeostatic conditions KAtp channels are closed. High 
ATP concentrations allow binding of ATP to Kir, closing the pore. Binding of ATP 
to NDB-1 and hydrolysis of Mg+2-ATP at NBD-2 allows limited resident binding of 
Mg+2-ADP to NBD-2 due to catalytic actions of Creatine Kinase (CK), thus 
preventing channel opening. Under conditions of ischaemia ATP concentrations 
are decreased and ADP concentrations are increased and the catalytic actions of 
CK are reduced or inhibited and resident binding of Mg+2-ADP to NBD-2 is 
increased, allowing conformational stabilisation and KATp channel opening and K+ 
flux across the inner membrane.
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The pore forming inward rectifying K+ channel belong to the two transmembrane 
one pore category of K+ channels. They are comprised of two transmembrane 
domains linked by a pore loop in between (Fig. 1.5.2). These channels are 
conducting K+ more in an inward rather than an outward fashion and are 
important in setting the resting membrane potential. This inward rectification is 
attributed to gating mechanisms by Mg+2 and polyamines that occlude access of 
K+ to the internal vestibule of a conducting pore (Shieh, et al., 2000).
Two types of Kir and three types of SUR have been identified as part of K At p  
channels, Kir 6.1 and Kir6.2 and SUR1, SUR2A and SUR2B. It has been shown 
that the two Kir can combine to form functional channels in HEK293 cells (Cui et 
al., 2000). In the myocardium, two sensitive ATP channels have been isolated, 
one subtype in the sarcolemma and the other in the inner membrane of the 
mitochondria. The cardiac sarcolemmal channels have been characterised as 
SUR2A/Kir6.2. The Kir6.2 subunit has a molecular mass of 51 kD, whereas the 
SUR2A subunit has a molecular mass of 140kD (Shieh, et al., 2000). The 
mitochondrial channel has yet to be molecularly characterised.
The K a t p  channels can be pharmacologically modulated by a family of 
structurally diverse agents collectively known as potassium channel openers and 
blockers. Most channel openers are non-selective and act through binding to the 
SUR subunits. The potassium channel openers are thought to act by interaction 
or by active competition at regulatory ATP binding sites in the K At p  channel, 
allowing conformational stabilization through interaction with a conserved amino 
acid motif. In contrast potassium channel blockers act to inhibit conformational
stabilisation (Shieh, et al., 2000). The best known potassium channel blocker is 
glibenclamide which acts on both sarcolemmal and mitochondrial K a t p  channels. 
It binds to a high affinity site localised on any SUR subunit and with a low affinity 
on the Kir subunit (Cui et al., 2000; O’Rourke, 2000; Shieh, et al., 2000).
The selectivity of sarcolemmal and mitochondrial K a t p  channel openers and 
blockers is primarily dependent upon SUR phenotype and SUR subunit 
sensitivity. Pinacidil, cromakalim, nicorandil and related analogues are potassium 
openers that have been shown to act preferentially on SUR2A/B subunits and 
have relatively little effect on SUR1 containing K a t p  channels. Potassium channel 
blockers, act in a very similar manner. Recombinant and in vitro studies, 
however, have shown that the mitochondrial K a t p  channels can be selectively 
blocked with 5-hydroxy-decanoate (5-HD) (Cui et al., 2000; O’Rourke, 2000; 
Shieh, et al., 2000).
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1.5.2.1.2 K a t p  channel and cardioprotection
Several studies have shown that the K a t p  channel is implicated in 
cardioprotection after iscaemia/reperfusion injury, because blockers like 
glibenclamide attenuate protection and the use of openers confer protection 
(Garlid et al., 1997, Liu et al., 1998, Kevelaitis et al., 1999, Baines et al., 1999, 
O’Rourke, 2000; Pain et al., 2000; Sato et al., 2000; Xu et al., 2001; McCully and 
Levitsky, 2003; Oldenburg et al., 2003; Baczko et al., 2004). In addition, there is 
no conclusive evidence for the role of sarcolemmal K a t p  channels in 
cardioprotection (O’Rourke, 2000; Pain et al., 2000; Sato et al., 2000; Xu et al., 
2001; McCully and Levitsky, 2003; Oldenburg et al., 2003; Baczko et al., 2004).
There are several possible mechanisms suggested as to how K At p  channels can 
protect against ischaemic injury. Mitochondrial swelling induced by mitochondrial 
K a t p  opening might improve mitochondrial energy production. Pharmacological 
opening of mitochondrial K At p  improves oxidative phosphorylation during 
ischaemia reperfusion and this effect is inhibited by 5-hydroxy-decanoate or 
glibenclamide (Tanonaka et al., 1999; Iwai et al., 2000; Miura et al., 2000).
Another mechanism might be through an effect on Ca+2 handling. K At p  channel 
openers decreased the rate of Ca+2 uptake by isolated mitochondria and a similar 
effect was observed in intact neonatal myocytes. 5-hydroxy-decanoate inhibited 
that effect (Holmuhamedov et al., 1999; Baczko et al., 2004). Depolarisation of
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the mitochondrial membrane potential (ATm) was thought to be responsible for 
the decrease in the rate of Ca+2 entry. However, another study showed that 
depolarisation of AH^ m by activation of K a t p  was not accompanied by changes in 
Ca+2, and they rather attributed the protective effects of K a t p  opening to 
prevention of cytochrome c release from the mitochondrion (Xu et al., 2001).
A third possible mechanism suggests that the protection is conveyed through 
alteration of the rate of reactive oxygen species (ROS) release from the 
mitochondrion. ROS have long been implicated in the cellular damage 
associated with ischaemia and reperfusion (von Harsdorf et al., 1999a). 
However, ROS generation has been considered as a trigger in ischaemic 
preconditioning, a phenomenon where brief series of ischaemia, confer 
protection against infarction, prior to a prolonged period of ischaemia (Murry et 
al., 1986). In embryonic myocytes both protection and ROS production were 
inhibited by 5-hydroxy-decanoate, suggesting that the opening of K At p  channels 
could stimulate ROS production (Yao et al., 1999; Oldenburg et al. 2003). ROS 
production can in turn activate protein kinase C, which can influence 
mitochondrial K a t p  activity (Sato et al., 1998; Sasaki et al., 2 0 0 0 ;  Huh et al., 
2001; Liu etal., 2002).
The involvement of K a t p  channels in hypertrophy is as yet unclear. However, 
evidence suggests that K a t p  channels might have some kind of involvement in 
hypertrophy. K At p  has been shown to be a potent regulator of A N F  secretion (Xu
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et al., 1996) and K At p  channel opening inhibited stretch induced ANF release in 
atrial cardiomyocytes (Jiao et alM 2000). However more work is needed to 
further elucidate the possible role of K a t p  in cardiac hypertrophy.
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1.6 The Corticotropin Releasing Factor family of peptides
In this chapter I am providing background information for the peptides whose 
effects in the cardiac cell we are studying.
The Corticotropin-Releasing Factor family consists of a number of structurally 
related peptides that include CRF, Urocortin (UCN), urotensin and sauvagine in 
vertebrates and the diuretic peptides present in insects (Lovejoy and Balment, 
1999). Recently, two new homologues have been cloned from mice that show 
high similarity to UCN; they are UCNII and UCN III (Lewis et al., 2001; Reyes et 
al., 2001). At the same time a different group cloned the human homologues of 
UCN II and III, which they named Stress Related Peptide (SRP) and Stresscopin 
(SCP), respectively (Hsu and Hsueh, 2001). Henceforth, the murine homologues 
will be refered to as UCNII and III and the human homologues as SRP and SCP 
respectively.
1.6.1 Synthesis, structure and tissue distribution of CRF and UCN
The CRF gene is located on chromosome 8 and the UCN gene on chromosome 
2, in humans. Both genes consist of two exons and the entire coding region for 
both peptides is located in the second exon (Zhao et al., 1998). Both proteins are 
produced by cleavage of the C-terminus of a pre-pro-peptide (Vale et al., 1997). 
The mature peptides are of similar size consisting of 41 aminoacids for CRF and 
40 for UCN.
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The human and rat CRF are identical, but they differ to the ovine CRF by seven 
amino acids (Lovejoy and Balment, 1999) (Fig. 1.6.1). The amphibian peptide 
sauvagine (SVG) and the fish peptide urotensin (URO), share approximately 
50% homology to the human and rat CRF (Lovejoy and Balment, 1999) (Fig. 
1.6.1).
UCN is more highly conserved among species than CRF and is closely related to 
fish URO (53-63% amino acid homology) and diverges from CRF (43-45% 
homology) and SVG (35% homology).
CRF mRNA is widely expressed in the central nervous system, with major sites 
of expression in the paraventricular nucleus of the hypothalamus, the cerebral 
cortex, the cerebellum and the amygdala-hippocampal complex (Bittencourt and 
Sawchenko, 2000). In the periphery, CRF is expressed in the adrenal gland, the 
testis, placenta, gut, spleen, thymus and skin (Vale et al., 1997).
UCN was originally identified in the rat midbrain, and has been shown to be 
expressed in the central nervous system, mainly in the Edinger-Westphal 
nucleus, hypothalamus, lateral superior olive cerebellum, substantia nigra pars 
compacta and ventral tegmental area (Skelton et al., 2000). In the periphery, 
UCN is expressed in the vasculature, the digestive system, the adrenal gland, 
placenta, lung, thymus, spleen, in leucocytes and the heart. In the heart, UCN is 
expressed in both myocytes and non-myocytes, as well as in vascular smooth 
muscle cells of the cardiac blood vessels, with highest concentration detected in
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the left ventricle (Leitch et al., 1998 and Kimura et al., 2002). CRF has not been 
detected in the heart.
Although, CRH and UCN activate both type 1 and 2 receptors2, the lack of a 
pervasive UCN projection to CRH receptor 2 expressing cells (Bittencourt et al., 
1999) and the absence of CRH or UCN projections to brain anxiety centers 
(Weninger et al., 1999) pointed to the existence of additional CRH related 
peptides.
Following this hypothesis SRP/UCN II and SCP/UCNIII were cloned in humans 
and mice. Human SCP encodes a prepro-protein of 161 aminoacids and a 
putative mature protein of 40 amino acids (Hsu and Hsueh, 2001). Human SRP 
on the other hand encodes a prepro-protein of 112 amino acids that gives rise to 
a predicted 43 amino acid mature peptide (Hsu and Hsueh, 2001).
The open reading frames of hSCP and hSRP contain a signal peptide for 
secretion and the predicted mature regions are flanked by potential proteolytic 
cleavage sites and an a-amidation donor residue. However, the human SRP 
precursor lacks an obvious C-terminal proteolytic cleavage site and has two 
uncommon cysteine residues flanking the predicted mature peptide, suggesting 
that new proteolytic enzymes, yet undiscovered, might be responsible for SRP 
maturation (Hsu and Hsueh, 2001).
2 For more information on CRH receptors please refer to chapter 1.6..4
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Although, the CRH family shares similar secondary structures, the predicted 
structures of mature SCP and SRP are distinct from those of other family 
peptides at the N-terminus. The mature CRH, UCN, URO and SVG all share a 
similar structure with an N-terminal random coil, followed by an extended a- 
helical structure. In contrast, the N-terminal sequence of SCP, SRP, their two 
pufferfish orthologs and murine UCNII adopted an extended strand, followed by a 
short random coil (Hsu and Hsueh, 2001).
The SCP transcript has been shown to be abundantely expressed in the brain, 
colon, small intestine, muscle, stomach, thyroid, adrenal gland, pancreas, heart, 
kidney and spleen (Hsu and Hsueh, 2001; Takahashi et al., 2004). SRP has 
been shown to be expressed mainly in the brain, adrenal gland, heart and 
peripheral blood cells (Hsu and Hsueh, 2001).
Sequence homology analysis shows that there is only a 37% homology between 
SCP and SRP, 42% between SCP and murine UCNII, 26% with human UCN and 
SCP and 26% between human CRH and SCP (Hsu and Hsueh, 2001). 
Additionally, phylogenetic analysis of 10 CRH family proteins from fish and 
mammals indicated an ancient evolution of three subgroups of CRH family 
proteins with the human and pufferfish SCPs clustered in a separate branch from 
human SRP and murine UCNII (Hsu and Hsueh, 2001).
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1.6.2 CRH Peptide family evolution
It Is becoming well clear now that the vertebrate genomes contain four distinct 
genes of the CRH family:
1. CRH
2. UCN/URO
3. SCP/UCNIII and
4. SRP/UCNII.
Each of these genes is highly conserved during evolution (Chang and Hsu, 
2004).
Phylogenetic analysis shows that the origin of each of these peptides predates 
the evolution of tetrapods and teleosts, spanning an evolutionary history of 550 
milion years (Fig. 1.6.2) (Chang and Hsu, 2004). It appears that this family of 
peptides evolved from an ancestral gene that developed the CRF/UCN and 
SCP/SRP branches through an early gene duplication (Fig. 1.6.2) (Chang and 
Hsu, 2004).
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Peptide Sequence Length Identity
(%)
hCRF SEEPPISLDLTFHLLREVLEMARAEQLAQQAHSNRKLMEII 41 100
oCRF SQEPPlfeLDLTFHLLREVLEMTKADQLABQAHSNRKLLDIA 41 83
URO NDDPPISIDLTFHLLRNMIEMARIENEREQAGLNRKYLDEV 41 54
hUCN DNPSLSIDLTFHLLRTLLELARTQSQRERAEQHRIIFDSV 40 43
SVG ZGPPISI&LSLELLRKMIEIEKQEKEKQQAANHRLLLDTI 40 48
hSRP IVLSLDVPIGLLQILLE QARARAAREQATTNARILARV 38 34
mUCNII VILSLDVPIGLLRILLE QARYKAARNQAATHAQILAHV 38 34
hSCP FTLSLDVPTNIMNLLFNIAKAKNLRAQAAANAHLMAQI 38 32
mUCNIII FTLSLDVPTNIMNILFNIDKAKNLRAKAAANAQLMAQI 38 26
Fig. 1.6.1. Alignment of members of the Corticotropin releasing factor family. The amino 
acids that are homologous between the CRF family are boxed. Human stresscopin related 
peptide (SRP) and human urocortin II (UCN II) are identical. Human stresscopin and 
human urocortin III are also identical. Abbreviations: h: human, o: ovine, m: murine, SVG: 
sauvagine, URO: urotensin I. Adapted from Dautzenberg and Hauger, 2002.
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SCP/SRP
branch
CRFl.rocortin
branch
h S C P / U r o c o r t i n  I I I
m S C P / U r o c o r t i n  I I I  
p S C P / U r o c o r t i n  I I I  
h S R P / U r o c o r t i n  I I
m S R P / U r o c o r t i n  I I
g U r o t e n s i n  I
p U r o c o r t  i n  
h U r o c o r t i n
m U r o c o r t i n
h C R F
mCRF
u C R F - 1
u C R F - 2
p C R F
Fig. 1.6.2. Evolution of the CRH family of peptides. The four vertebrate family 
peptides probably derived from an ancestral gene through gene duplication. 
During the first gene duplication, two ancestral genes, a SCP/SRP like gene and 
a CRH/UCN like gene, were created. A second round of gene duplication 
generated the four core ligand peptides in vertebrates. H: human, m: mouse, p: 
puffer fish (Fugu rubripes), u: white sucker (Catostomus commersioni), g: 
goldfish (Carassius auratus). Adapted from: Chang and Hsu, 2004.
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1.6.3 Actions of CRF peptides
CRF and related peptides have been implicated in the regulation of the stress 
responses of organisms, by mediating the release of adrenocorticotropin (ACTH) 
from the anterior pituitary (Lovejoy and Balment, 1999; Skelton et al., 2000; 
Reyes et al., 2001). In addition, the CRF family of peptides has been implicated 
in the regulation of the cardiovascular system (Nishikimi et al., 2000; Parkes and 
May, 2000; Parkes et al., 2001; Terui et al., 2001), the gastrointestinal system 
(Kihara et al., 2001; Okamoto et al., 2001; Shade et al., 2002) and inflammatory 
processes (Kohno et al., 2001; Radulovic and Spiess, 2001).
CRF administration increases blood pressure, cardiac output and heart rate and 
CRF perfused through isolated rat hearts can increase coronary flow and 
maximal aortic pressure (Parkes and May, 2000).
Urocortin administration in fasted rats stopped gastroduodenal motility and 
provoked fed-like patterns (Kihara et al., 2001). Leptin a protein that decreases 
food intake was shown to be mediated by CRF as injection of anti-CRH 
attenuated the effects of leptin aministration in rats (Okamoto et al., 2001). 
Intracerebroventricular injections of CRH in baboons significantly reduced the 
daily food intake in the subject animals (Shade et al., 2001).
UCN increased IL-1 beta and IL-6 secretion by human peripheral blood 
mononuclear cells and CRH receptor immunoreactivity was strong in
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mononuclear inflammatory cells of rheumatoid arthritis synovia, suggesting that 
acts as an immune-inflammatory mediator (Kohno et al., 2001).
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1.6.4 CRF receptors
The functions of the CRF peptides are elicited by binding to G protein-coupled 
receptors (Grammatopoulos et al., 2000). Two families of receptors are known 
thus far: CRF receptor type 1 (CRFR1) and CRF receptor type 2 (CRFR2). There 
is further redundancy in the CRFR2 family, as there are so far three splice 
variants or subtypes cloned named CRFR2a, CRFR2P and CRFR2y(Kostich et 
al., 1998). The two receptors have different anatomical distribution, different 
pharmacology and different affinities for the various CRF family peptides. In 
rodents both receptors are expressed in the central nervous system (CNS), but 
their peripheral distribution differs. CRFR1 is expressed in the gonads and the 
skin, whereas CRHR2P (a splice isoform of CRFR2) is mainly expressed in the 
epididymis, the gastrointestinal tract and in cardiac and skeletal muscle. 
CRFR2a, the other splice variant is expressed mainly in the brain (Perrin and 
Vale, 1999).
Comparisons of the binding affinities and potencies of the known UCN peptides 
to CRFR1, CRFR2a and CRFR2P stably expressed on CHO cells showed that 
UCN II and III exclusively bind to type 2 receptors whereas UCN I seems to be 
able to bind to both types albeit with a higher affinity to type 2a (Lewis et al., 
2001). In contrast, CRF has a 10 fold higher affinity for the type 1 receptor 
(Vaughan et al., 1995).
This difference of ligand affinity of the receptors and their different anatomical 
distribution strengthens the possibility that CRF and UCN may have different 
functions. Indeed, the two types of receptor have been associated with the 
different functional aspects of the CRF peptide family. Thus, the type 1 receptors 
have been implicated with anxiogenic-type behaviours as shown by experiments 
on CRHR1 knock-out mice (Tazi et al., 1987; Smith et al., 1998). As far as the 
CRHR2 type is concerned, until recently, due to the lack of knock-outs and 
antagonists that specifically block this type of receptor, it has been difficult to 
attribute specific functions to it. However, following behavioural studies on 
CRHR2 knock-out mice, it is suggested that the type 2 receptor mediates a 
general anxiolytic response, as the knock-out mice were more susceptible to 
stressful behaviour than the wild type ones (Bale et al., 2000; Coste et al., 2000; 
Kishimoto et al., 2000). In addition, knock-out mice exhibited larger edema 
responses in response to thermal injury than their wild type littermates (Kishimoto 
et al., 2000), validating the main role of CRHR2 in the peripheral responses of 
the CRH family of peptides.
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1.6.5 UCN cardioprotective and hypertrophic effects.
UCN has been shown to protect cardiac myocytes from cell death after exposure 
to hypoxia/reoxygenation injury in vitro (Okosi et al., 1998; Brar et al., 1999; Brar 
et al., 2000). In addition, UCN has similar effects in the isolated perfused rat heart 
(Brar et al., 2000). As CRFR2p is the only subtype expressed in the rat heart 
(Nishikimi et al., 2000), the cardioprotective effects of UCN against 
hypoxia/reoxygenation (Okosi et al., 1998; Brar et al., 1999; Brar et al., 2000; 
Latchman, 2001; Brar et al., 2002a; Brar et al., 2002b; Latchman, 2002) are 
attributed to the binding to the CRRFR2. In more detail, UCN has been shown to 
decrease mean arterial blood pressure and increase heart rate (Terui et al., 
2001; Parkes et al., 1997; Abdelrahman and Pang, 2003) and in addition 
increase aortic flow and cardiac contractility (Parkes et al., 1997). Similarly, 
UCNII has been shown to also induce a dose dependent reduction in mean 
arterial blood pressure and increase in heart rate when given intravenously in 
rats (Mackay et al., 2003). Moreover, it has been shown that UCN is able to 
protect neonatal cardiac myocytes (Okosi et al., 1998; Brar et al., 1999; Brar et 
al., 2000; Brar et al., 2002b; Railson et al., 2002), adult cardiomyocytes (Brar et 
al., 2002b; Railson et al., 2002) and whole hearts either in vitro (Brar et al., 2000; 
Lawrence et al., 2002; Scarabelli et al., 2002b; Schulman et al., 2002) or in vivo 
(Schulman et al., 2002) from hypoxia-reoxygenation injury.
However, UCN has also been shown to be involved in cardiac hypertrophy. UCN 
is able to increase distinct markers of hypertrophy, such as protein synthesis, 
cell size, atrial (ANP) and brain (BNP) natriuretic peptide secretion and collagen 
in cardiomyocytes (Ikeda et al., 1998; Nishikimi et al., 2000; Railson et al., 2002). 
In addition, expression of UCN mRNA was higher in human hearts with left 
ventricular hypertrophy (Nishikimi et al., 2000) and UCN immunoreactivity was 
more intense in cardiomyocytes of human failing hearts, than in normal human 
hearts (Nishikimi et al., 2000). However, in sheep with experimental heart failure, 
ovine UCN administration, increased cardiac output, while arterial peripheral 
resistance and mean arterial pressure fell. Furthermore, it induced dose 
dependent decreases in plasma vasopressin, natriuretic peptides and endothelin- 
1 (ET-1) (Rademaker et al., 2002), showing that, although UCN clearly induced 
hypertrophic markers, the overall systemic effect of the peptide administration 
improved the viability of the sheep with heart failure, indicating that more work is 
needed to elucidate the balance of its cardioprotective effect and its effect on 
hypertrophy.
We have previously shown that cardioprotection from hypoxia/reoxygenation 
injury induced by UCN and its homologues in rat neonatal cardiomyocytes is 
dependent on activation both of Akt and MAPK p42/44 as inhibiton of Akt and 
p42/44 pathways by chemical inhibitors, or with overexpression of dominant 
negative constructs abolished cardioprotection by the peptides (Brar et al., 2000; 
Latchman, 2001; Brar et al., 2002a; Brar et al., 2002b; Railson et al., 2002; 
Schulman et al., 2002; Brar et al., 2004a; Brar et al., 2004b).
In addition, it was shown that the MAPK p42/44 pathway is not involved in the 
manifestation of the hypertrophic effects of UCN in rat neonatal cardiomyocytes, 
as transfection of cardiomyocytes with a dominant negative MEK1 construct, 
prior to UCN administration, failed to attenuate the increase in mean cell area by 
UCN (Railson et al., 2002). It was previously postulated that the increase in 
cAMP by UCN administration is mediating its hypertrophic effects (Nishikimi et 
al., 2000; Rademaker et al., 2002). However, Akt activation has also been 
implicated in cardiac hypertrophy (Frey and Olson, 2003), but its role in the 
hypertrophic effects of UCN has not been studied.
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1.7 AIMS
In our work we have tried to identify and compare the effects of stresscopin and 
stresscopin related peptide to urocortin on cardioprotection and hypertrophy.
We wanted to identify whether the newly identified UCN homologues are 
expressed in the rat cardiomyocytes and if ischaemia had any effects on its 
expression; also we studied and compared the effects of the peptides on cell 
death and apoptosis after hypoxia reoxygenation, in order to identify any 
differences on the potency of the three peptides (Chapter III).
We also wanted to examine the effects of the three peptides on primary neonatal 
cardiomyocyte cell size, protein synthesis and expression of the natriuretic 
peptides, in order to determine whether the three peptides have any hypertrophic 
effects (Chapter IV).
The role of MAPK and Akt in cardioprotection and hypertrophy by the UCN 
homologues was examined (Chapter V).
The role of three signalling molecules PLA2 , PKC£ and Kir 6.1 in cardioprotection 
by the three homologues, recently indentified to be involved in the UCN signalling 
pathway, was examined (Chapter VI).
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Lastly, I examine whether the three homologues affect the expression of SAG. In 
addition we investigated whether SAG is able to protect cardiomyocytes from 
hypoxia/reoxygenation injury and look further into a possible role for SAG in the 
cardiomyocytes (Chapter VII).
CHAPTER II
MATERIALS AND METHODS
2.1 Preperation of rat neonatal cardiomyocytes
2.1.1 Materials
Digestion buffer
• 100mlsADS
60mg ~250u/mg collagenase type II CLS2 (Worthington) 
25mg pancreatin from porcine pancreas (Sigma #P-3292)
• 500mls ADS Buffer 
500mls MilliQ H20
3.4g NaCI 
2.38g HEPES
0.06g NaH2P04
0.5g Glucose
0.2g KCI
0.05g MgS04
Adjust to pH 7.35 and filter sterilize.
• Foetal Calf Serum (FCS)
• Plating Media
DMEM (Dulbeco’s Modified Eagle’s Medium)
15% FCS
1X Penicylin/Streptomycin
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• Maintenance media
DMEM 
1% FCS 
1X Pen/Strep
• 1% Gelatin in PBS
PBS
1% Gelatin
Boil gelatin and filter sterilize
2.1.1.2 Method
1. Weigh out 60 mg collagenase and add to 100 ml ADS. Also, weigh out 25 
mg pancreatin.
2. Oxygenate buffer using cylinder in primary TC during heart isolation.
Heart Isolation
1. For isolation take ADS buffer in petri dish and 1L of 70% EtOH.
2. Cull pups, rinse in 70% EtOH, isolate hearts into ADS buffer.
3. In primary TC dissect hearts with scissors.
88
Serial Digestion
1. Add 25 mg pancreatin to oxygenated ADS and filter sterilize.
2. Pipette hearts into 25 cm2 TC flask and remove buffer using pipette.
3. Rinse hearts once with 10 ml digestion buffer, let hearts settle and discard 
buffer. Add 10 ml of fresh digestion buffer and incubate at 37°C for 15min.
4. Gently shake flask, let the hearts settle and pipette out buffer. Discard this 
first digestion.
5. Repeat digestion and following incubation add buffer to 2 ml of FCS in 15 
ml falcon (as soon as this is done add another 10mls of digestion buffer 
and begin the next digestion) and centrifuge @ 10OOrpm for 5min. Discard 
supernatant, re-suspend in 4 mis FCS and incubate in 37°C.
6. Repeat digestion for a total of 8 times. (There are 9 altogether including 
the first that is discarded).
Pre-plating
Calculate volume of plating media required. Cells are plated at 1x106/ml and 
approximately 4.5 hearts yield enough for 1 plate (6 or 24 wells), which is 
24mls.
1. To pre-plate use 175 cm2 TC flasks, up to 200 ml per flask. Measure out 
plating media into flasks.
2. Pool the eight myocyte suspensions and centrifuge @ 1000rpm for 5min. 
Discard supernatant and re-suspend in 20 ml 15% plating media. Pipette 
equal volumes of cell suspension to pre-plating flasks and incubate at 37°C 
for 1 h.
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Plating
1. Coat TC plates with 1 % gelatin (in PBS) at 37°C for 1 h.
2. Remove gelatin.
3. Pool cells into one 175 cm2 flask and plate cells. Gently shake flask after 
every few plates so all the cells haven’t settled to the bottom.
4. Allow overnight for cells to attach and the following morning replace media 
with 1% maintenance media.
2.2 Simulated ischaemic insult
Prior to induction of simulated ischaemia cells were washed twice with phosphate 
buffered saline (1xPBS) and fresh Esumi modified Ischaemic Medium (Brar et al.,
1999) was added to the cells which were transferred to a gas chamber for 
induction of hypoxia in an atmosphere of 95% Argon and 5% CO2 for the desired 
amount of time. After completion of the hypoxic treatment, cells were washed 
twice with 1xPBS and Esumi Modified control medium (Brar et al., 1999) was 
added. Cells were then transferred to the incubator for up to 16 hours in an 
atmosphere of 21% O2 and 5% CO2 . Control cells were maintained in these 
conditions in an incubator for the duration of the experiment in Esumi modified 
control medium.
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2.3 Langendorff Perfused Rat Hearts
Hearts from anaesthetized adult male Sprague-Dawley rats were mounted in a 
Langendorff perfusion apparatus, and ischemia/reperfusion was performed as 
described previously (Scarabelli et al., 1999; Brar et al., 2000). Isolated hearts 
were divided into 3 groups. The first group contained control hearts that were 
continuously perfused. The second group was exposed to 35 min of ischaemia 
alone, which was achieved by occlusion of the left coronary artery. The hearts in 
the last group were reperfused for 60 min, after 35 min of ischaemia. Heart 
samples were frozen on liquid nitrogen immediately at the end of the experiment 
and protein extracted from the tissues as described previously (Brar et al., 1999).
2.4 RNA isolation
Total RNA was isolated from 5x106 cardiomyocytes that were washed with 
1xPBS prior to being lysed in 1 ml of TRIzol (GIBCO BRL, Invitrogen Life 
Technologies, Invitrogen Corporation, Carlsbad, CA, USA). 100pl of chloroform 
was added to the lysate and the mixture centrifuged at 13000 rpm for 15 min on 
a table top centrifuge. The aqueous phase was transferred to a fresh tube and an 
equal amount of isopropanol was added, mixed and incubated on ice for 30 min. 
After centrifuging as above the pellet was washed with 70% ethanol and left to 
dry prior to resuspending in DEPC treated H20. The amount of RNA was 
determined by spectrophotometry and the samples stored at -80°C.
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2.5 cDNA preparation
First strand synthesis was done using 1 jug of total RNA, and 1 jllI of oligo-dT 
primers (Promega UK Ltd, Southampton, UK). AMV reverse transcriptase 
(Promega UK Ltd, Southampton, UK) was used according to the manufacturer’s 
instructions. Semi-quantitative PCR was performed as described before (Smith et 
al., 2001) using Imolase polymerase (Bioline Ltd, London, UK) and the following 
primers
SAG forward: 5’-CTCGAGATGGAGGACGGCGAGGAA-3’
SAG reverse: 5’-GGTACCCTCTCATTTGCCGATTCT-3’
Actin forward: 5’-TCATGAAGTGTGACGTTGACATCCGT-3’
Actin reverse: 5’-CCTAGAAGCATTTGCGGTGCACGACGATG-3\
The PCR products were visualised on 2% polyacrylamide gel and analysed using 
the GeneGenious system and Gene Tool software (Syngene, Cambridge, UK).
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2.6 Western Blotting
Cells were washed In 1xPBS and harvested in solution containing 150 mmol 
NaCI, 50 mmol Tris-HCI (pH 8.0), 0.1% sodium dodecyl sulfate SDS and the 
protease inhibitor cocktail COMPLETE (Roche-Boehringer Manheim, Roche 
Diagnostics, Lewes, East Sussex, UK). The lysates were spun at 13000 rpm for 
10 min at 4°C and the supernatants were assayed for protein concentration using 
the BIO-RAD protein assay kit according to the manufacturer’s instructions (BIO­
RAD Laboratories Ltd, Hemel Hempstead, UK). An equal amount of protein from 
each sample was boiled at 100°C in SDS sample buffer (100 mmol Tris-HCI, 4% 
SDS, 0.2% bromophenol blue and 20% glycerol) for 5 min and loaded onto a 
15% SDS-polyacrylamide gel.
The proteins were transferred onto a polyvinyl membrane (Amersham Pharmacia 
Biotech, Amersham Biosciences UK Ltd, Little Chalfont, Buckinghamshire, UK) 
using the Trans-Blot SB Semi-Dry Transfer Cell apparatus (BIO-RAD 
Laboratories Ltd, Hemel Hempstead, UK) according to the manufacturers 
specifications. After blocking for 20 minutes in 1xPBS, containing 5% non-Fat 
milk, 0.1% Tween 20 and 0.2% Sodium Azide (PBST), the membranes were 
blotted with the appropriate antibody (For a list of the various antibodies used 
and their dilutions see table 2.1) in PBST at 4°C overnight. After immuno­
detection with the appropriate secondary antibody (table 2.1) (DAKO Ltd., Ely, 
Cambridgeshire, UK) diluted 1:2000 times in PBST for 2 hours the blots were
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washed twice with PBST at room temperature and the blots were visualised 
using an enhanced ECL kit (Amersham Pharmacia Biotech, Amersham 
Biosciences UK Ltd, Little Chalfont, Buckinghamshire, UK).
After stripping in 0.2M NaOH for two washes of 5 min each and washing with 
PBST for 10 min the same blots were probed with goat anti-Actin-beta polyclonal 
antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) diluted 1:2000 
times in PBST at room temperature for 2 hours. Immunodetection and 
visualization was performed as described above. Densitometric analysis of 
western blots was performed in the linear range using a GS-800 Calibrated 
Densitometer (BIO-RAD Laboratories Ltd, Hemel Hempstead, UK) linked to the 
Quantity One v 4.3 analysis software package (BIO-RAD Laboratories Ltd, 
Hemel Hempstead, UK).
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Table 2.1 List of antibodies used
Antibody Type Dilution for 
Immunoblotting
Dilution for
Immunocytoch
emistry
Source
Anti-SAG Rabbit
poluclonal
1:1500 1:200 Gift by Sun Y.
Anti-
Caspase-3
Mouse
monoclonal
1:200 1:50 Novocastra, 
Newcastle, UK
Anti HOS Goat
polyclonal
N/A 1:100 Santa Cruz, USA
Anti-Actin Goat
polyclonal
1:2000 N/A Santa Cruz, USA
Anti-MAPK
p42/44
Rabbit
polyclonal
1:1000 N/A Cell Signalling
Anti-Akt Rabbit
polyclonal
1:1000 N/A Cell Signalling
Anti-
phospho-
MAPK
P42/44
Rabbit
polyclonal
1:1000 N/A Cell Signalling
Anti-
phospho-
Akt
Rabbit
polyclonal
1:1000 N/A Cell Signalling
Anti p38 Mouse
polyclonal
1:1000 N/A Cell Signalling
Anti-
phospho-
p38
Mouse
polyclonal
1:1000 N/A Cell Signalling
Anti-Kir 6.1 Mouse
polyclonal
1:1000 N/A Gift by Tinker A.
Anti-iPLA2 Goat
polyclonal
1:1000 N/A Santa Cruz
Anti-PKC8 Goat
polyclonal
1:1000 N/A Santa Cruz
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Anti-PKCe Goat
polyclonal
1:1000 N/A Santa Cruz
HRP
conjugated
Anti-Mouse
IgG
1:2000 N/A DAKO
HRP
conjugated 
Anti Rabbit 
IgG
1:2000 N/A DAKO
HRP
conjugated 
Anti Goat 
IgG
1:2000 N/A DAKO
Flurescent 
Anti mouse 
IgG
N/A 1:10000 ALEXA
Fluorescent
anti-rabbit
IgG
N/A 1:10000 ALEXA
Fluorescent
anti-goat
IgG
N/A 1:10000 ALEXA
96
2.7 Cloning
The wild type SAG gene and the mutant SAG MM14 were cloned in pcDNA 3.1 
vectors (Gift from Sun Y.). For cloning the antisense SAG (GAS) plasmid, pcDNA 
3.1-SAG plasmid was digested with Xhol and Kpnl restriction enzymes (Promega 
UK Ltd, Southampton, UK) overnight at 37°C to release the SAG fragment which 
was subsequently purified by gel extraction and cloned in reverse orientation at 
the same sites on the pBluescript II KS- plasmid (Stratagene, La Jolla, CA, USA). 
Digestion with Xhol and Sstl released the GAS fragment that was cloned in the 
corresponding sites of pcDNA3.1 (GIBCO BRL, Invitrogen Life Technologies, 
Invitrogen Corporation, Carlsbad, CA, USA).
Cells were co-transfected overnight with 2.5 pg of p-galactosidase plasmid (to 
mark the successfully transfected cells) and 2.5 pg of SAG, MM14 or pcDNA3.1. 
For transfection of GAS 1pg of the plasmid was transfected using 
LIPOFECTAMINE 2000 (GIBCO BRL, Invitrogen Life Technologies, Invitrogen 
Corporation, Carlsbad, CA, USA) following the manufacturers instructions. The 
day after, the cells were washed twice with 1xPBS and exposed to simulated 
ischaemia/reperfusion as described above. To discriminate between transfected 
and untransfected cells, after washing and fixing with 2.5% glutaraldehyde in 
PBS for 30 min at 25°C, the cells were stained with X-gal overnight at 37°C. Cells 
expressing the transfected p-galactosidase gene were stained blue.
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2.8 Assessment of apoptosis.
The fixed cells were permeabilised with 0.1% Triton X-100 for 15 min and 
washed five times with PBS. Terminal deoxynucleotidyl transferase solution, 
containing 15 U/ml of terminal deoxynucleotidyl transferase (Roche-Boehringer 
Manheim, Roche Diagnostics, Lewes, East Sussex, UK) and 2.5 pM of 
fluorescein-conjugated dUTP (Roche-Boehringer Manheim, Roche Diagnostics, 
Lewes, East Sussex, UK), was added to the cells for 1.5 hours in a 37 °C 
humidified incubator. Cells were then washed five times with 1xPBS and 1% of 
propidium Iodide (w/v) was added to the cells for 2 min at 25°C. Following a triple 
wash in PBS cells were examined under an inverted fluorescent microscope. The 
percentage of apoptotic nuclei is expressed as a percentage of total nuclei from 
scoring at least 150 cells. Each count was repeated three times to make sure 
that the right number of cells per well was measured.
2.9 Statistics
Data are expressed as means ± S.D. Multiparametric analysis of variance 
(MANOVA) with a Bonferroni post-hoc test was performed for each group of 
treatments and significance was assumed when P<0.05. Differences among 
means were compared within the treatment groups using Student’s t test and 
significance was assumed when P<0.05. The experiments were repeated at least 
three times. The SPSS Base 11.0 for Windows (SPSS Inc., Chicago, IL, USA)
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statistical software package was used to perform all the statistical analyses 
described above
2.10 Peptides
Stresscopin (SCP) and stresscopin related peptide (SRP) were synthesized as 
described before (Hsu and Hsueh, 2001) and rat urocortin was purchased by 
Sigma (Sigma-Aldrich, Poole, UK). All peptides were diluted in 1XPBS and were 
used at a concentration of 10‘8M, unless otherwise stated.
2.11 Cardiomyocyte transfection
For assessing the effects of p42/44 MAPK, PKB/Akt and p38 MAPK on the 
cardioprotective effects of the peptides, primary neonatal cardiomyocytes were 
co-transfected overnight with 2.5pg of (3-galactosidase plasmid (to mark the 
successfully transfected cells) and 2.5 pg of dominant negative MEK1 (activator 
of p42) (Lavoie et al., 1996), Akt (Kotani et al., 1999), MKK6 (an activator of p38) 
(Lavoie et al., 1996), or pcDNA3.1 (control), by the calcium phosphate method. 
The day after, the cells were washed twice with 1xPBS and exposed to simulated 
ischaemia/reperfusion as described. To discriminate between transfected and 
untransfected cells, after washing and fixing with 2.5% glutaraldehyde in PBS for 
30min at 25°C, the cells were stained with X-gal overnight at 37°C. Cells 
expressing the transfected p-galactosidase gene were stained blue.
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2.12 Hypoxic insult
Prior to induction of hypoxia cells were washed twice with phosphate buffered 
saline (1xPBS) and 1% FCS supported DMEM medium was added to the cells 
which were transferred to a gas chamber for induction of hypoxia in an 
atmosphere of 95% Argon and 5% CO2 for the desired amount of time. After 
completion of the hypoxic treatment the cells were transferred to the incubator for 
up to16 hours in an atmosphere of 21% O2 and 5% CO2 . Control cells were 
maintained in these conditions for the duration of the experiments.
2.14 Trypan Blue
For Trypan Blue exclusion assays, one million cells were harvested and spun 
down briefly by centrifugation at 900 rpm at room temperature for 1 min. The 
supernatant was discarded and cells were resuspended in 1xPBS. 50 pi of the 
cell suspension was added to 50 pi of 10% Trypan Blue (Sigma-Aldrich, Poole, 
UK), and 10pl were used to be counted on a Neubauer haematocytometric slide. 
Measurements were repeated at least three times for each experiment. At least, 
700-900 cells were counted for each experiment.
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2.15 Quantitative PCR
cDNA preparation and quantitative PCR
First strand synthesis was done using 1 pg of total RNA, and 1 jllI of oligo-dT 
primers (Promega UK Ltd, Southampton, UK). AMV reverse transcriptase 
(Promega UK Ltd, Southampton, UK) was used according to the manufacturer’s 
instructions. PCR was performed with the ABIprism lightcycler PCR to amplify 
the pool of cDNAs using QIAGEN SYBR Green system and the following primers
ANF forward: 5’-TGCCGGTAGAATGAGGTC-3’
ANF reverse: 5’-AGCCCTCAGTTTGCTTTTCA-3’
BNP forward: 5’-TAATCTGTCGCCGCTGGGAGGG-3’
BNP reverse: 5’-GAGCTGGGGAAAGAAGAGCCG-3’
GAPDH forward: 5’-GCCATCAACGACCCCTTCATTG-3’
GAPDH reverse: 5’-TGCCAGTGAGCTTCCCGTTC-3’
2.16 Measurement of Planimetric Area
Cells were observed under phase contrast or fluorescent light in the case of 
transfected cells, and the image was conveyed to a computer via a video 
camera. A mouse was used to draw around the perimeter of each cell and NIH 
image analysis was used to calculate the planimetric area. Measurements were 
calibrated by measurement of a known standard and results converted to pm.
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2.17 Measurement of Protein:DNA ratio
Forty-eight hours after treatment cells were harvested by harvested by 
mechanical separation with a rubber policeman in ice cold 1xPBS and gently 
spun down and resuspended in ice cold 70% ethanol in PBS. Cells were fixed at 
4° C overnight, centrifuged at 145xg for 2 min and resuspended in 100 pi FITC 
stain (0.1 pg/ml FITC, 50 pg/ml RNAse A in PBS) and were stained for 1-2 hours. 
Cells were then centrifuged as above and washed twice by resuspending in 1 ml 
PBS. Cells were then stained with 400 pi of Propidium Iodide (PI) stain (50 pg/ml 
PI, 0.1% NaaCitrate, 0.1% Triton X-100 in dH20). Cells were then analysed in a 
Coulter XL FACS maschine and mean fluorescence from 10000 cells at a time 
were measured for FITC (protein) at 525 nm and PI (DNA) at 620 nm. The mean 
ratio of protein to DNA was then calculated.
2.18 Blocking of signaling pathways
The LY294002 (Sigma-Aldrich, Poole, UK), a selective inhibitor of PI-3K, was 
used at a concentration of 50 pM. PD98059 (New England Biolabs Inc., Beverly, 
MA, USA), a selective inhibitor of MEK1/2 was used at a concentration of 100 
pM, and SB203580 (Promega UK Ltd, Southampton, UK), a selective inhibitor of 
p38 MAPK was used at a concentration of 10 pM. The concentrations used are 
adequate to block the appropriate signaling pathways in rat neonatal 
cardiomyocytes, as described before (Lavoie et al., 1996; Brar et al., 2002; Brar 
et al., 2000). All inhibitors were used for 30 min prior to any other treatments.
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CHAPTER III
Protective effects of the urocortin homologues against 
hypoxia/reoxygenation injury
3.1 Introduction
UCN has been shown to protect cardiac myocytes from cell death after exposure 
to hypoxia/reoxygenation injury in vitro (Brar et al., 1999; Brar et al., 2000). In 
addition, UCN has similar effects in the isolated perfused rat heart (Brar et al., 
2000). As CRFR2P is the only subtype expressed in the rat heart (Nishikimi et al.,
2000), the cardioprotective effects of UCN against hypoxia/reoxygenation (Okosi 
et al., 1998; Brar et al., 1999; Brar et al., 2000; Latchman, 2001; Brar et al., 2002; 
Latchman, 2002) are attributed to the binding to the CRRFR2. Since SCP and 
SRP show higher affinity for the CRFR2 than UCN (Hsu and Hsueh, 2001; Lewis 
et al., 2001), we hypothesised that these peptides might exhibit higher protective 
effects than UCN and, or might produce these effects with higher specificity, 
since they bind only to CRFR2.
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3.2 Results
3.2.1 UCN Homologues are expressed in Rat primary cardiomyocytes
Initially, we wished to determine whether the UCN homologous genes SCP and 
SRP are expressed in neonatal rat cardiomyocytes. We isolated total mRNA from 
untreated cardiomyocytes (Lanes 1, 2, 1’ and 2’, Fig. 3.1) and cardiomyocytes 
that were exposed to 4 hours of hypoxia, followed by 16 hour reoxygenation 
(Lanes 3 and 4 and 3’ and 4’, Fig. 3.1). We failed to amplify SRP in the untreated 
cardiomyocytes (lane 2, Fig.3.1), although SRP was expressed in the 
cardiomyocytes after hypoxia/reoxygenation injury (lane 4, Fig. 3.1). SCP was 
expressed in untreated cardiomyocytes and after hypoxia/reoxygenation (Fig. 
3.1). SRP was present at a similar level to SCP after hypoxia/reoxygenation, 
although it was undetectable prior to the insult (Fig. 3.1).
In addition, we tried to confirm the above results by performing real time PCR on 
the above samples, as it was previously suggested that SRP is actually 
expressed in the heart (Hsu and Hsueh, 2001). This time, we managed to detect 
SRP mRNA in normoxic conditions, albeit the levels of SRP were 5 times lower 
than SCP mRNA levels (Fig. 3.2). After hypoxia reoxygenation the SCP and SRP 
levels were increased to similar levels and were comparative to the levels 
detected by our quantitative PCR methods (Fig. 3.1 and 3.2)
These results show that SCP and SRP are expressed in the rat neonatal 
cardiomyocytes and that their levels are increased following a hypoxic insult.
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Figure 3.1. SCP and SRP mRNA are induced by hypoxia/reoxygenation. A. 
Ethidium Bromide stained agarose gel of RT-PCR amplification products for SCP 
(lanes 1 and 3) and SRP (lanes 2 and 4) and actin (lanes 1’-4’) from RNA 
isolated from untreated rat neonatal cardiomyocytes (lanes 1, 2 and 1’,2’) and 
from rat neonatal cardiomyocytes undergone Hypoxia/Reoxygenation (lanes 3, 4, 
3’ and 4’). Lane M is a 1kb DNA marker and lanes N are negative controls. B. 
Densitometric analysis SCP and SRP RT-PCRs. Actin was used for 
normalisation. Values are the average of at least three experiments with their 
standard deviation represented by the bars. Stars represent statistical 
significance (2-way ANOVA, p<0.05).
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Figure 3.2. Quantification of SCP and SRP mRNA levels in primary rat neonatal 
cardiomycytes by real time PCR. Columns represent the mean fold change over 
control of four experiment and bars are SEM.
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3.2.2 Protective properties of UCN homologues
As SCP and SRP are newly identified members of the CRF family we wanted to 
test whether these peptides have any cardioprotective effects. It was previously 
shown in our laboratory that CRF and UCN had such cardioprotective properties. 
Furthermore, UCN exhibited better cardioprotection compared to CRF, a property 
that is suggested to be attributed to the higher binding affinity of UCN to CRF 
receptor type 2 (CRFR2) (Nishikimi et al., 2000). As SCP and SRP bind 
exclusively to CRFR2 we hypothesised that any cardioprotection elicited by the 
application of these peptides should be more pronounced when compared to 
UCN.
To test cardioprotective properties of the UCN-related peptides we incubated 
primary cardiomyocytes with 1 nM of each peptide for 1 hour prior to subjecting 
the cells to an anoxic environment for 4 hr. After a 16 hr reoxygenation, the cells 
were harvested and stained with Trypan Blue. In these experiments, some death 
was observed on untreated cells, due to damage during the isolation and 
harvesting procedures. However, a dramatic increase in cell death was observed 
upon exposure of the cells to hypoxia/reoxygenation.
As shown in Fig. 3.3 all peptides improved the viability of the primary 
cardiomyocytes exposed to hypoxia/reoxygenation (2-way ANOVA, p<0.05 vs
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Figure 3.3. UCN and its homologues protect cardiomyocytes from cell death 
induced by hypoxia/reoxygenation. Percentage of live cells as assessed by 
trypan blue exclusion is represented by the columns. Values are the average of 
at least three experiments with their standard deviation represented by the bars. 
For statistical differences see text.
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Control). We could not detect any difference in the levels of protection among the 
three different peptides at this concentration. (2-way ANOVA, p>0.05, Bonferroni 
post-hoc).
In order to further examine the protective effects of the peptides we added 1 nM 
of each peptide at the onset of reoxygenation (Fig. 3.4). Again all peptides were 
found to be protective (2-way ANOVA, p<0.05 vs Control). However, SRP 
showed the least amount of protection compared to SCP (2-way ANOVA, 
p<0.05,) and also compared to UCN (2-way ANOVA, p<0.05).
When we compared the levels of protection of the different peptides when added 
prior to, or following hypoxia, we observed that the levels of protection for UCN 
and SCP are no different, regardless of when we added the peptides (2-way 
ANOVA, p>0.05 followed by Bonferroni post-hoc between SCP at reoxygenation 
vs SCP at hypoxia and p>0.05 between UCN at reoxygenation vs UCN at 
hypoxia). SRP in comparison showed higher levels of protection when added 
prior to hypoxia (2-way ANOVA Bonferroni post-hoc, p<0.05 between SRP at 
hypoxia vs SRP at reoxygenation).
The above results indicate a slight difference in the levels of protection among 
the different peptides. Moreover, it shows that SCP, like UCN, is able to 
attenuate cell death, even if it is administered after the hypoxic insult.
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Figure 3.4. UCN and its homologues can protect cardiomyocytes from cell death 
caused by hypoxia/reoxygenation when added at the onset of reoxygenation. 
Percentage of live cells as assessed by trypan blue exclusion is represented by 
the columns. Values are the average of at least three experiments with their 
standard deviation represented by the bars.
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3.2.3 Antiapoptotic properties of UCN homologues
To examine further the cardioprotective properties of the three peptides we 
incubated primary cardiomyocytes with 10‘12M, 10'11 M, 10'1° M, 10‘9 M, 10‘8 M 
and 10'7 M of each of the peptides for 1 hour, prior to subjecting the cells to an 
anoxic environment for 4 hr. After a 16 hr reoxygenation, the cells were fixed and 
assessed for apoptosis with TUNEL staining to measure the number of apoptotic 
cells.
All three peptides were strongly protective at all concentrations used compared 
to the control (2-way ANOVA Bonferroni post-hoc, p<0.05 vs control) (Fig. 3.5). 
When we compare the protective effects between the peptides, SCP exhibited 
higher levels of protection from apoptosis compared to UCN at all concentrations 
up to and includinglO'10 M (2-way ANOVA Bonferroni post-hoc, p<0.05) (Fig. 
3.5). Similarly, SRP was more protective than UCN for concentrations up to 10'1° 
M (2-way ANOVA Bonferroni post-hoc, p>0.05). However, at a concentration of 
10‘9 M UCN was the more protective of the two (Fig. 3.5) (2-way ANOVA 
Bonferroni post-hoc, p>0.05). SCP was even more protective than SRP when 
used at concentrations of 10'12 M and 10'9 M. For concentrations between 10'11 
M and 10’8 M the two peptides exhibited similar cardioprotective effects (2-way 
ANOVA Bonferroni post-hoc, p<0.05) (Fig. 3.5).
I l l
When the peptides were added at the onset of reoxygenation, again they all 
showed antiapoptotic properties at all concentrations examined (2-way ANOVA 
Bonferroni post-hoc, p<0.05 vs control) (Fig. 3.6). Again, SCP was significantly 
more protective than UCN at concentrations of 10'12 and 10‘8 M (2-way ANOVA 
Bonferroni post-hoc, p<0.05) and there was no difference in the levels of 
protection between SCP and SRP for any of the concentrations used (2-way 
ANOVA Bonferroni post-hoc, p>0.05). SRP was more protective than UCN only 
at concentration of 10'8 M (2-way ANOVA Bonferroni post-hoc, p<0.05).
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Figure 3.5. UCN and its homologues can protect cardiomyocytes from apoptotic 
cell death caused by hypoxia/reoxygenation. Percentage of TUNEL positive 
cardiomyocytes is represented by the columns. Values are the average of at 
least three experiments with their standard deviation represented by the bars.
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Figure 3.6. UCN and its homologues can protect cardiomyocytes from apoptotic 
cell death caused by hypoxia/reoxygenation when added at the onset of 
reoxygenation. Percentage of TUNEL positive cardiomyocytes is represented by 
the columns. Values are the average of at least three experiments with their 
standard deviation represented by the bars.
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3.2.4 Discussion
Previous studies have shown relatively low levels of expression of UCN III or 
SCP in the heart of mice and human respectively (Hsu and Hsueh, 2001; Lewis 
et al., 2001). Here we are able to demonstrate for the first time the expression 
pattern of UCN homologues in neonatal rat cardiomyocytes. In contrast to what 
has been described for the adult heart of human and mouse, here SCP is 
expressed highly, whereas we failed to amplify any SRP mRNA from neonatal 
cardiomyocytes.
However, again for the first time we are able to show that the mRNAs encoding 
both peptides are induced after a hypoxia/reperfusion injury (Fig. 3.1). We have 
not examined the expression levels of the peptides in the intact heart or in adult 
rat cardiomyocytes. Furthermore, although we were unable to detect any SRP 
mRNA with conventional PCR methods, we were able to show that SRP is 
indeed expressed in the neonatal cardiomyocytes, albeit in lower levels than 
SCP by real time PCR (Fig. 3.2). These results do demonstrate the higher 
sensitivity of the real time PCR method. It is possible that SRP might become the 
predominant peptide in adult life.
Urocortin has been shown to be able to bind to CRFR2 types with higher affinity 
than to CRFR1 and binds with higher affinity to CRFR2 than CRF (Vaughan et 
al., 1995). In addition, the exclusive presence of CRFR2p in the heart (Nishikimi 
et al., 2000) and the fact that UCN failed to increase cardiac function in CRFR2
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knock out mice (Coste et al., 2000) has always led to the speculation that CRFR2 
is responsible for the effects of UCN in the periphery. As a result, we initially 
hypothesised that because of the higher affinity of the SCP and SRP peptides for 
the CRFR2p (Hsu and Hsueh, 2001; Lewis et al., 2001) these peptides might 
exhibit augmented cardioprotective properties in the heart compared to UCN. In 
this study we are able to show that all three homologues exhibit similar 
cardioprotective effects. Nevertheless, SCP and SRP were able to promote 
higher levels of protection against apoptosis when 1pM of the peptides were 
used (Fig. 3.5 and 3.6). Hence, cardioprotective effects can be observed with 
UCN-related peptides which bind only to the CRFR2.
UCN II and III have been recently shown to exhibit potent cardioprotective effects 
against a hypoxic insult in neonatal cardiomyocytes, (Brar et al., 2004a) in adult 
cardiomyocytes and in Langerdorff perfused hearts (Brar et al., 2004a). The 
effects of the two peptides was comparable or higher than UCN, and most 
importantly the administration of the peptides in the presence of a specific 
CRFR2 inhibitor, or in CRFR2-/- mice failed to exhibit any cardioprotection, 
showing that UCN II and III bind exclusively to CRFR2 to elicit their 
cardioprotection (Brar et al., 2004a).
It is worth noting that although SRP has a higher affinity for the CRFR2P 
compared to SCP (Lewis et al., 2001), in our studies SCP usually showed higher 
protective effects compared to SRP (Fig. 3.4, 3.5 and 3.6). This could be due to a
possible lower affinity of the human SRP to the rat receptor or because of the 
higher ability of SCP to activate the receptor CRFR2P compared to UCNII/SRP, 
as measured by accumulation of cAMP (Lewis et al., 2001). This could also 
explain the similar protective properties of UCN to the two homologues, as the 
relative potencies of SCP, SRP and rat UCN to functionally activate the receptor, 
overlap (Lewis et al., 2001).
In summary, we showed for the first time that SCP and SRP are expressed in the 
neonatal cardiomyocytes. We also demonstrated that they are peptides with 
higher or equal cardioprotective properties than UCN, but more importantly they 
are more specific than UCN as they do not bind to CRFR1, making them better 
candidates as possible therapeutic agents.
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CHAPTER IV
Hypertrophic effects of the UCN homologues
4.1 Introduction
UCN not only is able to induce cardioprotective effects in cardiac myocytes and 
the whole heart, but has also been shown to be involved in cardiac hypertrophy. 
UCN is able to increase distinct markers of hypertrophy, such as protein 
synthesis, cell size, ANP and BNP natriuretic peptide secretion and collagen in 
cardiomyocytes (Ikeda et al., 1998; Nishikimi et al., 2000; Railson et al., 2002). In 
addition, expression of UCN mRNA was higher in human hearts with left 
ventricular hypertrophy (Nishikimi et al., 2000) and UCN immunoreactivity was 
more intense in cardiomyocytes of human failing hearts, than in normal human 
hearts (Nishikimi et al., 2000).
In our current study, we compare the hypertrophic properties of UCN, SCP and 
SRP in rat neonatal cardiomyocytes. As SCP and SRP are more specific for 
CRFR2 than UCN it would be interesting to examine whether any differences in 
the hypertrophic effects of the three peptides do occur.
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4.2 Results
4.2.1 UCN Homologues increase cell size
UCN has been previously shown to increase cardiomyocyte size (Railson et al., 
2002). As SCP and SRP have a higher affinity for the CRFR2 than UCN and they 
do not bind to CRFR1, we wanted to examine whether their administration to 
primary cardiomyocytes would have a similar effect to UCN on cell size. We 
chose to use the measurement of the cell area as an indicator of cell size. When 
10‘8 M of each peptide was added to the cells for 48 hours a distinct increase in 
cell area was observed (MANOVA p<0.05) (Fig. 4.1 A). Furthermore, SCP was 
the most potent of the three peptides in increasing cell area, whilst SRP and 
UCN had similar effects on cell area (MANOVA p>0.05) (Fig. 4.1 A). UCN and 
SRP caused an approximately 15% increase in cell area over control, whereas 
SCP caused an approximately 35% increase in cell area comparable to the 
increase caused by phenylephrine, a known hypertrophic factor (MANOVA 
p>0.05).
These results therefore, show that all three peptides are causing an increase in 
cell size and that SCP is the most potent of the three at 10'8 M concentration.
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Figure 4.1. (A) Effects of the UCN peptides on cell size. 10-8 M of each peptide was added to the medium of 
rat neonatal cardiomyocytes for 48 hours, prior to measuring their cell area. Columns represent the mean of 
four experiments and bars are SEM. # represent p<0.05 after MANOVA test. (B). Effect of the UCN peptides 
on protein:DNA ratio. 10"8 M of each peptide was added to the medium of rat neonatal cardiomyocytes for 
48 hours, prior to measuring their protein:DNA ratio by FACS. Columns represent the mean change in 
percentage over control of six experiments and bars are SEM. # represent p<0.05 after MANOVA test.
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4.2.2 UCN homologues induce protein synthesis
Although an increase in cell size is a good indication of hypertrophy, it is 
necessary to measure other parameters in order to establish whether a factor is 
hypertrophic or not. The increase in cell size during hypertrophy is accompanied 
by an increase in protein synthesis that is not followed by DNA replication. So, 
the protein to DNA ratio is a reliable marker of hypertrophy. Cells were incubated 
in the presence of phenylephrine, trichostatin A, and the peptides for 48 hours 
and subsequently harvested, fixed and stained by FITC (for total protein content) 
and PI (for DNA content) and analysed by FACS. Phenylephrine and Trichostatin 
A are known inducers of hypertrophy and as such they were used as positive 
controls (Gusterson et al., 2002; Gusterson et al., 2003). As with the cell size, all 
three peptides caused an increase in protein to DNA ratio (MANOVA, p<0.05 to 
control) (Fig. 4.1B). SCP and UCN were the more potent peptides with a 49% 
and 46% increase on the ratio over control, whilst SRP induced a 38.5% increase 
(Fig. 4.1 B).
The above results show that all three peptides are able to induce protein 
synthesis after a 48 hour administration and their effects are comparable to those 
of known hypertrophic agents like phenylephrine and Trichostatin A.
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4.2.3 UCN homologues induce the expression of Atrial Natriuretic and 
Brain Natriuretic peptides
Hypertrophy is characterised by a switch to a fetal gene program. The ANP and 
BNP genes fall into this category and their expression is shown to be elevated in 
patients with progressive heart failure. CRF and UCN has been previously shown 
to induce expression of ANP and BNP (Grunt et al., 1992; Haug et al., 1994; Tojo 
et al., 1996; Ikeda et al., 1998). To examine the effects of SCP and SRP on ANP 
and BNP expression we treated rat cardiomyocytes for 48 hours and analysed 
the mRNA levels in the cells using quantitative real time PCR analysis. All three 
peptides were able to induce the expression of ANP and BNP mRNA after 48 
hours (MANOVA, p<0.05 vs control) (Fig. 4.2). SCP caused a 2.5 fold induction 
of ANP mRNA and a 5.5 fold induction of BNP (Fig. 4.2). UCN was more potent 
than SRP in inducing the natriuretic peptides, but less pronounced in the 
induction of ANP compared to SCP (MANOVA, p<0.05). In comparison, all three 
peptides are able to induce BNP levels more efficiently than ANP.
In conclusion, all three peptides are able to cause an increase in all the 
hypertrophic markers we examined and SCP appears to be the most potent of 
three peptides, exactly as shown before for its cardioprotective effects compared 
to UCN and SRP (Chapter III).
Control UCN SCP SRP
Control UCN S C P  SR P
Figure 4.2. Effects of the UCN peptides on the expression of the genes encoding (A) 
Atrial natriuretic peptide and (B) Brain natriuretic peptide. 10'8 M of each peptide was 
added to the medium of rat neonatal cardiomyocytes for 48 hours, prior to measuring the 
changes on gene expression by real time PCR. Columns represent the mean fold 
change over control of four experiment and bars are SEM. # represent p<0.05 after 
MANOVA test.
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4.3 Discussion
Previous studies have shown that UCN and CRF are able to induce hypertrophy 
in cardiac myocytes (Ikeda et al., 1998; Nishikimi et al., 2000; Railson et al., 
2002). We hypothesised that the UCN homologues might demonstrate more 
pronounced hypertrophic properties than UCN, due to the their higher affinity to 
the CRFR2R (Hsu and Hsueh, 2001; Lewis et al., 2001; Reyes et al., 2001). In 
our study, similarly to what we have shown before, when we studied the 
cardioprotective effects of the UCN homologues, SRP exhibited the least ability 
to increase the levels of any of the hypertrophic markers we examined. We 
previously hypothesised that this might be due to a lower affinity of the human 
SRP peptide to the rat CRFR2, or due to the lower ability of SRP to activate the 
receptor. In addition, it has been proposed that because SRP lacks the C- 
terminal amidation signal, present on other CRF peptides, that might impair its 
biological function (Hsu and Hsueh, 2001; Dautzenberg et al., 2002; Hauger et 
al., 2003).
The UCN peptides were able to induce the levels of BNP mRNA more efficiently 
than ANP (Fig. 5). This is in agreement with previous results where, although, the 
levels of ANP protein were higher than BNP in rat neonatal cardiomyocytes, the 
fold induction of BNP protein levels were higher than ANP after UCN 
administration (Ikeda et al., 1998). This difference between the two natriuretic 
peptides would indicate some difference in the gene regulation. It could be that a
124
factor or factors that are induced by UCN administration might have a different 
affinity for the two gene promoters, or that one promoter is exclusive for a certain 
factor or factors. Clearly closer examination and studies into the promoter region 
of the two genes could provide us with some clues concerning the promoter 
regulating peptides that are induced by UCN and are responsible for the 
hypertrophic effects.
In conclusion, it appears that all three peptides are able to protect cardiac cells 
from hypoxia/reoxygenation injury, but unfortunately at the same time they do 
induce hypertrophy. If we were able to find some differences among the 
mechanisms that induce cardioprotection and hypertrophy we might be able to 
isolate those that cause hypertrophy, in order to use the peptides as protective 
agents. For these reason we are going to examine the pathways that UCN and 
its homologues are inducing.
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CHAPTER V
Signalling Pathways involved in protective and Hypertrophic 
Effects of UCN homologues
5.1 Introduction
Cardioprotection from hypoxia/reoxygenation injury induced by UCN and its 
homologues in rat neonatal cardiomyocytes is dependent on activation both of 
Akt and MAPK p42/44, as inhibiton of Akt and p42/44 pathways by chemical 
inhibitors, or with overexpression of dominant negative constructs abolished 
cardioprotection by the peptides (Brar et al., 2000; Latchman, 2001; Brar et al., 
2002a; Brar et al., 2002b; Railson et al., 2002; Schulman et al., 2002; Brar et al., 
2004a; Brar et al., 2004b). In addition, the level of activation of MAPK p42/44 
phosphorylation is correlated to the cardioprotective effects of the peptides, as 
UCN II and III are able to induce higher phosphorylation levels of MAPK p42/44 
than UCN (Brar et al., 2004a; Brar et al., 2004b). Furthermore, it was shown that 
the MAPK p42/44 pathway is not involved in the manifestation of the hypertrophic 
effects of UCN in rat neonatal cardiomyocytes, as transfection of cardiomyocytes 
with a dominant negative MEK1 construct, prior to UCN administration, failed to 
attenuate the increase in mean cell area by UCN (Railson et al., 2002).
It was previously postulated that the increase in cAMP by UCN administration is 
mediating its hypertrophic effects (Nishikimi et al., 2000; Rademaker et al.,
2002). However, Akt activation has also been implicated in cardiac hypertrophy 
(Frey and Olson, 2003), but its role in the hypertrophic effects of UCN or its 
homologues has not been studied. In this chapter we will try to establish the role 
of MAPK and Akt in the cardioprotective and hypertrophic effects of UCN and its 
homologues.
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5.2 Results
5.2.1 UCN homologues activate MAPK and Akt
We wanted to establish whether the differences in cardioprotection that we 
observed between the three peptides were due to differences in their ability to 
activate certain signalling molecules, such as p42/44 MAPK, and Akt.
To do this, we treated cardiomyocytes for 30 minutes with the p42/44 MAPK 
inhibitor PD98059 prior to the addition of 10'8 M of UCN, SCP or SRP. Also, we 
treated cells with the peptides alone to compare the levels of phosphorylated 
p42/44 MAPK between the different sets of cells. After one hour of incubation in 
the presence of one of the three peptides and the presence or absence of the 
inhibitor, the cells were harvested and analysed by western blotting with an 
antibody specific for phosphorylated p42/44 MAPK.
SCP treatment leads to a more pronounced p42/44 MAPK phosphorylation than 
UCN and UCN exhibits a higher phosphorylation signal than SRP (Fig. 5.1). The 
ability of the peptides to activate the p42/44 MAPK pathway seems to correspond 
with their cardioprotective potency, as SCP appears to be slightly more potent 
than UCN and SRP at least at lower concentrations. The presence of the inhibitor 
PD203580 completely abolished p42/44 MAPK phosphorylation by the peptides. 
So, the ability of the peptides to protect is connected with their ability to activate 
the p42/44 MAPK signalling pathway in rat neonatal cardiomyocytes.
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We examined the levels of phosphorylation of Akt induced by the three peptides, 
in order to discover if the UCN homologues are able to induce phosphorylation of 
Akt. To do this we treated cardiomyocytes for 30 min prior to the peptide addition 
with the PI3-K inhibitor LY294002. Also cells were treated with the peptides alone 
to compare the effects of the inhibitor on the Akt phosphorylation. After one hour 
of incubation in the presence of one of the three peptides and the presence or 
absence of the inhibitor, the cells were harvested and analysed by western 
blotting with an antibody specific for phosphorylated Akt.
SCP was able to induce more pronounced phosphorylation of Akt, than UCN 
and SRP (Fig. 5.1). Furthermore, LY294002 was able to block Akt 
phosphorylation in the concentration used. Interestingly, blocking the MAPK 
pathway caused an increase on the levels of phosphorylation of Akt (Fig. 5.1).
Although, we were aware that p38 MAPK is not activated after CRFR2 activation 
by either CRF or UCN we treated neonatal rat cardiomyocytes with the p38 
MAPK inhibitor SB203580, to examine any possible effects of p38 MAPK 
inhibition on the levels of p42/44 MAPK and Akt activation (Fig. 5.1). 
Interestingly, blockage of the p38 MAPK pathway with SB203580 enhanced the 
ability of SCP to activate p42/44 MAPK. In contrast, blockage of the Akt pathway 
with LY294002 enhanced the ability of UCN and SCP to activate p42/44 MAPK 
(Fig. 5.1).
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Figure 5.1. Phosphorylation of p42/44 MAPK and Akt by UCN SCP and SRP on 
rat neonatal cardiomyocytes. Western blotting analysis of phosphorylated p42/44 
MAPK (Top) and phosphorylated Akt (Bottom) by the UCN peptides in the 
presence and absence of specific kinase inhibitors. LY: LY294002 a PI3-K 
inhibitor, PD: PD98509 a p42/44 MAPK inhibitor, SB: SB203580 a p38 MAPK 
inhibitor.
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5.2.2 MAPK activation and Akt activation is required for 
cardioprotective effects of UCN homologues.
It has been previously shown that UCN protection is dependent upon its ability to 
activate the p42/44 MAPK and the PI-3K/Akt pathway in cardiac cells (Brar et al., 
2000; Brar et al., 2002a; Railson et al., 2002). For this reason we examined 
whether SCP and SRP are also dependent on activation of the same kinases in 
order to protect primary cardiomyocytes from hypoxia/reperfusion injury.
Therefore we treated primary rat cardiomyocytes with the inhibitors LY294002, 
PD98059 and SB203580 for 30 minutes prior to the addition of 10'8M UCN, SCP 
and SRP and following hypoxia reoxygenation. The above inhibitors are known to 
block activation of PI3-K, MAPK p42/44 and p38 kinase signalling pathways, 
respectively (Brar et al., 2000; Brar et al., 2002a; Railson et al., 2002). At the end 
of the reoxygenation cells were fixed and stained by TUNEL, a method that 
stains the nicked ends of DNA in a cell with a fluorescent uridyl nucleotide, to 
reveal DNA that has been cut with CAD, as a result of apoptosis taking place. 
This assay will also reveal the antiapoptotic effects of UCN and its homologues 
and will strengthen the results we obtained by the use of the Trypan Blue assay.
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Figure 5.2. The antiapoptotic properties of UCN and its homologues are attenuated by blocking the 
activation of p42/44 MAPK and PI-3K. A. The effect of chemical inhibitors on the cardioprotective effects of 
UCN and its homologues. PD98059 was used to block p42/44 activation, LY294002 was used to block Pl- 
3K activation and SB203580 for the blocking of p38 MAPK. The inhibitors were used as described in the 
Materials and Methods. B. Abrogation of the activation of p42 and Akt attenuates the cardioprotective effects 
of UCN and its homologues. Cells were transfected with DNMEK1 to block p42/44 activation, DNAkt to block 
PI-3K activation and DNMEKK6 to block p38 MAPK, prior to undergoing simulated ischaemia/reoxygenation 
injury. The transfections were carried out as described in the Materials and Methods.
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The presence of LY294002 or PD98059 completely abolished the antiapoptotic 
effects of all three peptides (Fig. 5.2A). On the contrary, SB203580 was unable 
to completely inhibit the cardioprotective effects of the three peptides (2-way 
ANOVA Bonferroni post-hoc, p<0.05 for UCNSB vs SB and for UCNSB vs 
Control; p<0.05 for SCPSB vs SB and for SCPSB vs Control; and p<0.05 for 
SRPSB vs SB and for SRPSB vs Control) (Fig. 5.2A).
The above results indicate that SCP and SRP are dependent on the activation of 
PI-3K and p42/44 MAPK, but not p38 MAPK for their antiapoptotic effects in 
cardiomyocytes, exactly as shown previously for UCN.
As the use of inhibitors alone can not be conclusive, since chemical inhibitors are 
not specific and could be inhibiting a number of kinases, we tried to support 
these results by a more direct approach. For this reason, we transfected rat 
neonatal cardiomyocytes with plasmids expressing dominant negative forms of 
MEK1 (DNMEK1), an upstream activator of p42 MAPK (Lavoie et al., 1996), Akt 
(DNAkt) (Kotani et al., 1999) and MEKK6 (DNMEKK6), an upstream activator of 
p38 MAPK (Pandey et al., 1999). The use of dominant negative kinases ensures 
that only the specific kinases will be made redundant. After overnight transfection 
the cells were treated for an hour with the peptides, and undergone simulated 
ischaemia reoxygenation as before.
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The presence of DNMEK1 was able to completely abolish the cardioprotective 
effects of all three peptides (2-way ANOVA, p<0.05) (Fig. 5.2B). In a similar 
manner DNAkt was able to attenuate the cardioprotection of all peptides (Fig. 
5.2B) (2-way ANOVA, p<0.05). In contrast, the presence of DNMEKK6 had no 
effect on the cardioprotective effects of the peptides, and in addition, it improved 
the viability of cardiomyocytes without the presence of peptides (Fig. 6B).
These results, in combination with the chemical inhibitor experiments, clearly 
show the dependence of all three peptides on activation of both p42/44 MAPK 
pathway and Akt, in order to elicit their cardioprotective effects.
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5.2.3 Hypertrophic effects of UCN are attenuated by Akt inhibition, but 
not by MAPK p42/44 inhibition
UCN peptides have been shown to elicit their cardioprotective effects through 
activation of MAPK p42/44 and Akt (Brar et al., 2000; Latchman, 2001; Brar et 
al., 2002a; Brar et al. 2002b; Dautzenberg and Hauger, 2002; Railson et al., 
2002; Schulman et al., 2002). Although, the effects of MAPK activation by UCN 
have been shown not be involved in hypertrophy (Railson et al., 2000), the role of 
Akt activation in this context has not been studied. For these reason we elected 
to study the effect of Akt activation by the UCN peptides on cell size, protein 
synthesis and natriuretic peptide induction.
When the PI3K pathway was blocked by the chemical inhibitor LY294002, we 
observed an inhibition on the cell area increase by the UCN peptides (Fig. 5.3 
Top). In contrast, chemical inhibition of MAPK caused an increase on the cell 
area in the presence of the peptides, which was significant in the case of SCP 
(MANOVA, p<0.05 versus SCP) (Fig. 5.3 Top).
Similarly, when we examined the effect of the chemical inhibition of MAPK and 
PI3K on protein synthesis, we observed that only inhibition of the PI3K pathway 
was able to attenuate the increase in the protein to DNA ratio by the UCN 
peptides (Fig. 5.3 Middle).
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Figure 5.3. The role of PI3K and MAPK pathways in the effect of UCN peptides 
on cell area (Top) and (Bottom) cell area and protein synthesis (Middle). 10'8 M 
of each peptide was added to the medium of rat neonatal cardiomyocytes for 48 
hours in the presence or absence of the chemical inhibitors LY294002 and 
PD98059 (Top) and (Middle), or dominant negative Akt and dominant negative 
MEK1 (Bottom) as described in materials and methods, prior to measuring their 
cell area. Columns represent the mean of at least four experiment and bars are 
SEM. # represent p<0.05 after MANOVA.
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Interestingly, unlike the effect of PI3K inhibition on cell area, inhibition of PI3K in 
the presence of the peptides failed to bring the levels of protein:DNA ratio to 
control levels observed in the absence of the peptides, indicating that other 
pathways might be involved in the regulation of protein synthesis by the peptides.
To find out whether Akt, a kinase downstream of PI3K, was implicated in the 
hypertrophic effects of the peptides, we transfected cells with a dominant 
negative Akt construct or a dominant negative MEK1 construct (MEK1 is an 
upstream kinase of p42/44). Once more, only blocking of Akt was able to 
attenuate the increase in cell area by the UCN homologues (Fig. 5.3 Bottom).
The above results demonstrate that Akt activation is necessary for the increase 
in cell size and induction of protein synthesis by the UCN peptides. Finally, we 
examined whether Akt is involved in the induction of ANP and BNP genes by 
UCN. Blocking PI3K by LY294002, attenuated the induction of ANP and BNP by 
all three peptides. It is of interest that the levels of the natriuretic peptides were 
similar to control levels when the peptides were administered in the presence of 
LY294002 (MANOVA p<0.05 for LY294002 plus peptide groups vs control) (Fig. 
5.4), indicating that the PI3K pathway is of major importance in the induction of 
the hypertrophic effects of the UCN peptides.
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F ig u re  5 .4 . The role of PI3K pathway in the induction of (A) ANP gene and (B) BNP gene. 10'8 M 
of each peptide was added to the medium of rat neonatal cardiomyocytes for 48 hours, prior to 
measuring the changes on gene expression by real time PCR. Columns represent the mean fold 
change over control of four experiment and bars are SEM. # represent p<0.05 after MANOVA.
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5.3 Discussion
UCN has been shown to require the activation of MAPK p42/44 and Akt/PKB in 
order to elicit its protective effects in the rat heart and in isolated cardiomyocytes 
(Brar et al., 2000; Latchman, 2001; Brar et al., 2002a; Brar et al. 2002b; 
Dautzenberg and Hauger, 2002; Railson et al., 2002; Schulman et al., 2002). 
Here we are able for the first time to show that SCP and SRP require activation 
of p42/44 MAPK and Akt to bring about their antiapoptotic functions in the 
primary rat neonatal cardiomyocytes (Fig. 5.2).
In addition, we show that blocking phosphorylation of Akt and p42/44 MAPK 
either by chemical inhibitors, or by dominant negative constructs, we can 
increase the amount of cell death following hypoxia reoxygenation (Fig. 5.2), in 
accordance with previous results (Yue et al., 2000; Yamashita et al., 2001). 
Moreover, blocking of p38 MAPK can improve viability following hypoxic insults 
(Fig. 5.2), as shown before (Ma et al., 1999; Mackay et al., 1999; Yue et al., 
2000). Extracellular signalling kinases (ERKs, or p42/44 MAPK) are involved in 
cardioprotection in the heart (Sugden and Bogoyevitch, 1995; Bogoyevitch, 2000; 
Yaoita et al., 2000; Michel et al., 2001). They are Ser/Thr kinases activated by G- 
protein coupled receptors and protein tyrosine kinases through activation of ras 
and raf (Yaoita et al., 2000; Johnson and Lapadat, 2002). Downstream effectors 
of their survival effects include Bcl-xL (Mori et al., 2003) and they have been 
shown to be required for prevention of cytochrome C release from the 
mitochondria (Erhardt et al., 1999).
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Furthermore, we are able to demonstrate that SCP is a more potent activator of 
the p42/44 MAPK, followed by UCN and SRP last (Fig. 5.1). This pronounced 
activation of p42/44 MAPK by SCP can also explain the potent cardioprotective 
effects of SCP, and can further strengthen the notion that SCP is binding to 
CRFR2 with higher affinity than UCN. It has been previously shown in myometrial 
cells that phosphorylation of the MAPK p42/44 is a downstream event that 
follows the activation of CRFRIa and CRFR2(3 (Grammatopoulos et al., 2000).
Our results demonstrate that UCN homologues require activation of both p42/44 
MAPK and Akt, in order to protect cardiomyocytes from hypoxia/reoxygenation 
injury (Fig. 5.1 and 5.2). This would suggest that the two pathways might be 
linked. It has been shown before that cAMP can stimulate Akt in 293-EBNA cells 
and in WIF-B9 cells through activation of G-protein coupled receptor protein Gfty 
(Sable et al., 1997; Kagawa et al., 2002).This is possibly through a direct 
interaction of PI3K with Ras as shown before (Rubio et al., 1997). Taken together 
it would mean that G-protein coupled receptor activation by the UCN homologues 
can induce both pathways at the same time through activation of Ras. This 
model could explain the increase in p42/44 phosphorylation observed after 
treatment with SCP and UCN in the presence of LY294002 (Fig. 5.1). However 
this had no effect in protection (Fig. 5.2), suggesting that UCN peptides need 
activation of downstream protective effectors regulated by both pathways.
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Finally, inhibition of p38 MAPK increased phosphorylation of p42/44 MAPK (Fig. 
5.1), in the presence of UCN and SCP. Again, this would suggest a crosstalk 
between the different pathways. This crosstalk between p38 MAPK and p42/44 
MAPK has been shown to occur in epithelial corneal cells, where chemical 
inhibition of p38 MAPK increased phosphorylation of p42/44 MAPK in the 
presence of hepatocyte growth factor (Sharma et al., 2003).
Although, previous studies on UCN hypertrophic effects speculated that PKA 
activation was important for these effects, this is the first report to show a distinct 
mechanism for the UCN induced hypertrophy. It is clear that PI3K and Akt 
activation in particular is at least one of the factors required not only for the 
hypertrophic effects of the UCN peptides, but for cardioprotection as well. Akt 
activation is known to be an important factor in hypertrophy (Frey and Olson,
2003). Possible downstream effectors include such regulators of hypertrophy as 
GSK3p and mTOR. CRF has already been shown to regulate GSK3p expression 
in neuronal cells (Bayatti et al., 2003).
We previously speculated that Akt and MAPK pathways converge at a point 
downstream of the CRFR2. This notion is strengthened by the results presented 
here. Akt phosphorylation (Fig. 5.1) was increased after blocking MAPK and in 
addition, in some of the experiments, blocking MAPK increased protein synthesis 
and cell area after peptide treatment (Fig. 5.3). These increases were not 
statistically significant however, apart from the effect of SCP on cell area (Fig. 5.3
Top and Bottom) and in the case of SRP when cells were transfected with 
DNMEK1 (Fig. 5.3 Bottom). These results indicate that there is a convergence of 
the two pathways upstream of MEK1 and that the MAPK pathway might act as a 
negative feedback loop on the Akt pathway stimulation on cell area after the 
peptide activation of the CRFR2, and probably only after an increased stimulation 
of Akt, as is the case with SCP and SRP. However, this hypothesis needs to be 
tested. It has been previously shown that certain isoforms of the PI3K can be 
activated by Gsq trimeric proteins and also PI3K is able to induce MAPK 
activation either by interacting with ras, or by activating protein kinase C, which in 
consequence acts on raf-1 to activate the MAPK pathway (Bondeva et al., 1998; 
Graness et al., 1998; Murga et al., 1998;Clerk and Sugden 1999; Bayatti et al., 
2003; Bayer et al, 2003; Foncea et al., 2000; Wetzker and Bohmer, 2003). In 
addition, protein kinase A, which is activated by Gs, can stimulate Akt 
independently of PI3K (Sable et al., 1997; Filippa et al., 1999).
In conclusion it appears that although all three peptides require activation of 
p42/44 MAPK and of Akt to bring about their cardioprotective effects, only 
activation of Akt is required for hypertrophy to be induced. This would mean that 
it might be possible to identify the factor or factors downstream of Akt responsible 
for the hypertrophic effects and maybe be able to block them in order to pave the 
way for the use of the peptides as therapeutic agents.
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CHAPTER VI
Other mechanisns of cardioprotection by UCN homotogues
6.1 Introduction and aims
UCN and its homologues are dependent on activation of p42/44 MAPK and PI3- 
K/Akt in order to confer their effects, as shown in the previous chapters. 
However, it was previously shown that UCN cardioprotection (Brar et al., 2002a) 
requires de novo protein synthesis, as the cardioprotective effects of UCN were 
abolished in the presence of the protein synthesis inhibitor cyclohexamide. This 
observation led us to suggest that activation of the MAPK and Akt is not the sole 
required event for UCN cardioprotection. The identity and function of these end- 
effector proteins is important in not only understanding the mechanism of action 
of the UCN homologues, but also in the development of novel protective 
pharmacological compounds that could be used prior or consequent to an 
ischaemic episode.
The proteins that are examined here were identified and shown to be regulated 
by UCN through an affymetrix gene chip assay (Lawrence et al., 2002). The 
three molecules that we selected to examine further are iPLA2, PKCe and Kir 6.1 
All three molecules were shown before to be involved in ischaemia reperfusion 
injury in the heart, but were not associated with UCN. PKCeand iPLA2 are 
proteins that are involved in signalling, whereas Kir6.1 is a subunit of the KAtp
channel. All three molecules are either up- or down- regulated by UCN and 
were interested to find out whether SCP and SRP would be affecting those 
molecules in a similar manner.
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6.2 Results
6.2.1 UCN homologues induce PLA2 expression
iPLA2 is a an enzyme that belongs to the superfamily of esterases that hydrolyse 
the sn-2 ester bond in phospholipids, releasing arachidonic acid and lyso 
metabolites, principally lysophosphatidylcholine. Only iPLA2 from all the PLA2 
lipases has been shown to increase its activity during ischaemia/reperfusion, with 
a resulting increase in its metabolites (Shizume et al., 1997; Daleau et al., 1999; 
Cummings et al., 2000). The transcript for iPLA2 was shown to be decreased by 
2.5 fold by UCN treatment (table 6.1).
We wanted to establish whether the levels of iPLA2 are decreased by UCN and 
its homologues in rat neonatal cardiomyocytes following a hypoxic insult. For that 
cells were treated with 10'8 M of UCN, SCP or SRP for 24 hours prior to a 4 hour 
hypoxia and 16 hour reoxygenation. The protein levels were analysed by western 
blotting with an antibody specific for iPLA2 (Fig. 6.1).
All three peptides attenuate the levels of iPLA2 not only in control condition, but 
after hypoxia/reoxygenation as well (Fig. 6.1). The levels of the phospholipase 
were increased after hypoxia/reoxygenation 3 fold approximately. UCN treatment 
was able to reduce the levels of the enzyme at least 2 fold in control conditions 
and at least 3-fold reduction was observed after hypoxia/reoxygenation (Fig. 6.1). 
SRP showed similar levels of iPLA2 reduction to UCN both under control and 
hypoxia/reoxygenation conditions. SCP showed the greatest effect on the levels 
of iPLA2(Fig. 6.1).
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Figure 6.1. UCN homologues attenuate iPLA2 protein levels in rat neonatal 
cardiac myocytes. Cells were treated for 24 hours with 10'8 M of UCN, SCP or 
SRP prior to 4 hours hypoxia and 16 hour reoxygenation. A. Western blot of 
iPLA2 from protein isolated from rat neonatel cardiomyocytes treated with UCN 
homologues with and without hypoxia/reoxygenation insult. B. Densitometric 
analysis of at least 3 western blots. Actin was used for normalisation. Values are 
the average of at least three experiments with their standard deviation 
represented by the bars. Stars represent statistical significance (2-way ANOVA, 
p<0.05, followed by Bonferroni post-hoc analysis).
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The above results establish that iPLA2 is a target of the UCN homologous 
peptides and that the administration of the peptides can lead to a pronounced 
reduction of the levels of the iPLA2 enzyme, causing a possible reduction in the 
levels of its metabolites AA and LPC, minimising the deleterious effects of the 
metabolites on the cardiac cell.
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6.2.1.1 UCN homologues induced protection is attenuated by LPC and increased 
by BEL
Lysophosphatidylcholine (LPC) one of the metabolites of iPLA2 has been shown 
to be involved in ischaemia/reperfusion injury. For this reason we treated cells 
with 5x1 O'9 M of LPC for 24 hours in the presence or absence of UCN 
homologous peptides and analysed the effect of the metabolite on apoptotic cell 
death by TUN EL assays.
LPC showed devastating effects on rat neonatal cardiomyocytes causing almost 
70% of the cells to die by apoptosis (Fig. 6.2). The effects of LPC were 
attenuated when the cells were treated at the same time with 10'8 M of any of the 
three peptides UCN, SCP or SRP. However the amount of death present was still 
greater than in the control cells, indicating that the effect of the peptides is on the 
iPLA2 enzyme, rather than the metabolites and their downstream targets. The 
amount of cell death among the three different peptides was comparable 
(MANOVA, p>0.05) and none of the three peptides appears to work significantly 
better against LPC induced damage.
To determine the role of the increase of endogenous levels of LPC after a 
hypoxic insult, cells were treated with bromoenol lactone (BEL) an inhibitor of 
iPLA2, in the presence or absence of UCN homologues for 24 hours prior to 
hypoxia/reperfusion. Subsequently, the cells were fixed and analysed by TUN EL 
to determine the amount of apoptotic cell death occurring (Fig. 6.3).
Control UCN SCP SRP LPC UCN+LPC SCP+LPC SRP+LPC
Figure 6.2. Effect of LPC on UCN peptide cardioprotective effects. Rat neonatal 
cardiomycytes were treated with 5x10‘9 M LPC and 10‘8 M of UCN, SCP or SRP 
and the effects on cell survival were determined by TUNEL assay. Columns 
represent the average of at least six experiments, and bars represent standard 
deviation of the groups. ***: p<0.05 compared to control group, ###: p<0.05 
compared to LPC group (MANOVA).
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BEL alone was able to minimise the amount of cell death following 
hypoxia/reperfusion to the levels of the peptides (MANOVA, p>0.05). When cells 
were cotreated with BEL and any of the three peptides no additive effect on cell 
protection was observed (MANOVA, p>0.5 between UCN and UCN+BEL groups, 
between SCP and SCP+BEL and between SRP and SRP+BEL) (Fig. 6.3). This 
result shows that UCN and the peptides work in a similar manner to BEL by 
inhibiting the iPLA2 enzyme, as no additive effect was observed in the presence 
of BEL and any of the peptides. It is, in addition, hinting on the possibility that 
iPLA2 attenuation and inhibition is one of the important steps in UCN protection 
as the levels of protection shown by BEL alone were similar to the levels 
conferred by any of the three peptides alone.
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Control UCN SCP SRP BEL UCN+BEL SCP+BEL SRP+BEL
Figure 6.3. Effect of BEL on the cardioprotective effects of the UCN homologues. 
Rat neonatal cardiomyocytes were treated with 10‘6 M of BEL and 10'8 M of 
UCN, SCP or SRP prior to a four hypoxia-sixteen hour reoxygenation period, and 
then cell death was analysed by TUNEL assay. Columns represent the average 
of at least six experiments with bars representing the standard deviation in the 
group. ***: MANOVA, p<0.05 vs Control.
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6.2.2 UCN homologues induce Protein Kinase Ce expression and 
translocation
The PKCe isoform was the only PKC isoform whose transcript levels were 
changed on the affymetrix gene chip assay (Lawrence et al., 2005). Interestingly 
the particular isoform has been previously shown to be involved in 
cardioprotection during ischaemic injury and appears to be one of the major 
steps in ischaemic preconditioning.
The levels of PKCe were increased after treatment with any of the UCN 
homologous peptides (Fig. 6.4). The peptides had no effect on the levels of 
another PKC isoform, PKCs (Fig. 6.4). Once more SCP had more pronounced 
effects on the levels of PKCe than any of the other two peptides, with UCN being 
the next most potent peptide (Fig 6.4).
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Figure 6.4. UCN homologues peptides induce PKCe expression. A. Western blot 
analysis for PKCe and PKCs of protein extracts from rat neonatal cardiomyocytes 
treated for 24 hours with 10'8 M of UCN, SCP and SRP. Actin was used for 
normalisation. B. Densitometric analysis of at least three blots of the western 
blot. Columns represent the means and the bars the SD. Stars: MANOVA, 
p<0.01 vs PKC£ control, #: MANOVA p>0.05 vs PKCs control, and $: MANOVA, 
p<0.01 vs all other homologues (Bonferroni post-hoc analysis).
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6.2.3 UCN and its homologues induce K ir 6.1 expression
We were able to show so far that all three UCN homologues have a considerable 
impact on cardiac stress cell physiology and we were able to identify four 
different signalling pathways that are required for the peptides to produce their 
effects.
However, as yet no target gene has been identified that could be an end effector. 
Looking back at the results from the affymetrix gene we decided to concentrate 
on the ATP sensitive inward rectifying potassium channel, Kir 6.1, as a good 
candidate. Kir 6.1 transcript levels changed by 2.6-fold, and a number of 
experiments with pharmacological compounds that either open or close the 
channel, have shown that the opening of the channel has cardioprotective effects 
against ischaemia and is likely to be involved in ischaemic preconditioning 
(Bernardo et al., 1999; Takashi et al., 1999; O’Rourke, 2000; Takano et al.,
2000). Moreover, the effect on the Kir 6.1 subunit seems to be a specific one, as 
the other subunits, Kir6.2 and SUR2, showed no change in the affymetrix gene 
chip assay (Lawrence et al., 2002). This specificity of action of UCN on the 
channel was confirmed by reverse transcription PCR, RNA slot blots and 
westerns (Lawrence et al., 2002), where no change in Kir 6.2, SUR1 or SUR2 
was shown after 24 hour of UCN treatment.
To compare the effects of the UCN homologues we treated rat neonatal 
cardiomyocytes for 24 hours with UCN, SCP or SRP and analysed their effects
on the Kir 6.1 protein levels by western blotting (Fig. 6.5). All three peptides were 
able to induce Kir 6.1 expression after a 24 hour treatment with SCP inducing a
4.5 fold increase compared to a 3 fold increase by UCN and a 1.5 fold by SRP. 
Once again SCP proves to be the most potent peptide of the three followed by 
UCN. In addition none of the peptides had any effect on the levels of the Kir 6.2 
isoform (Fig. 6.5).
CONTROL UCN SCP SRP
Figure 6.5. Effect of the UCN homologues on the protein levels of Kir 6.1. A.Rat 
neonatal cardiomyocytes were treated with 10‘8 M of Ucn, SCP or SRP for 24 
hours and the protein levels of Kir 6.1 and 6.2 were analysed by western blotting. 
Actin was used for normalisation. B. Densitometric analysis of at least three 
Kir6.1 blots. Columns represent the means and the bars the SD. Stars: 
MANOVA, p<0.05 vs control and $: MANOVA, p<0.05 vs all other homologues 
(Bonferroni post-hoc analysis). No densitometry for Kir 6.2 is presented as there 
were no statistical significant differences between the treated groups and the 
control sample and no differences among the treated groups.
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6.2.3.1 UCN homologous peptide-mediated protection is attenuated by blocking 
mitochondrial K ir
Having established that the UCN homologues cause a specific increase in K a t p  
channel expression, we wished to determine whether such channels were of any 
functional significance in the protective effect of the peptides. We therefore 
examined the effect of a general opener of such channels, cromakalim or the 
K a t p  channel blocker tolbutamide, when added to cultured cardiac myocytes 
exposed to hypoxia either alone or in the presence of the UCN homologues.
In these experiments, both cardiotrophin 1 (CT-1), a cytokine with known 
cardioprotective effects that was used to show the specificity of UCN peptides 
action on Kir, and the UCN homologues caused an approximately 50% reduction 
in cell death induced by hypoxia/reoxygenation. A similar degree of protection 
was observed with the K a t p  channel opener cromakalim, whereas addition of 
tolbutamide enhanced the levels of cell death (Fig. 6.6). Most interestingly, 
addition of tolbutamide attenuated the protective effects of the UCN homologues, 
whereas it had no effect on the protective effects of CT-1, underlying the fact that 
the effects of the UCN homologues on the K a t p  channel are specific.
Tolbutamide is generally considered to be a sarcolemmal channel blocker, 
although inhibition of mitochondrial K a t p  channels has been reported. However, it 
is generally believed that it is the mitochondrial channel that is respnsible for the 
cardioprotective effect of K a t p  channel opening. We therefore wished to 
determine wheher the effect of the UCN homologues would be prevented by a 
selective mitochondrial K a t p  channel blocker, 5-hydroxy decanoate (5-HD). In
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Figure 6.6. Effect of KAtp channel blockers (A, B) and opener (C, D) on the 
cardioprotective effects of the UCN homologues. Rat neonatal cardiomyocytes 
were exposed to simulated ischaemia/reoxygenation injury after treatment with 
10'8 M of a UCN homologue, 10‘6 M CT-1, 10‘8 M cromakalim (O), 10'7 M 
tolbutamide (TLB), or 5-hydroxydecanoate (5-HD) for 2 hours. Values are 
averages of at least 3 experiments; bars, SD.
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these experiments, 5-HD induced enhanced cell death in cardiac myocytes 
exposed to simulated ischaemia. Most interestingly, 5-HD treatment completely 
abrogated the protective effect of the UCN homologues, in exactly the same 
manner as tolbutamide (Fig. 6.6). Moreover this effect was once more specific as 
it had no effect on the protection afforted by CT-1.
The above experiments demonstrate the importance of of K a t p  channels in UCN 
protection, but fail to identify the exact channel involved. However, if the 
induction of Kir6.1 subunit is involved in the UCN protective effect, then inhibition 
of Kir6.1 activity should enhance damage during simulated ischaemia. We chose 
to transfect cardiomyocytes with dominant negative Kir 6.1 and 6.2 prior to 
simulated ischaemia. Cells transfected with dominant negative Kir 6.1 showed 
higher levels of apoptotic cell death following hypoxia/reoxygenation injury, 
significantly higher levels of cell death compared to cells transfected with Kir 6.2 
(Fig. 6.7). Furthermore, addition of UCN homologous peptides failed to rescue 
cells transfected with dominant negative Kir 6.1, strengthening the involvement of 
Kir in the protective mechanisms of UCN (Fig. 6.7).
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Figure 6.7. Effect of Kir 6.1 on cardiomycyte survival after hypoxia/reoxygenation 
and on UCN cardioprotection. Rat neonatal cardiomyocytes were transfected 
with 0.5pg of GFP and 0.5 pg of either dominant negative Kir 6.1 or dominant 
negative Kir 6.2 and treated with 10‘8 M a UCN homologue or 10'6 M of CT-1 and 
analysed by TUNEL. Values are the averages of at least three experiments; bars 
SD.
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6.3 Discussion
The results presented so far converge to the point that SCP is the most potent 
among the UCN homologues. It is able to induce a greater cardioprotective and 
hypertrophic effect than its counterparts and this is due to its ability to induce a 
greater expression of all the effector proteins we examined.
Moreover, we provide evidence that shows that the action of UCN and its 
homologues is multifaceted as it involves at least four different signalling 
pathways: MAPK, PI3-K, PKC and PLA2. Additionally, it is able to regulate the 
levels of a number of proteins including PKCe, iPLA2 and Kir6.1, and thus 
affecting cell signalling, lipid metabolism and ion homeostasis, in order to assist 
the cardiomyocyte in conditions of stress.
For the first time we are able to show target proteins of UCN and to exhibit 
evidence that LPC and Kir 6.1 are involved in cardiomyocyte survival after a 
hypoxic stress.
UCN and its homologues were able to downregulate the levels of iPLA2, as 
expected from the affymetrix gene results (Lawrence et al., 2002). However, the 
effect of SCP on the levels of iPLA2 was even more pronounced. iPLA2 is a 
phospholipase that cleaves the sn-2 ester bond of phospholipids and it has been 
involved in apoptosis (Jaattela et al., 1995; Atsumi et al., 1998; Zhao et al.,
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2001a; Zhao et al., 2001b). Additionally, in RAW264.7 cells and in mouse 
peritoneal macrophage cultures, iPLA2 was shown to be the form of 
phospholipase involved in oxidative stress (Martinez and Moreno, 2001). Only 
iPLA2 was shown to be significantly active after H20 2 stress, and that the 
arachidonic acid release, due to increased activity of iPLA2, was dose dependent 
to H20 2. Arachidonic acid release by H20 2 was blocked by BEL. In addition, 
antisense cPLA2 had no effect on the arachidonic acid release (Martinez and 
Moreno, 2001).
UCN and its homologues might be able to reduce apoptotic cell death by 
attenuating expression of iPLA2 and minimising the increase in the concentration 
of the metabolites AA and PLC after ischaemia/reperfusion. We observed that 
BEL alone is able to reduce the amount of apoptotic cell death after 
hypoxia/reoxygenation, but addition of UCN or any of the homologues showed no 
additive effects, suggesting that BEL and UCN homologues act in a similar 
mechanism; Similarly UCN and its homologues attenuated the amount of cell 
death caused by the product of iPLA2, LPC, even if they failed to reduce the 
amount of cell death to control levels.
We also examined the effects of UCN and its homologues on the levels of 
another signaling molecule, PKCe. PKCe is an isoform that has been shown to 
be involved in ischaemia and in cardiac hypertrophy. It appears that the end 
result of PKC activation in the heart is dependent on the levels of PKCe and
PKC6. More PKCe leads to protection whereas more PKC6 leads to death. In our 
experiment we showed that all three homologues induce expression of PKCe 
without affecting the levels of PKC6, introducing another mechanism of 
protection by the UCN peptides. It has been recently shown that PKCe inhibition 
with specific RACK peptide inhibitors, attenuated the cardioprotection conferred 
by UCN, exhibiting the importance of PKCe translocation for the protective effects 
elicited by UCN (Lawrence et al., 2005). Interestingly, it was shown that PKC 
epsilon is localised in the mitochondrial membrane, suggesting a possible role in 
regulated K a t p  channels and iPLA2 on the mitochondrial compartment and being 
the main orchestrator of the UCN effects on maintaining mitochondrial integrity 
and abolishing apoptosis caused by the mitochondrial pathway.
Finally the third protein we selected to study was Kir6.1, a subunit of the ATP 
sensitive inward rectifying potassium channel, K a t p - It was previously shown that 
K a t p  opening is cardioprotective and that K a t p  is involved in ischaemic 
preconditioning. Our results show that the peptides are able to induce Kir 6.1 
expression, which is specific, as it had no effect on the Kir isoform 6.2 or on the 
sulfonylurea receptor SUR. Additionally, Kir6.1 expression is a requirement for 
cardioprotection by the peptides, as dominant negative Kir6.1 induced death 
even in the presence of the peptides. There has been considerable discussion, 
whether the sarcolemmal or the mitochondrial subtype of Kir6.1 is involved in 
cardioprotection. We show that the effects of a general K At p  (TLB) and a 
mitochondrial K At p  (5-HD) blocker had similar effects on cell death, suggesting
the dominant role of the mitochondrial K a t p  channel on protection, and the 
possibility that Kir6.1 is the specific type involved in the formation of the 
mitochondrial K a t p  channel.
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CHAPTER VII
SAG is induced by UCN homologues
7.1 Introduction and aims
Apoptosis is characterised by activation of caspases that orchestrate a cascade 
of events that lead to cellular degradation. A main manifestation of apoptosis is 
nuclear condensation and DNA degradation, a process that is used in TUN EL 
staining to visualise apoptotic cells.
There is a great need to characterise the pathways that regulate apoptosis in the 
heart, in order to establish new therapeutic strategies in failing hearts. There is 
considerable knowledge of the pathways that lead to activation of caspases from 
extracellular signals and from mitochondrial damage. There is also considerable 
interest in genes that are characterised as anti-apoptotic such as the inhibitors of 
apoptosis (lAPs) which inhibit the onset of apoptotic cascades by interacting with 
caspases and preventing their activation (Goyal, 2 0 0 1 ).
One such gene that was recently identified was named Sensitive to Apoptosis 
Gene (SAG) and was cloned as a factor that is induced after oxidative stress 
(Duan et al., 1999). SAG is a 13 kD protein, containing a C2 H2C4 Zn-RING finger 
motif. It was recently shown to be expressed in hypoxic conditions in the brain 
and to co-localise with newly produced radical oxygen species (ROS), indicating 
the function of SAG as a possible antioxidant. The RING finger motif of SAG has
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been shown to be important for its antiapoptotic function, as mutants of the SAG 
at the RING motif are unable to protect from apoptosis when overexpressed 
(Yang et al., 2001).
SAG is shown to be localised in the cytoplasm and nucleus of the cell and is 
ubiquitously expressed in many different organs and tissues, but predominantly 
in heart, brain and the gonads (Duan et al., 1999).
Additionally, SAG is overexpressed in several carcinomas (Sun, 1999; Huan et 
al., 2001; Sasaki et al., 2001), although overexpression of SAG alone is not 
enough to induce neoplastic transformation of cells (Huang et al., 2001). SAG 
was shown to promote S-phase and serum free growth of cells (Duan et al.,
2001) and downregulation of SAG, by transient transfection of an antisense SAG 
construct in cancer cells resulted in reduction of the proliferation rate of these 
cells (Huang et al., 2001) demonstrating the importance of SAG in control of cell 
proliferation. Furthermore, the involvement of SAG in cell proliferation was 
demonstrated in yeast, where it was shown by gene chip profiling to regulate 
expression of components of the cell cycle (Sun, 1999; Swaroop et al., 2000).
SAG belongs to a family of proteins known as regulator of Cullins (ROC) that 
bind through cullin to the SCF (Skp, Cullin, F-box) multisubunit proteins (Ohta et 
al., 1999). One proposed mechanism by which SAG might elicit its antiapoptotic 
effects is by regulating p27K,p1 (Ohta et al., 2000; Duan et al., 2001).
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Although SAG is highly expressed in the heart (Duan et al. 1999) its role in 
cardiac cells has not been previously characterised. In view of the critical clinical 
importance of ischaemia in the heart, we tested whether SAG is able to protect 
cardiomyocytes from ischaemic insults.
In addition, we were interested to show whether UCN and its homologues had 
any effect on SAG, as it is a molecule that is expressed in the heart and brain 
and it has antiapoptotic properties.
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7.2 Results
7.2.1 SAG induction by UCN peptides
SAG is a novel gene with antiapoptotic properties and we wanted to establish 
whether the gene is induced by UCN and its homologues. Primary rat neonatal 
cardiomyocytes were treated with 10'8 M of each peptide prior to determining the 
levels of SAG protein in the cells by western blotting. UCN and its peptides failed 
to induce SAG after 24 hours, but the levels of SAG protein doubled after 36 
hours of peptide addition (Fig. 7.1).
Although, there was SAG induction by the peptides in neonatal cells this 
induction was only detectable at the 36 hour mark, showing that SAG is a late 
target of UCN peptide action in the neonatal cardiomycyte. The role of SAG 
induction by UCN needs to be further investigated.
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Figure 7.1. Western blot analysis showing SAG induction by UCN and its 
peptides on primary neonatal cardiomyocytes. A. Cells were treated with 10‘8 M 
of a peptide for 36 hours prior to protein harvest and analysed by western 
blotting. Actin was used as control. B. Densitometric analysis of at least three 
SAG blots. Columns represent the means and the bars the SD. Stars: MANOVA, 
p<0.05 vs control and $: MANOVA, p<0.05 vs all other homologues (Bonferroni 
post-hoc analysis).
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7.2.2 SAG is inducible by hypoxia/reperfusion
Initially, we assessed the levels of SAG in cardiac cells exposed to 4 hrs of 
simulated ischaemia (Hypoxia) alone (H) or 4 hrs of simulated ischaemia plus 16 
hrs of reoxygenation (H/R). As shown in Fig. 1, SAG protein levels were 
enhanced by 2.5 fold in primary neonatal cardiac myocytes exposed to 4 hrs of 
hypoxia alone compared to untreated control cells. The expression levels of SAG 
in neonatal cardiac myocytes following exposure to reoxygenation after hypoxia 
returned to control levels (Fig. 7.2).
We also assessed SAG expression in the isolated perfused rat heart that was 
exposed to either 35 mins of global ischaemia alone (I) or 35 mins of ischaemia 
followed by 60 mins of reperfusion (l/R). As shown in Fig. 7.3, the levels of SAG 
in the isolated intact heart exposed to 35 mins of ischaemia alone resulted in a
4.5 fold increase over the levels of SAG in the control (continuously perfused 
hearts). Additionally, as observed in neonatal cardiac myocytes, SAG levels 
dropped following reperfusion after ischaemia although they remained above 
control levels (Fig. 7.3). These results suggest that SAG expression in the heart 
is enhanced acutely by an ischaemic stress response, and that the increased 
levels fall during the reoxygenation/reperfusion phase.
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Figure 7.2. SAG is expressed in rat cardiomyocytes. Western Blot analysis with 
antibody to SAG of extracts from primary neonatal rat cardiomyocytes following 4 
hours of hypoxia (H), or 4 hours of hypoxia followed by 16 hours reoxygenation 
(R), or no treatment (C). Actin is shown as a standard for the calibration of the 
SAG.
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Figure 7.3. SAG is expressed in the intact rat heart. Western blot analysis with 
antibody to SAG of extracts from perfused rat hearts following 1 hour of global 
ischaemia (I) or 35 minutes of ischaemia followed by 1 hour reperfusion (l/R). 
The bar chart represents the Densitometric analysis of the above western blot.
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In addition, immunocytochemical analysis of neonatal cardiomyocytes (Fig. 7.4A 
and B) revealed a strong expression in the cytoplasm and the nucleus of the 
cells. Confocal microscopy of those cells (Fig. 7.4B) revealed that the SAG 
expression in the nucleus appears to be restricted around the periphery of the 
nucleus. The pattern of localisation of SAG in neonatal cells appears to be 
maintained in the adult cells (Fig. 7.4C).
Since SAG has been described as an antioxidant factor, we were interested to 
explore the kinetics of SAG expression and to see whether the changes in SAG 
levels observed in cardiac myocytes following H/R are due to alterations in 
mRNA levels or due to alterations in SAG protein stability.
Time course of SAG protein (Fig. 7.5a) and SAG mRNA (Fig. 7.5b) induction 
reveals that the SAG protein level increased between 1 and 2 hours of simulated 
ischaemia (MANOVA p<0.05 vs. control) and reached a plateau after 2 hours 
(MANOVA p>0.05 between time points of 2 and 3 hours). Interestingly there was 
a steady increase of mRNA levels over the time period of the simulated 
ischaemic insult for the first four hour period (MANOVA p<0.05 for all time points 
vs. control).
In the case of reoxygenation following a 4 hour simulated ischaemia period, 
protein levels increased only slightly during the first hour of reoxygenation 
(MANOVA p>0.05), and were maintained for up to 4 hours (MANOVA p<0.05 for
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all time points vs. control) (Fig. 7.6a). As before, SAG protein levels fell to almost 
that of the control cells after 16 hours of reoxygenation (Fig. 7.7).
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Similarly, SAG mRNA levels were also slightly elevated for the first 4 hours of 
reoxygenation (MANOVA p>0.05 among the groups, but p<0.05 for all the groups 
vs. control) (Fig. 7.6b), only to return to control levels after 16 hours of 
reoxygenation. These results demonstrate that SAG expression involves 
enhanced mRNA levels leading to enhanced protein levels following a hypoxic 
signal. However, we cannot rule out that posttranslational events may also be 
contributing to SAG upregulation during exposure of cardiac myocytes to H/R. As 
SAG levels were increasing with increasing times of simulated ischaemia we 
were interested to see if the levels of SAG protein might be different following 
reoxygenation after different periods of simulated ischaemia. Surprisingly, SAG 
protein levels were always similar to control after 16 hours of reoxygenation 
(MANOVA p>0.05 for all groups at reoxygenation vs. control), regardless of the 
duration of simulated ischaemia, where SAG protein levels increased over time, 
suggesting a very tight control of SAG protein levels (Fig. 7.7). Moreover, this 
suggests that SAG has an important role during periods of low oxygen supply to 
the cell.
Figure 7.4. SAG is expressed in heart cells. SAG is expressed in primary 
neonatal cardiomyocytes (A and B) and in adult heart (C). Immunocytochemistry 
(A and C) reveals a nuclear and cytoplasmic localisation of SAG in 
cardiomyocytes. Negative reactions (no secondary antibody) are shown in the 
right column.
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Figure 7.5. SAG is induced by hypoxia in cardiomyocytes. Densitometric 
analysis of SAG protein (A) and mRNA (B) temporal kinetics following different 
periods of simulated ischaemia. Bars represent standard deviations of at least 
three independent experiments. Western blotting for actin (A) and RT-PCR for 
actin was used as a standard for the calibration of the amounts of SAG in each 
case.
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Figure 7.6. SAG levels remain elevated for the first four hours of reoxygenation. 
Densitometric analysis of SAG protein (A) and mRNA (B) temporal kinetics 
during different periods of reoxygenation, following 4 hours of simulated 
ischaemia. Bars represent standard deviations of at least three independent 
experiments. Western blotting for actin (A) and RT-PCR for actin was used as a 
standard for the calibration of the amounts of SAG in each case.
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Figure 7.7. SAG levels increase with increasing periods of hypoxia. 
Densitometric analysis of western blots of extracts from primary neonatal rat 
cardiomyocytes following different periods of simulated ischaemia followed by 16 
hour reoxygenation. Western blotting for actin was used as a standard for the 
calibration of the amounts of SAG.
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7.2.3 SAG attenuates apoptosis by simulated ischaemia
Since we have shown that SAG expression was altered during hypoxia, we 
wanted to find out whether that had any physiological significance and whether 
SAG had a role in protecting cells from hypoxia. For this reason the cardiac cell 
line CLEM and primary rat neonatal cardiomyocytes were transfected with 2.5 pg 
of wild type SAG, mutant SAG (MM14) or empty vector plasmids and apoptotic 
cell death was assessed by TUNEL after the cells had undergone 4 hours of 
simulated ischaemia followed by 16 hours of reoxygenation. The mutant SAG 
MM14 has two cysteines in the RING finger mutated to serines. This mutation 
has been previously shown to render the SAG protein non-functional. To 
discriminate between transfected and non-transfected cells the beta- 
galactosidase plasmid was used as a marker of transfected cells.
Overexpression of SAG was able to reduce the amount of apoptosis after H/R 
almost to the control levels not only in CLEM cells (MANOVA p>0.05 vs. 
normoxia control group) (Fig. 7.8) but also in primary cardiomyocytes (MANOVA 
p>0.05 vs. normoxia control group) (Fig. 7.9). TUNEL positivity in SAG 
transfected CLEM cells after H/R was 50% of that in cells transfected with the 
empty vector (MANOVA p<0.05 vs. control group). The antiapoptotic effects of 
SAG after reoxygenation was even more pronounced in the primary neonatal rat 
cardiomyocytes, where the TUNEL positive SAG transfected cells were almost
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60% of the cells transfected with the empty vector (MANOVA p<0.05 vs. control). 
Interestingly, SAG was able to protect cells from apoptotic death due to 
simulated ischaemia alone (MANOVA p>0.05 vs. control), as well as after 
reoxygenation (MANOVA p>0.05 vs. control).
In addition, the apoptotic protection observed by SAG was dependent on a 
functional RING finger, as transfection of MM14 a mutant that has a 
dysfunctional RING finger, attenuated the protective effects of SAG, both in 
CLEM cells (Fig. 7.8) and primary rat cardiomyocytes (Fig. 7.9). The levels of 
protection in the CLEM cells transfected with MM 14 was similar to those of 
CLEM cells transfected with the empty vector not only after H (MANOVA, p>0.05 
vs. control hypoxia) but also after H/R (MANOVA, p>0.05 vs. control 
reoxygenation) (Fig. 7.8). Similarly transfection of MM14 in primary rat 
cardiomyocytes had no effect on the levels of protection after H (MANOVA, 
p>0.05 vs. control hypoxia) and also after H/R (MANOVA, p>0.05 vs. control 
reoxygenation) (Fig. 7.9). These results clearly demonstrate the importance of 
the integrity of the RING finger domain of SAG for the antiapoptotic function of 
the protein.
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Figure 7.8. SAG is protective against simulated ischaemia reoxygenation injury 
in CLEM cells. 5|iig of total DNA was transfected in CLEM cells, by the calcium 
phosphate method as described in Materials and Methods, prior to 4 hours of 
hypoxia or 4 hours of hypoxia followed by 16 hour reoxygenation. MM 14 is a 
mutant of SAG that has a non-functional RING finger domain. Percentage of 
TUNEL positive transfected CLEM cells are represented by the columns. Values 
are the average of three experiments, whose standard deviations are 
represented by the bars. Stars represents statistical significance against control 
(MANOVA, p<0.05). NS represents no difference against control.
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Figure 7.9. SAG is protective against simulated ischaemia reoxygenation injury 
in rat neonatal cardiomyocytes. 5pg of total DNA was transfected in primary rat 
neonatal cardiomyocytes, by the calcium phosphate method as described in 
Materials and Methods, prior to 4 hours of simulated ischaemia and 4 hour of 
simulated ischaemia followed by 16 hour reoxygenation. Percentage of TUNEL 
positive transfected rat neonatal cardiomyocytes are represented by the 
columns. Values are the average of three experiments, whose standard 
deviations are represented by the bars. Stars represents statistical significance 
against control (MANOVA, p<0.05). NS represents no difference against control
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7.2.4 SAG is im portant for cell viability
As overexpression of SAG seems to attenuate cell death caused by a simulated 
ischaemic insult we were interested to test whether endogenous levels of SAG 
are able to contribute to cell survival after hypoxia. For this reason we abrogated 
the expression of cellular SAG by using an antisense approach. When we 
transfected 2.5 pg of antisense SAG (GAS) in rat neonatal cardiomyocytes we 
failed to see any cells surviving a hypoxia reoxygenation injury. For this reason 
we tried to transfect cells with 1 pg of GAS (Fig. 7.10). In this case although 
overexpression of SAG again led to attenuation of apoptotic cell death after 4 
hours of simulated ischaemia followed by 16 hour reoxygenation (MANOVA, 
p>0.05 vs. control reoxygenation), GAS overexpression led to an increase of 
apoptotic death following reoxygenation compared to control cells (MANOVA, 
p<0.05 vs. control reoxygenation) (Fig. 9). Moreover, we observed that the levels 
of apoptotic death in cells transfected with the antisense SAG were greatly 
increased even in the absence of hypoxia/reoxygenation (MANOVA, p<0.05 vs. 
control normoxia), indicating that SAG is essential for the survival of cultured 
neonatal rat cardiomyocytes.
The above results show that SAG is essential for the survival of cardiomyocytes 
not only after an ischaemic insult, but also under normal, non stressful 
conditions.
185
I  70.00%
> t
E  60 00%
1  50 00%
(B0
> 40 00%
2IS
a 30.00%
_jui
§  20 00%
H
2  10.00%
1 0 00%
“■ CONTROL SAG GAS
Figure 7.10. SAG expression is essential for the viability of neonatal 
cardiomyocytes under hypoxic and normoxic conditions. Overexpression of 
antisense SAG (GAS) is lethal for primary neonatal rat cardiomyocytes. 2pg of 
total DNA was transfected in primary rat neonatal cardiomyocytes, using 
lipofectamine 2000 as described in the Materials and Methods, prior to 4 hour of 
hypoxia followed by 16 hour reoxygenation. Percentage of TUNEL positive 
transfected rat neonatal cardiomyocytes are represented by the columns. Values 
are the average of three experiments, whose standard deviations are 
represented by the bars. Stars represents statistical significance against control 
(MANOVA, p<0.05). NS represents no difference against control.
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7.2.5 SAG localisation is im portant for its antiapoptotic properties.
We have already shown that SAG is able to localise to the nucleus and the 
cytoplasm of rat neonatal cardiomyocytes. We were interested to determine 
whether the localisation of the protein changes during hypoxia and moreover, if 
such a change does occur, what would be its physiological significance. For this 
reason, rat neonatal cardiomyocytes were exposed to hypoxia/roxygenation and 
the localisation of SAG was determined by immunocytochemistry (Fig. 7.11).
SAG appears to be localised to the nucleus in 82% of the cells during control 
conditions and only in 18% of the cells that express SAG does the protein appear 
exclusively in the cytoplasm (Fig. 7.11). This pattern of expression however 
changes after hypoxia reoxygenation, where even though the pattern of 
expression appears to be predominantly nuclear there is an increase in the 
cytoplasmic SAG (Fig. 7.11).
To examine further the role of cytoplasmic SAG we analysed the amount of 
apoptosis in cells stained for SAG by TUNEL. Interestingly only 20% of the cells 
expressing SAG were TUNEL positive after hypoxia reoxygenation (Fig. 7.12). 
When we looked at the SAG localisation only 10% of the cells that were 
expressing SAG in the cytoplasm were TUNEL positive compared to almost 40% 
apoptotic cells that were expressing SAG in the nucleus. Only 25% of the cells 
that were expressing SAG in both cell compartments were TUNEL positive. From 
the above we conclude that SAG localisation in the cell is important for cell
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viability. It appears that only when SAG is expressed in the cytoplasm of the cell 
is the protein able to bring about its antiapoptotic effects.
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Figure 7.11. Immuno-localisation of SAG in control rat neonatal cardiomyocytes 
and in cells undergone 4 hours of hypoxia and 6 hours of reoxygenation.
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Figure 7.12. SAG staining (red) on TUNEL stained (green) primary neonatal 
cardiomyocytes undergone 4 hour hypoxia and 4 hour reperfusion.
The graph shows the percentage of cells expressing SAG in the nucleus or the 
cytoplasm of the cell. Black bars represent percentage of cells expressing SAG 
under control conditions, dark grey: SAG positive after hypoxia and light gray: 
TUNEL positive and SAG positive cells
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7.2.6 SAG colocalises w ith caspase-3
From the previous results we are able to suggest that cytoplasmic SAG is 
important for cell viability after hypoxia reoxygenation in rat neonatal 
cardiomycytes. SAG or its family member, ROC1/Rbx1 is an active component of 
SCF (Skp1-Cullins-F-box proteins) E3 ubiquitin ligase. SAG binds to caspase 3 
via an F-box protein beta-TrCP/HOS through a typical TrCP binding motif and b- 
TrCP/HOS over-expression significantly shortens protein half life of caspase 3 
(Sun Yi, personal communication). It is possible that SAG as part of the SCF E3 
needs to translocate to the cytoplasm in order to keep the levels of caspase-3 in 
check. Caspase-3 has been shown to be expressed in the nucleus and the 
cytoplasm of cells (Loo et al., 2002), but its localization in cardiac cells has not 
been examined.
We tried to establish whether SAG and caspase-3 co-localise in rat neonatal 
cardiomyocytes by immunostaining and confocal microscopy.
SAG appears to be expressed around the nuclei of the cells in control conditions 
and co-localise in this area with caspase-3 (Figure 7.13).
After an hypoxic insult this perinuclear localization of SAG and Caspase-3 
disappears and the two proteins appear to colocalise in the cytoplasm of the 
cells. (Figure 7.14).
Figure 7.13. Rat neonatal cardiomyocytes stained with SAG (red) and caspase-3 
(green). Overlap of the two pictures shows SAG and caspase-3 colocalisation 
(yellow-brown) around the nucleus and in the cytoplasm.
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Figure 7.14. Rat neonatal cardiomyocytes were stained with Hoechst (blue), 
SAG (red) and caspase-3 (green) and analysed by confocal microscopy.
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7.3 Discussion
Previous work in non cardiac cells has shown that overexpression of SAG can 
protect non cardiac cells from apoptosis induced by redox compounds (Duan et 
al., 1999; Swaroop et al., 1999; Yang et al., 2001). This antiapoptotic property 
was attributed to the ability of SAG to scavenge ROS and chelate metals (Duan 
et al., 1999; Swaroop et al., 1999; Yang et al., 2001). SAG was identified by 
differential display as a gene that responds to 1,10-phenanthroline induced 
apoptosis (Duan et al., 1999). It was shown to inhibit or delay metal ion induced 
cytochrome c release and caspase 7 activation (Duan et al., 1999). SAG was 
also shown to protect against ischaemic induced apoptosis in mouse brains 
(Yang et al., 2001). Here we are able to show that SAG is induced in cardiac 
cells and in the intact heart during hypoxic stress and not during reoxygenation 
and that it protects cardiomyocytes from the damaging effects of these stresses. 
In addition, we show that UCN and its homologues is able to induce SAG 
expression in rat neonatal cardiomycytes and this may therefore be involved in 
their cardioprotective effect. Furthermore we show that SAG is expressed in the 
nucleus and the cytoplasm of the cells and that SAG cytoplasmic expression is 
important for cell viability. We go on to propose a possible mechanism for SAG 
action by possible interaction with caspase-3.
Interestingly, the levels of SAG rise during ischaemia/hypoxia in both cultured 
cells and in the intact heart, but decrease to control levels during subsequent
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reoxygenation/reperfusion. This suggests that SAG expression is induced 
specifically due to processes occurring during hypoxia/ischaemia, such as 
lowered oxygen levels and returns to normal as oxygen levels are restored 
during reoxygenation/reperfusion. The fact that SAG is upregulated during 
ischaemia might also suggest that it is involved in protecting cardiomyocytes 
from the incoming increase of ROS during reperfusion and acts as a first 
defensive mechanism for the cell.
As in other cell types, overexpression of SAG is able to protect primary cultured 
neonatal rat cardiomyocytes from apoptosis induced by simulated 
ischaemia/reoxygenation and also protects the intact heart from ischaemic 
damage. Moreover, we show for the first time that endogenous SAG expression 
is important for the viability of neonatal rat cardiomyocytes in the absence of 
stress.
The protection observed following overexpression of SAG is specific, as 
overexpression of the mutant MM14 with an abrogated RING finger (Swaroop et 
al., 1999), failed to show any protection. This result is in agreement with previous 
data in other cell types (Sun, 1999; Swaroop et al., 1999; Yang et al., 2001) and 
confirms the importance of the RING finger domain for the function of SAG. 
RING finger domains have been described to be important for protein-protein 
interaction and most importantly in mediating protein ubiquitination (Joazeiro and 
Weissman, 2000; Tyers and Jorgensen, 2000). This suggests that SAG may also
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bring about its antiapoptotic properties by targeting specific proteins for 
proteosomal degradation.
SAG belongs to a family of proteins that includes ROC1/Hrt1/Rbx1. SAG and 
ROC1 are evolutionary and functionally conserved as mammalian ROC1 and 
ROC2 can rescue ROC1 deficient yeast cells (Ohta et al., 1999). The RING 
domain of ROC1 has been shown to be essential for ubiquitin ligation (Chen et 
al., 2000). SAG has recently been implicated in regulating p27 in mammalian 
cells and promotes S-phase entry and cell growth under serum starvation (Duan 
et al., 2001). It is possible that SAG may also be regulating p27 levels in 
cardiomyocytes. Interestingly, the Insulin like Growth Factor I (IGFI) was shown 
to elicit its antiapoptotic effects in rat cardiomyocytes by downregulation of p27 
and p21 (Von Harsdorff et al., 1999). P27 belongs to the kinase inhibitor protein 
family of cell cycle inhibitor proteins that regulate cell cycle and promote cell 
cycle arrest. Such a model would explain the elevated cell death when we 
overexpressed GAS (anti-sense SAG) in cardiomyocytes, as upregulation of p27 
has been shown to be a step leading to apoptosis in a number of cell types (Von 
harsdorff et al., 1999; Donjerkovic et al., 2000; Li et al., 2000; Nakatsuji et al., 
2001).
Protection by SAG appears to be related to its location in the cell. We have 
shown that cytoplasmic SAG is translocated to the cytoplasm after hypoxia and 
that the cytoplasmic SAG is likely to be responsible for the antiapoptotic
properties of SAG. it appears that SAG needs to regulate the levels of a specific 
protein or proteins in the cytoplasm for cell protection, probably as part of an SCF 
E3 ligase. This explains the importance of the RING finger in our mutant 
overexpression experiments. SAG is an active component of SCF (Skp1 -Cullins- 
F-box proteins) E3 ubiquitin ligase. Beta-TrCP/HOS over-expression has been 
shown to significantly shorten the protein half life of caspase 3 (Sun Vi, personal 
communication). It is possible that SAG as part of the beta-TrCP/HOS containing 
SCF E3 needs to translocate to the cytoplasm in order to keep the levels of 
caspase-3 in check. Our results show a possibility for a SAG-caspase-3 
colocalisation in the heart cells. However, we lack evidence as yet for a direct 
interaction between the two proteins or through a third protein.
SAG is undoubtedly a protein that has an important function in the heart. Its 
expression increases after hypoxic conditions and it has a protective function in 
cardiomyocytes both prior to stress and when exposed to ischaemia/hypoxia. It 
also appears to be playing a role in UCN mediated cardioprotection.
It is important to identify the interactions of SAG in the heart and the mechanism 
of function of this protein, as its distinct anti-ischaemic properties indicate that it 
may have therapeutic potential in ischaemia and failing hearts.
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CHAPTER VIII
General Discussion
In this work we set out to examine the effects of urocortin and its homologues in 
the rat heart, after hypoxia/reoxygenation injury in order to determine possible 
differences in the level of cardioprotection conferred by the different peptides. In 
addition, we looked into the pathways that are activated by UCN and its 
homologues and their involvement in cardioprotection. Furthermore, the effects 
of UCN and its homologues on cardiac hypertrophy were examined and we 
present at least one of the pathways required for the hypertrophic effects of UCN. 
We selected the rat neonatal primary cardiomyocytes as our model for our 
experimentations, as they are easily isolated, retain cardiac contractility and are 
adequately transfected with exogenous plasmids, in order to study the effects of 
certain genes in the cardiac physiology and their involvement in the UCN action. 
In addition, a few experiments were performed in an adult rat heart to compliment 
some of the results obtained from the primary cells.
We started our studies by showing that UCN, SCP and SRP are all present and 
expressed in the rat primary neonatal cardiomyocytes.
We showed for the first time that SRP in control conditions is expressed at very 
low levels. On the contrary, it was previously shown that SCP mRNA in the adult 
mouse and human heart are expressed at low levels (Hsu and Hsueh, 2001; 
Lewis et al., 2001). These results were in contrast to our conclusions. A possible 
explanation could be that SCP and SRP levels change during heart
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development, or that SCP and SRP follow different patterns of expression in the 
rat due to species specific factors. Clearly, more work is needed in that part to 
determine why this is so. Interestingly enough, after a hypoxic stress, the levels 
of all three peptides in the rat neonatal cardiomyocyte were comparable.
The possibility that SCP or SRP are only expressed in certain species after a 
certain stress has occurred raises an interesting question that needs to be further 
examined. Could there be an evolutionary trend emerging, where the stress 
coping peptides evolving in order to be expressed only when required? That 
should certainly make sense as it could explain the specificity of the SCP and 
SRP for the CRFR2 and the presence of multiple CRF homologous peptides that 
is observed in the mammals. A study is needed to show the pattern of expression 
of the SCP and SRP peptides in higher mammals and especially primates. Also, 
if such a pattern occurs, then there must be differences in the promoter region of 
CRF and UCN compared to the SCP and SRP that could shed light in the factors 
that drive the expression of the SCP and SRP genes and these factors will 
probably emerge as key players in orchestrating the stress response at the 
molecular level.
Having established that all three peptides are expressed in the neonatal heart, 
we set out to determine their cardioprotective effects. We compared the effects of 
all three peptides in protecting neonatal cardiomyocytes after hypoxia alone, or 
after hypoxia/reoxygenation injury against total cell death as measured by Trypan
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blue exclusion. We showed that all three peptides minimised the levels of trypan 
blue exclusion when given either before or after hypoxia and no differences in the 
levels of protection were observed between the three peptides when used at a 
concentration of 10'8 M.
This result was somewhat surprising, as our original hypothesis was that 
because the three peptides show different affinities for the CRFR2b the 
cardioprotective effects of the peptides would resemble their affinities to the 
receptor. So, in order to further examine our hypothesis, we compared the effects 
of the three peptides against apoptosis using a series of concentrations. This 
time we were able to show that SCP and SRP were more protective than UCN 
when used at a concentration of 1pM, when added prior to 
hypoxia/reoxygenation and more protective than UCN at concentrations of 1 and 
10 pM when used prior to the onset of reoxygenation. Furthermore, SCP was 
more protective than SRP at a concentration of 1pM when used prior to 
reoxygenation, even though that SRP exhibits higher affinity to the CRF2b 
receptor than SCP (Hsu and Hsueh, 2001).
This could be due to a possible lower affinity of the human SRP to the rat 
receptor or because of the higher ability of UCNIII/SCP to activate the receptor 
CRFR2p compared to UCNII/SRP, as measured by accumulation of cAMP 
(Lewis et al., 2001). This could also explain the similar protective properties of
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UCN to the two homologues, as the relative potencies of SCP, SRP and rat UCN 
to functionally activate the receptor, overlap (Lewis et a!., 2001).
Another reason for the differences in the protective effects of the SCP and SRP 
at the 1pM level, could be due to the lack of C-amidation of the SRP peptide we 
used. Amidation of the CRF peptides has been proposed to be important for their 
biological activity. It is essential for peptide maturation and it might be required 
for correct protein folding or for additional places for receptor-peptide interaction. 
The lack of SRP amidation could explain the slightly lower biological activity of 
the peptide compared to SCP.
UCN has been shown to require the activation of MAPK p42/44 and Akt/PKB in 
order to elicit its protective effects in the rat heart and in isolated cardiomyocytes 
(Brar et al., 2000; Latchman, 2001; Brar et al., 2002a; Brar et al. 2002b; 
Dautzenberg and Hauger, 2002; Railson et al., 2002; Schulman et al., 2002). 
Here we are able for the first time to show that SCP and SRP require activation 
of p42/44 MAPK and Akt to bring about their antiapoptotic functions in the 
primary rat neonatal cardiomyocytes (Fig. 5.2).
Moreover, we show that blocking phosphorylation of Akt and p42/44 MAPK either 
by chemical inhibitors, or by dominant negative constructs, we can increase the 
amount of cell death following hypoxia reoxygenation (Fig. 5.2), in accordance 
with previous results (Yue et al., 2000; Yamashita et al., 2001) and extended to
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show that SCP and SRP work in a similar fashion indicating a common pattern of 
cardioprotection mechanism among the UCN homologues. Moreover, blocking of 
p38 MAPK can improve viability following hypoxic insults (Fig. 5.2), as shown 
before (Ma et al., 1999; Mackay et al., 1999; Yue et al., 2000).
Furthermore, we are able to demonstrate that SCP is a more potent activator of 
the p42/44 MAPK, followed by UCN and SRP last (Fig. 5.1). This pronounced 
activation of p42/44 MAPK by SCP can also explain the potent cardioprotective 
effects of SCP, and can further strengthen the notion that SCP is binding to 
CRFR2 with higher affinity than UCN. It has been previously shown in myometrial 
cells that phosphorylation of the MAPK p42/44 is a downstream event that 
follows the activation of CRFRIa and CRFR2P (Grammatopoulos et al., 2000).
Our results demonstrate that UCN homologues require activation of both p42/44 
MAPK and Akt, in order to protect cardiomyocytes from hypoxia/reoxygenation 
injury (Fig. 5.1, 5.2). This would suggest that the two pathways might be linked. 
We proposed that ras could be one of the signalling molecules induced by PKA. 
This model could explain the increase in p42/44 phosphorylation observed after 
treatment with SCP and UCN in the presence of LY294002 (Fig. 5.1). However 
this had no effect in protection (Fig. 5.2), suggesting that UCN peptides need 
activation of downstream protective effectors regulated by both pathways.
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Finally, inhibition of p38 MAPK increased phosphorylation of p42/44 MAPK (Fig.
5.1), in the presence of UCN and SCP. Again, this would suggest a crosstalk 
between the different pathways. This crosstalk between p38 MAPK and p42/44 
MAPK has been shown to occur in epithelial corneal cells, where chemical 
inhibition of p38 MAPK increased phosphorylation of p42/44 MAPK in the 
presence of hepatocyte growth factor (Sharma et al., 2003).
UCN and its homologues have attracted great attention because of their 
cardioprotective effects as possible pharmacological agents on patients with 
ischaemic heart disease. However, UCN has also been shown to be involved in 
cardiac hypertrophy. UCN is able to increase distinct markers of hypertrophy, 
such as protein synthesis, cell size, atrial (ANP) and brain (BNP) natriuretic 
peptide secretion and collagen in cardiomyocytes (Ikeda et al., 1998; Nishikimi et 
al., 2000; Railson et al., 2002). For this reason we set out to explore the 
hypertrophic effects of the three peptides on rat neonatal cardiomyocytes.
Hypertrophy is characterised by an increase in cell size, increase in protein 
synthesis and activation of specific genes. For these reasons we set out to show 
the effects of the three peptides on all three of the above markers of hypertrophy. 
All three peptides increased cell size, protein to DNA ratio and the levels of 
mRNA of ANP and BNP when used at 10'8M for 48 hours, showing that they are 
able to induce hypertrophy in rat neonatal cardiomyocytes. SCP showed a 
greater ability in increasing cell size than the other two peptides and was more
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capable of increasing protein to DNA ratio, ANP and BNP mRNA levels than 
SRP. However, compared to UCN, SCP showed a significant difference only in 
its ability to increase mRNA levels of BNP. It was previously shown that the 
levels of ANP protein in rat neonatal cardiomyocytes, after UCN administration 
were higher than BNP, but the fold induction of BNP protein was higher than 
ANP (Ikeda et al., 1998).
As there was a slight difference in the effects on the mRNA levels of ANP and 
BNP between SCP and UCN it leads us to speculate that there must be a factor 
or factors downstream of the CRFR2 that has a higher effect on the BNP 
promoter. BNP promoter has been shown to be regulated differently than ANP 
promoter in the heart (Thuerauf and Glembotski, 1997). Where ANP promoter is 
highly inducible upon SAP and MEK kinases, BNP promoter appears to be more 
sensitive to Akt activation (Thureauf and Glembotski, 1997).
It could be that the differences observed in the levels of BNP and ANP mRNA 
upon treatment with the various UCN homologues is dependent on the activation 
of Akt and, that possibly, SCP is more effective in Akt activation than the other 
homologues. A closer examination and study of the two promoters might be able 
to shed some light on possible factors that are downstream of the Akt and 
activated after UCN homologues treatment to induce BNP/ANP expression. It 
would lead to results that might enable us to control the hypertrophic effects of 
the UCN peptides without compromising the cardioprotective effects.
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To test this hypothesis and in order to understand the action of the UCN 
homologues in cardiomyocytes, we tried to characterise the differences in the 
activation of extracellular signal kinases and PI3 kinases upon stimulation by the 
UCN homologues. UCN was previously shown to be able to activate MAPK and 
Akt and that both pathways were important for cardiomyocyte survival after 
hypoxia/ reoxygenation injury. Additionally, the pathways that are involved in 
cardiomyocyte hypertrophy by UCN have not been examined. The only 
information available at the time the work was conducted was that the MAPK and 
p38 kinases are not involved in cardiomyocyte hypertrophy (Railson et al., 2002).
Although, previous studies on UCN hypertrophic effects speculated that PKA 
activation was important for these effects, this is the first report to show a distinct 
mechanism for the UCN induced hypertrophy. It is clear that PI3K and Akt 
activation in particular is at least one of the factors required not only for the 
hypertrophic effects of the UCN peptides (Fig. 5.4), but for cardioprotection as 
well. Akt activation is known to be an important factor in hypertrophy (Frey and 
Olson, 2003). Possible downstream effectors include such regulators of 
hypertrophy as GSK3f3 and mTOR. CRF has already been shown to regulate 
GSK3p expression in neuronal cells (Bayatti et al., 2003).
We previously speculated that Akt and MAPK pathways converge at a point 
downstream of the CRFR2. This notion is strengthened by the results presented
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here. Akt phosphorylation (Fig. 5.1) was increased after blocking MAPK and in 
addition, in some of the experiments, blocking MAPK increased protein synthesis 
and cell area after peptide treatment (Fig. 5.3). These increases were not 
statistically significant however, apart from the effect of SCP on cell area (Fig. 5.3 
Top and Bottom) and in the case of SRP when cells were transfected with 
DNMEK1 (Fig. 5.3 Bottom). These results indicate that there is a convergence of 
the two pathways upstream of MEK1 and that the MAPK pathway might act as a 
negative feedback loop of the Akt pathway stimulation on cell area after the 
peptide activation of the CRFR2, and probably only after an increased stimulation 
of Akt, as is the case with SCP and SRP. However, this hypothesis needs to be 
tested.
It has been previously shown that certain isoforms of the PI3K can be activated 
by Gsq trimeric proteins and also PI3K is able to induce MAPK activation either 
by interacting with ras, or by activating protein kinase C, which in consequence 
acts on raf-1 to activate the MAPK pathway (Bondeva et al., 1998; Graness et 
al., 1998; Clerk and Sugden 1999; Bayatti et al., 2003; Bayer et al, 2003; Foncea 
et al., 2000; Wetzker and Bohmer, 2003). In addition, protein kinase A, which is 
activated by Gs, can stimulate Akt independently of PI3K (Sable et al., 1997; 
Filippa et al., 1999).
In conclusion, we present a schematic diagram of the pathways that are 
stimulated by UCN and its homologues in the rat neonatal cardiomyocyte (Fig.
8.1). We believe that the UCN peptides after stimulation of the receptor lead to 
cAMP release and activation of PKA, MAPK and PI3K. Cyclic AMP can induce 
ras activation that can lead to activation of Akt either independently, or through 
PI3K. In addition ras activation can lead to MAPK activation either through PI3K 
and PKC or independently through raf-1. Two possible negative feedback loops 
are also presented. One negative feedback loop working through p38 on MAPK 
and another on Akt through MEK-1. This is the first time that the possible action 
of UCN and its homologues downstream of the receptor have been charted. It is 
by no means a definitive path, but it can be a basis for further exploration of the 
signalling events in the cardiomyocyte, following stimulation of the CRF receptor.
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FIGURE 8.1. Schematic representation of the possible signalling events following 
activation of CRF receptor in rat neonatal cardiomyocytes by UCN homologues. 
UCN: urocortin, SCP: Stresscopin, SRP: stresscopin related peptide, PI3K: 
Phospho-inositol 3 kinase, cAMP: cyclic adenine monophosphate nucleotide, 
PKC: protein kinase C, PKA: Protein kinase A, CRFR: CRF receptor, arrows 
represent activation and clubs represent inhibition. Pathways that are not certain 
are presented with a questionmark.
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Having shed light on the events that follow CRFR activation, we were interested 
in finding possible molecules that are downstream effectors of the physiological 
effects of the UCN homologues. For this reason a number of molecules, which 
were identified by an affymetrix gene chip assay, were tested for their 
involvement in the cardioprotective effects of the peptides. The molecules 
selected were PKCe, iPLA2 and Kir 6.1. The three molecules above were 
selected because of their known implication in ischaemia reperfusion injury in the 
heart.
PKC is a protein kinase that has been previously shown to be involved in all 
aspects of cardiac physiology, including ischaemic preconditioning and 
hypertrophy. We have shown that PKC epsilon is one of the downstream targets 
of UCN and its homologues as its levels rise after peptide administration for 24 
hours in rat neonatal cardiomyocytes. PKCe has been shown to be involved in 
cardioprotection after ischaemia reperfusion injury in neonatal (Chen et al. 1999; 
Dorn et al., 1999) and in adult cardiomyocytes (Dorn et al., 1999). Furthermore, 
PKCe has been shown to be involved in cardiac hypertrophy (Clerk et al., 1994). 
We are able to show that UCN and its homologues are able to induce the levels 
of PKCe without affecting the levels of the PKCs isoform in neonatal 
cardiomyocytes. In addition, UCN was able to induce rapid translocation of PKC- 
e, with no significant effect on the delta isoforms (Lawrence et al., 2005). PKCe 
translocation is a necessary step for MAPK p42/44 activation and could explain 
the necessity of MAPK in the cardioprotective effects of UCN.
Interestingly, as it was previously shown only the iPLA2 isoform is involved in 
induction of apoptosis after oxidative stress (Martinez and Moreno, 2001). We 
are able to show that UCN and its homologues are able to attenuate the levels of 
iPLA2following hypoxia/reperfusion in rat neonatal cardiomyocytes. SCP was the 
most potent of the three peptides once more followed by UCN and SRP. We 
were also able to show that UCN homologues act in a similar manner to BEL an 
inhibitor of iPLA2 as co-treatment of the homologues with the chemical inhibitor 
had no additional benefit to cell survival. Furthermore, UCN homologues were 
able to attenuate the amount of cell death caused by the addition of LPC, a 
product iPLA2. Taken together these results suggest that UCN and its 
homologues act not only by reducing the amounts of iPLA2 in the cell, but also by 
somehow inhibiting the release of the phospholipase metabolites arachidonic 
acid and LPC and blocking their deleterious effects. It is possible that UCN might 
be acting on other factors that are required for the mopping up of the 
phospholipase metabolites, or that the fact that it inhibits the positive feedback 
loop caused by LPC release in the induction of iPLA2, is enough for the cellular 
mechanisms to cope with the harmful metabolites. This is certainly an area that 
requires further attention in the future.
The question that arises is this, are UCN effects on iPLA2 only to inhibit the 
apoptotic effects of this molecule or is it somehow linked to lipid metabolism and 
maintenance of membrane integrity? Further work is certainly needed. In addition 
are the effects on iPLA2 to minimise possible activation of other PKC isoforms? It
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is not hard to speculate that phosphatidyl serine can be easily produced from 
lysopshosphatidyl serine. PS is one of the activators of PKC and the effects of 
UCN on iPLA2 could be to control PKC activation and to minimise activation of 
other PKC isoforms than PKC epsilon.
We also examined the effects of UCN and its homologues on an ion channel the 
inward rectifying potassium subunit Kir 6 .1 .  There are two types of K At p  channels 
in the myocardium, sarcolemmal and mitochondrial. The sarcolemmal channel 
has been cloned and shown to be an octameric complex consisted of four pore 
forming Kir 6.2 subunits and four SUR2A sulfonyl urea receptors (Day et al., 
1999; Gross and Fryer, 1999).
We have shown for the first time that the peptides are able to increase the levels 
of Kir6.1, and we provide evidence that this effect is specific for UCN as the 
sulfonyl urea subunit SUR and the isoform Kir 6.2 are not affected by UCN. We 
also show the importance of a functional Kir6.1 on the effects of UCN as 
transfection of a dominant negative form of Kir 6.1 blocked the protective effects 
of UCN. Moreover, for the first time we show that the mitochondrial K At p  channel 
is important in myocardial viability after hypoxia reoxygenation and that the 
sarcolemmal channel is not affected by UCN or its homologues.
But why are UCN and its homologues leading to opening of KATp channels? It 
was previously shown that opening of mitochondrial KATp channels is one of the
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steps during ischaemic preconditioning. K At p  channel opening lead to a flux of K + 
through the mitochondrial membrane and accumulation of K + in the 
mitochondrion. The ion flux can lead to production of ROS that are mimicking 
ischaemic injury and preconditioning the cardiac cell for ischaemic episodes. But 
is K a t p  channel opening important for blocking apoptosis. Is the K + influx in the 
mitochondria necessary to keep mitochondrial integrity or is it a way for the cell to 
counteract the excess Ca+2 released in the sarcoplasm after an ischaemic 
episode? Do K a t p  channels open during ischaemia, or is it not a normal cell 
response to oxidative stress. We know that mitochondrial K a t p  channel opening 
is one of the ways that cardiomyocytes can become preconditioned, as was 
shown by diazoxide treatment, but we need to find out the role of the channel 
during ischaemia. Again further work is needed to clarify the role of K a t p  in 
cardioprotection.
This work is by no means complete. We have just started to realise the way the 
UCN peptides bring about their action in the cell. If we are to construct a 
cardioprotective agent based on the UCN peptides we need to find out if the 
hypertrophic effects examined are going to be crucial in stopping us using the 
peptides long-term as a protective drug for cardiac ischaemia. This needs testing 
in whole animals to determine the level of hypertrophy induced.
For this reason, we need to examine the effect of the peptides on the size of 
adult hearts. This could be done by intravenous administration of the peptides in 
whole animals and examining the effect of the peptides on the heart size on
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regular time intervals and plot out the long term effects of UCN administration on 
heart size and more importantly on the ventricular and atrial wall muscle. Hearts 
would be removed for histochemical analysis and for RNA sampling to detect a 
change in the gene expression pattern of the heart after the UCN treatment. We 
will be looking for a possible upregulation of such hypertrophic gene markers as 
BNP and ANP.
It is not unthinkable that a peptide might be constructed that is not as potent in 
inducing PI-3K pathway. This is probably highly unlikely unless the activation of 
the PI3K pathway is dependent on certain stereochemical changes of the 
CRHR2 receptor that could possibly bring about a direct activation of PI3-K. It will 
be of great value in examining truncated SCP peptides to see the effects of the 
different parts of the molecule on the activation of the CRH receptor. It is an 
added benefit that SCP and SRP are exclusively binding to the CRFR2 and have 
no affinity to CRFR1. Apart from making possible studies easier as we only have 
to examine the effects on a single type receptor, SCP and SRP will have no 
effect on the brain via the CRFR1. This single characteristic of the SCP and SRP 
peptides makes them perfect candidates over UCN for the construction of 
synthetic peptides for therapeutic use.
For the last part, we examined the role of a novel gene called SAG in the 
neonatal cardiomyocytes that we show to be induced by UCN and its 
homologues. SAG is a 13kD RING finger protein that was shown to be
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expressed in the heart among other tissues and it was specifically cloned as a 
response gene to oxidative stress. For this reason we believed that it would be a 
good candidate gene to examine in the context of myocardial 
ischaemia/reoxynation injury.
We were able to show that SAG mRNA and protein is expressed in the rat 
neonatal cardiomyocytes and that the levels of mRNA and protein are induced 
within an hour of ischaemia and are also present for the first hours of 
reoxygenation. Cardiomyocytes transfected with SAG are able to attenuate the 
amount of cell death after hypoxia/reoxygenation injury, and that the trasfection 
of a mutant SAG, with a mutation on the RING finger, failed to attenuate cell 
death, indicating the importance of the RING finger in the protective functions of 
SAG. Moreover, we were able to show that SAG is an important gene for 
cardiomyocytes, as transfection of an antisense SAG construct in the cells 
caused the cells to die.
SAG localisation changes after hypoxia/reoxygenation, and that a cytoplasmic 
SAG localisation is important for cell survival and that hypoxia triggers SAG exit 
from the nucleus. We propose that SAG is able to regulate the levels of caspase- 
3 in the cytoplasm of the cells and that this interaction is the reason for the 
importance of the cytoplasmic SAG in cell protection.
SAG is a very interesting molecule to examine more closely. The translocation of 
SAG from nucleus to the cytoplasm needs to be examined in more detail. There
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three different possible mechanisms for SAG translocation. SAG might be able to 
shuttle in and out of the nucleus freely as it is of a small enough size. Adding a 
large epitope on the peptide might stop it from translocating to the cytoplasm. 
The lack of a possible nuclear -entry/ -exit signal, strengthens this hypothesis. 
SAG could also be able to exit the nucleus by attachment to another protein. This 
is the case with most proteins that make up the SCF E3 ligases for example 
cullin. SAG might be able to get in and out of the nucleus as part of the ligase. 
Lastly, the SAG translocation might be regulated by some kind of protein 
modification. SAG appears to contain a Casein kinase II phosphorylation signal. 
Kim et al., have shown that CKII phosphorylation of SAG is important for cell 
proliferation in HeLa cells and that SAG RING finger needs to be intact for the 
phosphorylation to take place. It would be of interest to examine the effect of CKII 
phosphorylation on SAG localisation and apoptosis.
The role of caspase-3 and SAG possible interaction needs to be established. If 
there is an interaction of SAG and caspase-3 then we would be able to show that 
by immunoprecipitation. The possibility of a regulation of a caspase by 
degradation is really exiting as it will show additional RING finger proteins 
involved in caspase regulation besides lAPs.
How can we explain the role of UCN in the cell? Why are there at least 3 different 
peptides that appear to do the same work in the cell and why is there such a 
multitude of signalling molecules activated by UCN and its homologues? Are all 
these signalling molecules interlinked and are all of them required for the actions
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of UCN? These are the main questions that have come to the surface from this 
work and we will try to put forth a few explanations for them.
Nothing in a cell, and extrapolating to a tissue organ or organism, is maintained 
with no reason. Not after millions of years of evolutionary trials that have put all 
these mechanisms that are keeping the cell working in an ordinary fashion to the 
test. CRF peptides and among them UCN and its homologues appear to have 
similarities to the insect diuretic peptides. These peptides act on the Malpighian 
tubules of insect after feeding and induce H2O removal and diuresis. So they 
have a role in homeostasis. Does that mean that CRF peptides have been 
evolved from a common ancestor between insects and vertebrates? That would 
indicate an evolutionary history of at least 450 million of years and that CRF 
peptides have evolved as osmoregulatory homeostatic mechanisms and their 
functions have evolved into a wider stress regulation response mechanism, that 
includes the fight or flight behavioural response that is manifested by the 
activation of the adrenal axis. We have already proposed that the presence of 
SCP and SRP could be evolutionary steps of having the stress coping 
mechanism activated on demand rather on maintaining low levels of the 
CRF/UCN peptides and controlling their function by the CRF binding peptide.
It would be interesting to find out if there is a binding peptide for SCP and SRP. 
Our theory would suggest that such a peptide could be absent, however it might
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still be necessary in order to minimise the effects of secreted SCP and SRP as 
they do work in an autocrine/paracrine manner.
So, SCP and SRP could be evolutionary steps in dissecting the stress response 
to the adrenal axis as a behavioural response, and the SRP, SCP response to 
the periphery with mainly cellular stress coping mechanisms rather than whole 
body stress coping. It is of interest that UCN has been shown to have anxiolytic 
effects in contrast to the anxiogenic effects of the CRF. Another opposing effect 
of CRF and UCN is on depression, where CRF induces and UCN decreases 
depression (Rademaker, 2002). These differences are reflected upon the 
evolution and tissue distribution of the CRF receptors as well, where CRFR1 is 
localised in the brain and the CRFR2 is produced in the periphery.
During stress a cell has two option cope or die. It is easy to see then why UCN 
and each homologue have such antiapoptotic properties. UCN is there to give 
cells a chance to either maintain cellular function, or die if it can not cope 
anymore. It gives the chance to the cell to check if it has enough resources to 
see it through the stress period or if it is far gone to die. That also explains the 
fact why death is still observed in the presence of UCN.
UCN and its homologues are able to block apoptosis induced by ischaemia 
reperfusion in the heart. To do that we have shown that the activation of several 
signalling molecules are required to be activated. We have also shown that all
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the signalling molecules that are activated by UCN peptides are required for UCN 
to be able to elicit its antiapoptotic effects. This indicates that all the signalling 
molecules are either downstream of a common activating molecule, such as 
PKA, and or they are communicating between them and that they are all required 
to activate all the necessary factors that are needed by UCN peptides to 
attenuate apoptosis. So, the cardioprotection elicited of UCN peptides is not the 
result of a single pathway, but of several pathways with probably PKA on the top 
of the signalling pyramid.
Interestingly some of the down-effector signalling molecules were recently shown 
by Lawrence to be located in the mitochondrion and to be important to maintain 
mitochondrial integrity (Lawrence et al., 2005). These molecules are PKC 
epsilon, Kir6.1 and iPLA2 . It is interesting to hypothesise that all these molecules 
are regulated by UCN peptides in order to maintain mitochondrial integrity in 
order to block the mitochondrial apoptosome to be formed and to guarantee 
mitochondrial functionality and production of ATP for cell viability. Also, we can 
hypothesise that iPLA2 activity and levels are downregulated by UCN peptides 
not only to block the production of arachidonic acid and blocking apoptosis 
induced by iPLA2 activity but also to maintain mitochondrial and cellular 
membrane integrity. The possible mechanism by which UCN and its homologues 
might act on the mitochondrion is shown on figure 8.2.
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The effect of UCN peptides on Kir 6.1 could also have the additional effect in 
maintaining mitochondrial membrane potential and to control cytoplasmic 
osmotic pressure. That would link it back to the role it has in the insects. In 
conclusion, UCN peptides need to activate a number of signalling molecules in 
order to bring about their antiapoptotic and homeostatic effects.
Further work is needed to elucidate the theory present concerning the effects of 
UCN on the mitochondrion through PKCe translocation. We need to examine 
whether blocking PKCe translocation would have any effects on Kir 6.1 levels 
after UCN administration by western blotting. Through voltage gating 
experiments on isolated mitochondria we might be able to find out whether 
blocking PKC epsilon has any effect on the K+ influx that is expected after UCN 
treatment. Experiments in PKCe7’ animals would show the effect of PKC epsilon 
on the Kir6.1 and K a t p  channel. Similarly, with the same experimental approach 
we can show the possible link between PKC epsilon and iPLA2-
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Figure 8.2. Effects of UCN on the mitochondrion. UCN treatment leads to PKCe 
translocation from the cytosol to the mitochondrion. There it might be able to 
regulate the K At p  channel and lower the activity of iPLA2 and thus maintaining 
mitochondrial membrane integrity and function. Longer term effects of UCN 
administration leads to additional PKCe synthesis, attenuation and lowering of 
iPLA2 levels and increase in the levels of K a t p , securing thus mitochondrial 
function.
UCN peptides are able to induce hypertrophy, as well. A big difference between 
the way that UCN peptides bring about their antiapoptotic and hypertrophic 
effects is that not all signalling molecules regulated by UCN are required for its 
hypertrophic effects. We are certain that MAPK p42/44 for example is not 
required for UCN peptide induced hypertrophy. Also, it would be hard to think 
that Kir6.1 and iPLA2 might be important for hypertrophy. That raises the 
question whether the hypertrophic effects of UCN peptides are a necessary evil 
and a consequence of the activation of certain pathways, like Akt, that have 
intrinsic antiapoptotic and proliferative effects. Could it be that the hypertrophic 
effects of UCN peptides in the heart is a consequence of the inability of 
cardiomycytes to proliferate? It has been shown that UCN has proliferative 
effects in other cells (Ikeda et al., 2002). It could be that blocking of apoptosis is 
intrinsically linked with growth and proliferation, and you can not avoid blocking 
apoptosis without causing either cellular growth or proliferation. It could be an 
unavoidable risk a cell might have to take in order to survive the stress that 
caused UCN production. After all, stress should only last a brief period of time in 
the life of a cell and the main aim of the cell is to survive that period of stress the 
best it can until more favourable conditions are available.
As a final note we managed to compare the effects of the UCN homologous 
peptides in the rat neonatal cardiomyocyte and to provide an outlook of their 
action in the cell in regard to the antiapoptotic and hypertrophic effects of the
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peptides. We also managed to show a mechanism of action for the three 
peptides and show some of possible targets of the peptides.
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